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Abstract 
Atherosclerosis is the most common cause of cardiovascular disease (CVD), which is the 
leading cause of death in the world. Atherosclerosis is characterised by aberrant lipid transport 
and metabolism that leads to the deposition of low-density lipoproteins (LDL) in the artery 
wall. The deposited LDL is then susceptible to modification, principally by oxidation, and is 
ingested by macrophages to form “foam cells”. Modified LDL can also be taken up by 
endothelial cells, which can lead to impairment of endothelium-dependent vasorelaxation, 
termed ‘endothelial dysfunction’. This dysfunction causes the arterial stiffening that is 
characteristic of atherosclerosis. 
There are several potential sources of LDL modification that have been implicated in vivo, 
including lipoxygenases, glucose, reactive oxygen and nitrogen species and the haem enzyme 
myeloperoxidase (MPO). However, the type(s) that are most relevant to atherosclerosis are still 
a subject of controversy. There is strong evidence for the role of MPO, an enzyme released by 
neutrophils upon inflammation, in causing oxidative damage to host tissue and biomolecules, 
including LDL, that leads to vascular cell damage in atherosclerosis. MPO produces oxidants 
hypochlorous acid (HOCl) and hypothiocyanous acid (HOSCN), by catalysing the reaction of 
hydrogen peroxide (H2O2) with the respective (pseudo)halides, Cl
- and SCN-. While it is well 
established that HOCl causes extensive LDL modification, which is present in atherosclerotic 
lesions, less is known regarding the impact of the other major MPO-derived oxidant, HOSCN 
in atherosclerosis. Generation of HOSCN may be of relevance to smokers, whom have 
significantly elevated plasma SCN- levels, which can shift the ratio of MPO oxidants to favour 
HOSCN formation. Elevated HOSCN formation and consequent modifications of important 
biomolecules such as LDL may therefore be a contributing factor to the deleterious effects of 
smoking in the development of CVD. 
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Chapter 3 examines alterations in the pattern of modification of LDL by HOSCN compared 
to HOCl. Exposure of LDL to HOCl led to extensive aggregation and non-specific 
fragmentation of apoB-100, whereas HOSCN was shown to selectively cleave apoB-100 at 
two sites. Peptide mass mapping experiments revealed the formation of two similarly sized 
apoB-100 fragments, resulting from cleavage near the N- and C-termini. This selective 
fragmentation was significantly ablated by the free radical scavenger, butylated 
hydroxytoluene, consistent with a radical-mediated fragmentation pathway. However, further 
work is required to characterise the mechanism involved and the specific peptide cleavage sites. 
Chapter 4 examines the effect of LDL modified by HOCl or HOSCN on endothelial 
dysfunction using human coronary artery endothelial cells (HCAEC) as a model. Exposure of 
HCAEC to LDL modified by HOCl or HOSCN did not result in altered scavenger receptor 
expression or significant lipid uptake. Similarly, there was no discernible effect on the 
expression of adhesion molecules or cytokines, or neutrophil adhesion, indicating that HCAEC 
did not promote an inflammatory response to HOSCN- or HOCl-modified LDL. Similarly, 
HOCl- and HOSCN-modified LDL did not induce endoplasmic reticulum stress and related 
signalling cascades in the unfolded protein response. However, each type of modified LDL was 
able to perturb nitric oxide (NO) production in the cells, which is described in Chapter 5. 
Exposure of HCAEC to HOSCN-modified LDL in particular, resulted in a significant 
decrease in endothelial nitric oxide synthase (eNOS) activity, which was linked to eNOS 
uncoupling. This decreased NO production, consistent with endothelial dysfunction, was 
supported by the observation that exposure of rat aortic segments to HOSCN- (and HOCl-) 
modified LDL ex vivo resulted in a decrease in endothelium-dependent vasorelaxation. An 
upregulation of eNOS mRNA expression in HCAEC was apparent after exposure to HOSCN-
modified LDL, but not HOCl-modified LDL, indicating that there are some differences in the 
HCAEC response to each type of modified LDL. 
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Vascular smooth muscle cells (VSMC) also play a crucial role in the development of 
atherosclerosis, as these cells can transdifferentiate from a contractile phenotype, which 
modulates vessel relaxation, to a synthetic phenotype, which aids in vascular remodelling in 
atherosclerosis. VSMC can also undergo calcification, which is common in complex 
atherosclerotic lesions, and has been shown to be caused by other types of modified LDL. 
Chapter 6 uses human coronary artery smooth muscle cells (HCASMC) as a model to assess 
the effect of exposure to HOSCN- and HOCl-modified LDL on the expression of the synthetic, 
contractile and calcification VSMC phenotype markers. The gene expression of contractile 
markers, α-smooth muscle actin and calponin were stunted, and the expression of the synthetic 
marker osteopontin was elevated by exposure to HOSCN- or HOCl-modified LDL compared 
to the non-treated control cells. This response was not due to lipid accumulation by the uptake 
of modified LDL, which can lead to VSMC-derived foam cell formation. These preliminary 
data are consistent with a potential role for LDL modified by MPO-derived oxidants HOSCN 
or HOCl to promote a synthetic phenotype in VSMC. 
Overall, the data from this study support a potential role for the MPO-derived oxidant 
HOSCN to promote vascular dysfunction by the modification of LDL, which is an important 
mechanism that promotes the development of atherosclerosis. That HOSCN-modified LDL 
induces endothelial dysfunction and promotes a synthetic VSMC phenotype is consistent with 
a role for SCN- to exacerbate atherosclerosis. This complements previous studies showing that 
elevated plasma SCN- levels correlate with increased LDL deposition in the arteries of young 
smokers. However, further work is needed to assess the role of HOSCN-modified LDL on the 
development of atherosclerosis in vivo, particularly as the role of SCN-, both as a circulating 
antioxidant and a substrate for MPO, in cell signalling pathways that maintain health and 
promote disease still need to be elucidated. 
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 Inflammation in Atherosclerosis 
In Australia, atherosclerosis-dependent cardiovascular disease (CVD) is the leading cause 
of hospitalisations and deaths [2]. Atherosclerosis is characterised by the accumulation of 
macrophage lipid-laden “foam” cell formation, leading, initially, to fatty-lesion formation and 
eventually a large lipid-laden and necrotic core of complex chemical composition and 
morphology in the intimal artery walls [3, 4]. This progressive, chronic inflammatory disorder 
of the arteries leads to a progressive narrowing of the lumen and a significant or total occlusion 
of blood flow. This may lead to ischaemia (inadequate supply of blood) of the tissue 
downstream of the artery. Prolonged ischaemia can result in infarction; i.e. tissue death and 
subsequent scarring. Alternatively, an unstable lesion can rupture to release a plethora of pro-
inflammatory material that can cause thrombosis (formation of a blood clot, termed a 
‘thrombus’, within the blood vessel which causes partial or total occlusion of blood flow) which 
in the coronary artery, can cause sudden cardiac death [5]. Coronary heart disease (CHD), also 
known as ischaemic heart disease, occurs when there is a blockage of the coronary artery 
impeding blood flow, resulting in cardiac muscle damage and subsequent scarring. CHD and 
its sequelae are the most common cause of death in Australia [6]. While thrombotic occlusion 
of vessels serving the brain can lead to stroke [7]. 
There are many risk factors involved in the initiation and progression of atherosclerosis. 
Some are deemed non-modifiable risk factors (gender [8], family history [9], age), while others 
are modifiable, or “lifestyle” risk factors (low fruit/vegetable diet [10, 11], replaced with a diet 
of high trans-fatty acids [12], smoking [13], lack of exercise, obesity and hypertension [14, 
15]), and both groups undoubtedly contribute to a person’s risk of developing CVD. In addition 
to measures of lipid metabolism and those of cardiovascular function, clinical measurements 
of CVD risk include increases in circulating levels of inflammatory markers and markers of 
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tissue damage (C-reactive protein, troponin T, serum amyloid-A, fibrinogen, reviewed [16]) as 
it is well established that inflammation is a driving force responsible for the development of 
atherosclerosis [3, 17]. 
The role of inflammation in the initiation, progression and destabilisation of atherosclerosis 
has been extensively reviewed [3, 17-20]. The peroxidase enzyme, myeloperoxidase (MPO; 
EC 1.11.1.7) is released during inflammation and is found in atherosclerotic plaques at multiple 
stages of the disease process [21]. MPO is a key peroxidase enzyme in the innate immune 
system that destroys pathogens by catalysing the production of reactive oxidants collectively 
called the hypohalous acids, namely; hypochlorous acid (HOCl), hypothiocyanous acid 
(HOSCN), hypobromous acid (HOBr) and hypoiodous acid (HOI) [22]. However, there is also 
evidence for host tissue damage caused by these oxidants, implicating MPO as having a role 
as a key effector of chronic inflammatory diseases including atherosclerosis [23, 24]. Whilst 
other peroxidase enzymes play a role in the immune system, including lactoperoxidase (LPO) 
[25], eosinophil peroxidase (EPO) [26], vascular peroxidase (VPO) [27] and thyroid peroxidase 
(TPO) [28]; MPO has been the most implicated in the pathogenesis of atherosclerosis 
(described in Section 1.6.6). 
 Myeloperoxidase 
1.2.1. Role of MPO in innate immunity 
Upon the invocation of inflammation, either by injury or an ingress of a pathogen, 
neutrophils (also called polymorphonuclear leukocytes) are the first recruited immune cells to 
the site of inflammation [29]. When activated, neutrophils undergo a “respiratory burst,” in 
which oxygen consumption is increased many fold compared to basal levels via NADPH-
oxidase (NOX), which catalyses production of the superoxide anion radical (O2
•-; Figure 1.1) 
[30]. O2
•- either spontaneously, or via the action of superoxide dismutase (SOD) [31], 
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dismutates to hydrogen peroxide (H2O2). Concomitantly, neutrophils will degranulate, causing 
the extracellular release of the contents of azurophilic granules (including MPO) at the site of 
inflammation [29]. MPO utilises H2O2 to convert halides, or the pseudohalide SCN
-, to produce 
hypohalous acids (refer to Figure 1.1). 
 
Figure 1.1. Neutrophil activation and the production of hypohalous acids. Activation of 
neutrophils promotes oxygen consumption by NADPH oxidase-2 to produce O2
•-, which 
dismutates to H2O2. Concurrently, MPO is released to catalyse the halogenation of H2O2 to 
the hypohalous acids HOCl, HOSCN and HOBr by the respective (pseudo)halides (Cl-, SCN- 
and Br-). At high concentrations of SCN-, HOCl and HOBr can be effectively scavenged to 
produce more HOSCN. 
1.2.2. The Catalytic cycle of MPO 
MPO is a cationic, homodimeric haem-peroxidase enzyme approximately 146 kDa in mass, 
with each monomer consisting of a heavy and light chain [32, 33]. MPO utilises H2O2 to convert 
halides (Cl-, Br- and I-) and the pseudohalide thiocyanate (SCN-) to their respective hypohalous 
acids (HOX, where X = Cl-, Br-, I- and SCN-; Figure 1.1). Collectively this combination is 
referred to as the MPO-H2O2-X
- system, with hypohalous acid formation occurring via the 
halogenation cycle (Figure 1.2). The haem group is the catalytic site for hypohalous acid 
production, however MPO has a complex catalytic cycle. The native MPO-Fe3+ haem group is 
enzymatically inactive, but reacts with H2O2 rapidly (k ~ 1.4 × 107 M-1•s-1) to form compound 
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I, the highly active MPO-Fe4+-oxo-porphyrin radical species [34]. Compound I then catalyses 
the production of HOCl, HOBr, HOI and HOSCN from Cl-, Br-, I- and SCN- ions, respectively 
(Reaction 1), by a two-electron redox reaction whilst reducing MPO back to the native state 
[35]. 
H2O2 + X
-  HOX + H2O (1)             (X = Cl, Br, I, SCN) 
 
Figure 1.2. The enzymatic cycle of MPO (adapted from [33]). Native MPO is oxidised by 
H2O2 to form compound I (MPO-Fe
4+=O). Hypohalous acids HOCl, HOBr, HOI and HOSCN 
are produced by a two-electron oxidation of the respective (pseudo)halides Cl-, Br-, I- or SCN- 
and restoring MPO to the native state (halogenation cycle). Alternatively, native MPO can be 
restored by one-electron oxidation of compound I to a compound II intermediate by reaction 
with H2O2
 or O2
•-, followed by reaction with O2
•- or a number of organic or inorganic substrates 
(RH) (peroxidation cycle). H2O2 can also convert compound II to compound III (MPO-
Fe2+=O2), which is an inactive state of MPO. RH can also restore compound I from compound 
II. O2
•- can also cycle MPO between native form and compound III.  
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Alternatively, MPO can conform to the MPO-Fe4+-oxy ferryl intermediate radical 
(compound II) before reducing back to the native enzyme involving two subsequent one-
electron reductions, via a peroxidase cycle [33]. The peroxidase cycle generates radicals from 
organic and inorganic substrates, including tyrosine, tryptophan, thiols, ascorbate, steroidal 
`compounds, urate and many drug compounds, which inhibit MPO halogenation activity [33]. 
MPO also has a reduced, enzymatically inactive MPO-Fe2+=O2/O
•- species (compound III), 
which is formed by the reduction of compound II by H2O2 or native MPO by O2
•- [36]. MPO 
has been reported to be oxidised in the presence of high levels of H2O2, from the compound I 
and III state, causing the destruction of the haem group and the release of iron [36]. Although 
iron release has prospects of being a secondary source of oxidative stress in cells [37], in the 
experiments reported [36], purified MPO was exposed to supra-physiological concentrations 
(1.5 mM) of H2O2, which presents an unlikely scenario in vivo, although these conditions may 
be relevant inside the phagosome under conditions of depleted (pseudo)halides. 
Although physiological concentrations of Cl- are orders of magnitude higher than SCN- and 
Br- in the plasma (cf. 100 – 140 mM Cl-, 20 – 120 µM SCN- and 20 – 100 µM Br-), 
approximately the same quantity of H2O2 is converted to HOCl and HOSCN, whilst 
comparatively low levels of HOBr are formed [38]. This is due to the high selectivity of MPO 
for SCN- compared to Br- and Cl- (specificity constants are 730:60:1, respectively [39]). As a 
result, SCN- is converted to HOSCN rapidly by MPO compared to the production of HOCl and 
HOBr (c.f. rate constants in M-1•s
-1; kHOSCN = 9.6 × 10
6, kHOBr = 1.1 × 10
6 and kHOCl 2.5 × 10
4, 
respectively [35]). In addition, HOCl and HOBr are rapidly reduced by SCN- ions to HOSCN 
(k ~ 2 × 107 M-1•s
-1 and 2.3 × 109 M-1•s
-1, respectively [40, 41]) with the calculated physiological 
half-life of HOCl in the plasma reported to be 400 µs before reduction by SCN- [40]. This 
conversion is likely to have considerable consequences for cigarette smokers, for whom SCN- 
is significantly elevated in the plasma [42, 43], reaching above 250 µM in some cases [43] 
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(described further in Section 1.6.6.1). The pKa values of HOCl, HOBr and HOSCN are 7.59, 
8.7 and 5.3, respectively [44, 45], resulting in a mixture of neutral and ionic HOX/OX- species 
being present at physiological pH (7.4). Therefore, approximately equal quantities of 
HOCl/OCl- are present, while HOBr predominates over OBr- and OSCN- is almost completely 
predominant (>99%) over HOSCN under physiological conditions. This is important in 
understanding the reactivity of these oxidants with cells, as the charged conjugate bases OSCN- 
and OCl- can differ markedly in their reactivity compared to the parent acid [46]. 
 Reactions of hypohalous acids with biomolecules 
MPO-derived hypohalous acids have a range of biological targets. HOCl and HOBr are very 
potent oxidants that indiscriminately react with a range of different biomolecules. 
Modifications of proteins, lipids, nucleotides and carbohydrates by HOCl have been 
extensively characterised, while biological damage wrought by HOSCN is more selective, in 
particular targeting thiols. HOCl and HOBr have both been implicated in many diseases, owing 
to the presence of specific chlorinated and brominated biomarkers in vivo [47-51]. The 
contribution of HOSCN to disease is less clear as there is no known biomarker for its reactivity 
and that the thiol oxidation can usually be repaired (reviewed in [33, 46, 52, 53]). Indeed, for 
this reason, it has been postulated that SCN- has a protective role as it reduces the formation of 
HOCl and HOBr by MPO and scavenges the oxidants directly [41, 54-56]. This section will 
overview the current knowledge of the biological reactivities of the MPO-derived oxidants 
HOCl, HOBr and HOSCN. 
1.3.1. Proteins 
Proteins and amino acids are an important target for oxidation by MPO-derived hypohalous 
acids and, with regard to these targets, there are significant differences in the comparative 
reactivities of HOCl and HOBr compared to HOSCN (Reviewed [52]). HOCl and HOBr are 
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potent oxidants that react with a range of amino acid side-chains, due to their large standard 
reduction potentials (1.28 V and 1.13 V at pH 7, respectively [57]) while HOSCN is regarded 
as a mild, thiol (R-SH)-selective oxidant (0.56 V at pH 7 [57]) (Table 1). What follows is a 
summary of the reaction products in approximate order of reactivity, particularly with regards 
to HOCl and HOBr. 
  
Table 1.1. Summary of the rate constants of HOCl, HOBr and HOSCN with amino acids. 
 k2 (M
-1
•s
-1) 
 HOCla  HOBrd HOSCNe 
Methionine (Met) 3.4 × 107 b 3.6 × 106 - 
Cysteine (Cys) 3.6 × 108 b 1.2 × 107 7.8 × 104 
Histidine (His) 1.0 × 105 3.0 × 106 - 
Tryptophan (Trp) 1.1 × 104 3.7 × 106 ND 
Lysine (Lys) 5.0 × 103 2.9 × 105 - 
Tyrosine (Tyr) 23c 2.3 × 105 - 
Arginine (Arg) 26 1.8 × 103 - 
Glutamine (Gln) 0.03 1.9 - 
Asparagine (Asn) 0.03 1.9 - 
Selenocysteine (Sec) 
Selenomethionine (SeMet) f 
ND 
3.2 × 108 
ND 
1.4 × 107 
1.24 × 106 
2.8 × 103 
a Rate constants for the reactivity of HOCl from Pattison et al [58]; b Revised rate constants 
for the reactivity of HOCl with Met and Cys [59]; c revised rate constant for HOCl with Tyr 
[60]; d kinetics of HOBr with peptidyl residues [61]. All reactions with HOCl and HOBr were 
measured at pH 7.4 and 22 °C; e Reactivity of peptidyl residues with HOSCN are only apparent 
with Cys [62], selenocysteine (Sec) [63] and Trp [64], however no kinetic data are available 
for Trp. No significant reactions are found with HOSCN and other peptidyl residues (-); f  rate 
constants for SeMet with HOCl, HOBr and HOSCN [65]. ND = not determined. 
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1.3.1.1. Methionine, cysteine and glutathione 
Both HOCl and HOBr oxidise the thioether moiety (R-S-CH3) of methionine (Met) to 
produce methionine sulfoxide (MetSO) [66-69], whereas no reaction occurs with HOSCN [64]. 
However, MetSO is not considered a reliable biomarker for these specific mechanisms of 
protein oxidation, as it is produced by oxidation of Met by a variety of oxidants and is 
enzymatically reversibly reduced back to Met [70]. Additionally, under conditions of high 
oxidant concentrations, MetSO can be further oxidised irreversibly to methionine sulfone 
(MetSO2) [71] as shown in Figure 1.3. There is strong support for the role of Met oxidation in 
protecting protein functionality as an oxidant scavenger that prevents the oxidation of other 
peptidyl residues essential to protein function, given the Met residues are not generally integral 
to the microenvironment of active sites [70, 72, 73]. When Met is in the catalytic domain and 
oxidation does lead to the inactivation of an enzyme, e.g. α1-antitrypsin [74-76], then Met 
oxidation may act as a switch for protein function [73]. In these cases, reduction of MetSO 
back to Met, catalysed by MetSO reductases (Msr) A and B [70, 77], can lead to reactivation 
of the enzyme. However, in a chronic inflammatory state, this switch mechanism could fail due 
to MetSO oxidation to MetSO2 [78], which may result in inactivation and catabolism of 
proteins. 
 
Figure 1.3. Reaction scheme of HOCl and HOBr with Met. Met oxidation by HOCl or HOBr 
forms MetSO, which can be reversed back to Met by MetSO reductase (Msr). Alternatively, 
further oxidation of MetSO by HOCl or HOBr can form Met sulfone, which is irreversible. 
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Two independent, simultaneous studies have also shown that N-terminal Met can be 
cyclised to dehydromethionine by HOCl and HOBr, which may be a potential biomarker for 
hypohalous acid-induced oxidative stress [67, 79]. Recently, exposure of calprotectin (isolated 
from human neutrophils) to HOCl resulted in N-Met oxidation and formation of 
dehydromethionine as well as MetSO [80]. However, the use of dehydromethionine as an in 
vivo biomarker has not been properly evaluated and requires further investigation. 
Recently, Ronsein et al [66] found that HOBr and bromamines (R-NHBr), and to a lesser 
extent, HOCl and chloramines (R-NHCl) induced sulfilimine cross-linking (>S=N-) of Met 
with the nucleophilic nitrogen-centre of the Lys ε-amino group in the model peptide formyl-
Met-Leu-Phe-Lys (fMLFK) for which they proposed independent mechanisms for 
intramolecular and intermolecular cross-links involving these peptidyl species. However, the 
biological significance of this cross-link species produced by hypohalous acid attack is yet to 
be determined with proteins in vivo. 
The thiol group (R-SH) of cysteine (Cys) residues is a major target of oxidation from HOCl, 
HOBr and HOSCN. Although HOCl and HOBr react with Cys at three orders of magnitude 
faster than HOSCN (cf. in M-1•s
-1; kHOCl = 3.6 × 10
8 [59], kHOBr = 1.2 × 10
7 [61] and kHOSCN = 
7.8 × 104 [62]), HOCl and HOBr undergo a number of competing reactions with other residues 
in competition with thiols, while HOSCN exhibits very limited reactivity with other biological 
substrates. Thus, in being thiol selective, increased production of HOSCN can consequently 
lead to increased cellular damage by targeted oxidation of thiols, such as cysteine residues, 
which are commonly biologically active functional groups [81]. Initially, the thiol is 
halogenated to produce sulfenyl halide intermediates (R-SX; X = Cl, Br and SCN) [62, 68, 69, 
82]. Sulfenyl chloride (R-SCl) then undergoes hydrolysis to produce sulfenic (R-SOH), sulfinic 
(R-SO2H); and ultimately and irreversibly, sulfonic acid (R-SO3H; Figure 1.4) [68, 69]. The 
sulfenyl thiocyanate (R-SSCN) derivative can also be formed by reaction of HOSCN with 
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thiols, which was shown to be more stable than the analogous R-SCl product [83]. However, 
at high molar ratios of HOSCN, further irreversible oxidation to sulfonic acid derivatives can 
also occur [83]. 
 
Figure 1.4. Reactions of hypohalous acids with Cys/thiols. Scheme summarises the reactions 
of thiols with hypohalous acids described in Section 1.3.1.1. Sources cited in the main text.  
Alternatively, sulfenyl chloride and sulfenic/sulfinic acid intermediates can react with non-
backbone amines (e.g. Lys or Arg) to form intra- and intermolecular sulfenamide, sulfinamide 
and sulfonamide cross-links [84-86] (Figure 1.4). There is currently no evidence for these 
cross-links being formed by sulfenyl bromides. Interestingly, HOSCN has been shown to react 
with sulfonamides to form a thiocyanatosulfonamide [87]. Unlike the R-SSCN, R-SCl is 
unstable and readily decomposes to a thiyl radical (R-S•) [88]. R-SCl, R-S• and R-SSCN can 
all oxidise other thiols to form disulfides (R-SS-R’) [89-91]. Most commonly, these disulfides 
will form between two Cys residues to produce cystine. Cystine can be oxidised by HOCl 
cleaving the disulfide bond (possibly via a sulfenyl chloride intermediate) and undergoing a 
series of intermediary hydrolysis reactions to form the sulfonic acid derivative, cysteic acid 
[68]. 
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Glutathione (GSH), a tripeptide of γ-Glu-Cys-Gly and a ubiquitous cellular antioxidant, is 
highly reactive towards HOCl, HOBr and HOSCN [85]. However, the products of GSH-
derived products differ between each oxidant. HOCl reacts with GSH to predominantly form 
GSH sulfonamide and some dehydroglutathione. HOBr preferentially forms the sulfinic acid 
and dehydroglutathione with minor amounts of sulfonamide. Only the glutathione disulfide 
(GSSG) is produced with HOSCN [85]. GSH can also react with the cysteinyl halide (R-SX) 
to form a mixed disulfide, also referred to as glutathionylation, which is an important regulatory 
signalling mechanism in cells [92]. 
1.3.1.2. Tryptophan 
HOCl and HOBr readily react with Trp (cf. 1.1 × 104 M-1•s
-1 [58] and 3.7 × 106 M-1•
 s-1 [61], 
respectively). These hypohalous acids cause hydroxylation of the indole group to produce 2-
hydroxytryptophan (oxindoylalanine) and dioxindoylalanine [93, 94] (Figure 1.5). When a Gly 
residue is adjacent to Trp, Trp can be chlorinated to form the chloroindole derivative 
chlorotryptophan [94, 95]. This is due to the lack of steric hindrance by Gly and it is likely that 
chlorinated Trp becomes increasingly minor as the adjacent residue is larger. These Trp 
modifications by hypohalous acids have been implicated in protein dysfunction. MPO-derived 
oxidation of apolipoprotein-A1 (apoA-1), the apolipoprotein of high density lipoprotein 
(HDL), leads to the impaired capacity of the protein to mediate cholesterol efflux from 
cholesterol-(over)loaded macrophages [96]. This largely attributed to the oxidation of Trp 
forming mono- and dihydroxytryptophan [97, 98]. 
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Figure 1.5. Trp oxidation by hypohalous acids. Tryptophan can be oxidised by HOCl, HOBr 
or HOSCN to form the 2-oxindoylalanine, which can be further oxidised again to 2,5-
dioxindoylalanine. 
Evidence for the reactivity of HOSCN and Trp is available [64]. Under conditions of 
localised thiol depletion or in the absence of thiols, Trp may become a viable target of HOSCN. 
HOSCN was shown to exhibit reactivity towards Trp residues of apolipoprotein A-I, which 
lacks Cys residues, resulting in the formation of mono- and dioxyindoylalanine which affected 
the ability of this protein to efflux cholesterol from cells [99]. In a related study, HOSCN was 
proposed to produce the oxindoylalanine species of Trp oxidation via hydrolysis of indole-
SCN intermediates [100]. However, a subsequent study has shown that HOSCN-mediated Trp 
oxidation is only significant under highly acidic conditions (pH 2) which may facilitate 
thiocyanogen ((SCN)2) reactivity [101]. Therefore, the physiological relevance of HOSCN-
derived oxidation of Trp remains to be established. 
1.3.1.3. Lysine and Histidine 
HOCl and HOBr are highly reactive with α-amino and side-chain nitrogen moieties of Lys 
and His forming reactive halamines [61, 102, 103]. HOCl and HOBr halogenate the secondary 
amine of the imidazolic ring of His, which can undergo halogen transfer reactions to other 
peptidyl groups, acting as an important intermediate oxidant [102]. Lys residues are 
halogenated at the α- and ε-amino groups (Reaction 3 and 4) [104]. These halamine species 
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also retain some oxidative properties of their parent oxidant (reviewed [105]), thus acting as 
secondary oxidants potentially causing additional oxidative damage [102]. Indeed, chloramines 
can be more efficient at oxidising thiols (leading to the formation of disulfides (Reaction 5 and 
6)) due to their higher specificity compared to HOCl [106, 107]. This may be applicable to 
analogous bromamines, but this has not been experimentally verified. 
R-NH2 + HOCl  R-NHCl  (3)  
R-NH2 + HOBr  R-NHBr  (4) 
R-NHCl + R-SH  R-NH2 + R-SCl (5) 
R-SCl + R-SH  R-SS-R + H+ + Cl- (6) 
The decomposition of side-chain chloramines and bromamines (e.g. Lys ε-amino group) on 
low-molecular mass amino acid derivatives, peptides and proteins can produce nitrogen-
centred radicals (ε-aminyl radicals; R-N(H)•) [108-110]. Nitrogen-centred radicals can 
rearrange to produce carbon-centred radicals via multiple radical intermediates leading to 
protein fragmentation [108, 109]. The decomposition of protein-derived chloramines has also 
been implicated in the propagation of damage to other targets. Lys chloramines formed on 
exposure of low-density lipoprotein (LDL) to HOCl are implicated in the induction of lipid 
peroxidation in the same particles [111]. Other studies present evidence for chlorination of Lys-
rich histones to form chloramines that break down to free-radicals, mediating cross-linking and 
fragmentation of DNA and nucleosides [112, 113]. DNA fragmentation and cross-linking 
could have implications for MPO activity in cell apoptosis in inflammatory diseases like 
atherosclerosis, and in carcinogenesis, but further investigation into the relevance of this 
chloramine activity in vivo is still required. 
Evidence suggests that HOSCN can react with imidazole (as in His) to form 
thiocyanatimines (R-N(SCN)-R’), which retain the oxidising capacity of HOSCN [87]. 
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Similarly, a poly-Lys model has shown amino thiocyanate (R-NH-SCN) species can form on 
the ε-amine of Lys [64] (Reaction 7). However, R-NH-SCN is unstable and is readily reversible 
by hydrolysis [87]. Thus, it is uncertain that amino thiocyanate formation is relevant in 
biological systems. Regardless, R-NH-SCN would not be as detrimental compared to 
chloramine species which can undergo auto-degradation to form nitrogen-centred radicals. 
R-NH2 + HOSCN  R-NH-SCN + H2O  (7) 
1.3.1.4. Tyrosine 
The reaction of HOCl and HOBr with Tyr residues involves the electrophilic halogenation 
substitution reaction with a hydrogen atom in the phenol group to produce the stable 
halogenated products 3-chlorotyrosine (3-Cl-Tyr) and 3-bromotyrosine (3-Br-Tyr; Reaction 8), 
as well as 3,5-dichlorotyrosine and 3,5-dibromotyrosine, respectively [61, 114-116]. 
RR’CH + HOX  RR’CX + H2O (8) [X = Cl, Br] 
Notably, ring halogenation occurs ~10 000-fold faster with HOBr to form 3-Br-Tyr 
compared with HOCl to form 3-Cl-Tyr [61]. Tyr chlorination by secondary chloramines, such 
as lysine chloramine, is shown to increase the formation of 3-Cl-Tyr in biological systems 
[117]. Despite the relatively slow reactivity of HOCl with tyrosyl residues (k = 23 M-1•s
-1 [60]), 
3-Cl-Tyr is a well-established biomarker of MPO activity and systemic inflammation [118]. 
Although 3-Cl-Tyr is an established biomarker, it was found to be unreliable as a quantitative 
measure of MPO activity, as it is oxidised further in the presence of high concentrations of 
HOCl and ONOO- [60, 119]. Another confounding factor is that elevated circulating SCN- 
levels perturb 3-Cl-Tyr formation, which was shown to be reduced in smokers with elevated 
plasma SCN- [120]. Even though 3-Cl-Tyr is a valid signature of MPO activity, it cannot be 
reliably used to quantify oxidation. Other biomarkers need to be assessed for this purpose. No 
appreciable reaction is believed to occur directly between HOSCN and Tyr at physiological 
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pH. However, Tyr-SCN adducts are observed upon following the exposure of proteins to 
thiocyanogen (SCN)2 or the LPO-H2O2-SCN
- system [82]. 
Tyr is also a substrate of MPO. MPO compound I catalyses the formation of tyrosyl radicals 
via 1 electron oxidation while transforming to compound II via the peroxidation cycle [121]. 
Tyr radicals can cause lipid damage by the generation of lipid hydroperoxides [122]. 
Alternatively, Tyr radicals can dimerise to form the major conformational product o,o’-
dityrosine (Figure 1.6) [123, 124]. Intra- and inter-molecular cross-linking can form between 
proteins via these dityrosine adducts, altering or inactivating proteins. Tyr was shown to be 
competitive to Cl- as a substrate of MPO, where supraphysiological Cl- concentrations (600 
mM) only halved the Tyr oxidation [121]. However, the greater specificity of SCN- compared 
to Cl- to MPO may effectively compete with Tyr oxidation by compound I, although inhibition 
of Tyr oxidation by SCN- supplementation has not been empirically tested. 
 
Figure 1.6. Dityrosine formation by MPO. Tyr residues can be oxidised by MPO compound 
I to produce a Tyr radical species and MPO compound II. Further reaction with another Tyr 
radical forms the o’o-dityrosine adduct. 
1.3.1.5. Selenium-containing amino acids 
Selenocysteine (Sec) is unique as the only selenium-containing amino acid that is 
genetically coded into proteins, albeit exclusively those of the cellular antioxidant defences, 
which will be summarised in Section 1.4.3. HOCl and HOBr reactivity towards Sec is too rapid 
to kinetically measure, while HOSCN has been measured to have high reactivity to Sec (kHOSCN 
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= 1.24 × 106 M-1•s
-1 [63]). The reaction of the selenol group (R-SeH) of Sec with HOSCN is 
similar with thiols, with the initial formation of a selenothiocyanate (R-Se-SCN) intermediate 
(Reaction 9). The R-Se-SCN species can react with another selenol to form a diselenide (R-
SeSe-R’) or thiols to form a mixed R-SSe-R bridge (Reaction 10 and 11) [63]. The higher 
reactivity of Sec as a selenium-based thiol analogue to hypohalous acids makes Sec an 
attractive exogenous antioxidant, in addition to bolstering the selenoenzyme antioxidative 
capacity of the thioredoxin and glutaredoxin (Section 1.4.3). 
R-SeH + HOSCN  R-Se-SCN + H2O   (9) 
R-Se-SCN + R’-SeH  R-SeSe-R’ + SCN- + H-  (10) 
R-Se-SCN + R’-SH  R-SeS-R’ + SCN- + H-  (11) 
Notably, all three hypohalous acids show high reactivity towards selenomethionine (SeMet; 
cf. kHOSCN = 2.8 × 10
3 M-1•s
-1 [63], kHOCl = 3.2 × 10
8 M-1•s
-1 [65] and kHOBr = 1.4 × 10
7 M-1•s
-1 
[65]), the selenium analogue of Met. Although there is no codon for SeMet, SeMet can 
substitute for Met into proteins as the tRNA for Met cannot discriminate between the two 
species [125]. Analogous to sulfoxides formed with the reaction of HOCl or HOBr to Met, this 
reaction with SeMet results in the formation of selenoxides (MetSeO; R-SeO-CH3) [63, 126]. 
A major difference between MetSO and MetSeO is that MetSeO formation is readily reversible 
by thiols and ascorbate [127, 128]. This has implications to bolstering the antioxidative 
capability of cells by the cycling between free SeMet and MetSeO, or protect SeMet-
incorporated proteins from oxidation-induced inactivation. Based on this, dietetic and 
pharmacological studies into selenium supplementation in preventative measures of 
cardiovascular disease may be performed in the future to investigate their efficacy. 
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1.3.1.6. Reactions with other amino acids 
HOCl and HOBr show relatively marginal activity towards arginine (Arg) [58, 61]. Products 
derived from Arg halogenation have not been extensively studied, but current evidence 
supports guanidine chlorination [129]. HOBr reacts approximately 70-fold faster with Arg than 
HOCl (see Table 1.1) and could form analogous bromamides, however no characterisation of 
this reaction has been performed. Gln and Asn react very slowly (kHOCl = 0.03 M
-1
•s
-1 [58] and 
kHOBr = 1.9 M
-1
•s
-1 [61]), therefore the halamides derived from these residues are unlikely to be 
relevant in vivo. As individual amino acids, alanine (Ala), valine (Val), proline (Pro), leucine 
(Leu), isoleucine (Ile), phenylalanine (Phe), aspartic acid (Asp) and glutamic acid (Glu) have 
reactive α-amino groups that form halamines when reacted with HOCl and HOBr [105], but 
show poor reactivity in proteins due to the low reactivity of amide linkages and aliphatic 
functional groups [53, 61].  
1.3.2. Lipids 
MPO-derived hypohalous acids are capable of oxidising lipids. HOCl and HOBr react with 
the double bonds of unsaturated fatty acids, phospholipids, and cholesterol to form halohydrins 
[130, 131] (Figure 1.7). Halohydrins are characteristic markers of hypohalous-derived lipid 
oxidation. Halohydrin-incorporated oleic acid micelles caused haemolysis [132], were 
cytotoxic to human umbilical vein endothelial cells (HUVEC) [133], and were shown to 
deplete adenosine triphosphate (ATP) levels in U937 cells and enhance leukocyte adhesion to 
arterial segments isolated from mice [134]. 
 
Figure 1.7. Halohydrin formation by HOCl and HOBr on unsaturated lipids. 
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HOCl and HOBr exert significantly lower reactivity to most lipids compared to sulfydryl or 
amino groups of proteins, but phosphatidylserine and phosphatidylethanolamine also react with 
HOCl and HOBr at rates competitive with hypohalous acid modification of amino acids (ca. 
kHOCl ~ 10
5 M-1•s
-1 [135] and kHOBr ~ 10
6 M-1•s
-1 [136]) and could be competitive reactants in 
vivo. As a result, stable chloramines are produced on the amine head group [131, 135]. The 
corresponding bromamines generated are unstable and could likely decompose to form radicals 
that propagate secondary oxidation reactions [136], however this remains unconfirmed. 
Plasmalogens are also a major lipid component of the plasma, lipid pools of cells and in LDL, 
and are reactive with the MPO-H2O2-Cl
- system at the ester linkage to form 2-chloro-fatty 
aldehyde derivatives and lysophosphatidylcholine [137-139], the latter of which can further 
react with HOCl to form chlorohydrins [130, 140]. Notably, 2-chloro-fatty aldehyde products 
have been detected in elevated levels in human aortic lesions compared to the normal aorta 
[141] and may have clinical relevance to atherosclerosis in myocardial ischaemia (reviewed 
[142]). 
The addition of SCN- to an MPO system has been shown to promote oxidation of plasma 
lipids [143]. Further, a study by Exner et al demonstrated the formation of lipid hydroperoxides 
and conjugated dienes when LDL was incubated with a MPO-H2O2-SCN
-system [144]. 
However, the mechanism of oxidation in a MPO-H2O2-SCN
- system is not well defined. It is 
postulated to involve the formation of SCN•, SCN•- or (SCN)2
•- species in the MPO system 
[144, 145], though LDL lipid oxidation is also seen with isolated HOSCN [146]. In contrast, 
Spalteholz et al showed no apparent reactivity of HOSCN with the double bonds of the lipid, 
1-palmitoyl-2-oleoyl-sw-glycero-3-phosphocholine (POPC) [147]. Therefore, it is likely that 
HOSCN reacts selectively with cholesteryl linoleate and arachidonate species [146]. LDL-lipid 
modification by HOSCN and SCN- in enzymatic systems will be further discussed in Section 
1.6.2.1.c. 
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1.3.3. Nucleic acids 
HOCl and HOBr are strong oxidants of DNA and RNA molecules forming stable and 
unstable halogenated species. HOCl and HOBr react with heterocyclic (ring-NH groups) and 
exocyclic (NH2 groups of guanosine, adenosine and cytidine) amino groups to form a variety 
of N-chlorinated and N-brominated derivatives, respectively. These are unstable intermediates 
that can lead to the formation of stable, carbon-bound halogenated products, 8-chloro-(2’-
dioxy)adenosine (8-Cl(d)A), 8-chloro-(2’-dioxy)guanosine (8-Cl(d)G), 5-chloro-(2’-
deoxy)cytidine (5-Cl(d)C) and 5-chlorouracil (5-ClU) [148-152]; while HOBr and bromamines 
can form the brominated equivalents [48, 50, 153-156]. Chlorinated nucleoside products are 
formed in various inflammatory conditions, including 5-ClU in human atherosclerotic tissue 
[49]. 5-ClU and 5-BrU have also been found in “neutrophil-rich human inflammatory tissue” 
[48]. However, brominated nucleosides may be more relevant in diseases involving eosinophil 
peroxidase (EPO) activity (e.g. Asthma, [157, 158]), known to be highly specific for HOBr 
production. Contrastingly, HOSCN does not seem to react with nucleosides or DNA [159, 160]. 
1.3.4. Carbohydrates 
Carbohydrates, particularly glycosaminoglycans such as hyaluronan and chondroitin 
sulfate, also react readily with MPO-derived hypohalous acids [161]. Glycosaminoglycans, 
which are heteropolysaccharides consisting of repeating amino and uronic sugar-based 
disaccharides [162], are an integral component of the extracellular matrix (ECM) [162]. The 
modification of these ECM structures by HOCl and HOBr, by targeting the amine groups 
present, leads to the formation halamines, dihalamines, halamides and halosulfonamide species 
[161, 163, 164]. Like other amine modifications mentioned previously, this involves the 
decomposition to free radical species, which may potentiate damage, leading to altered cell 
adhesion, growth and signalling [164]. Modification of ECM proteins by MPO-derived 
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oxidants is likely to play a key role in the development of atherosclerosis, as epitopes of HOCl-
induced damage have been colocalised with ECM proteins in diseased tissue [165]. HOCl 
displays very slow reactivity towards deoxyribose and ribose [166, 167]. Therefore, the 
reactivity of nitrogenous bases to hypohalous acids rather than the attached sugars is likely to 
be more significant when considering oxidation of nucleic acids. Unlike HOCl and HOBr, 
HOSCN has not exhibited any reactivity with carbohydrates [168]. 
 Exposure of mammalian cells to hypohalous 
acids 
Due to the diverse reactivities of hypohalous acids with biomolecules, there is the potential 
for cellular dysfunction, damage or death arising from exposure of cells to these oxidants, 
which can in turn exacerbate existing inflammation. HOCl exposure to mammalian cells has 
been studied extensively, while the actions of HOBr and HOSCN upon cells are comparatively 
less well characterised. Comparisons of the effects of these MPO-derived oxidants on cells has 
recently been reviewed [24]. This section will briefly summarise the effects of HOCl, HOBr 
and HOSCN on mammalian cells. 
1.4.1. Haemolysis 
The most extensively studied model of HOCl-induced cellular damage is exposure of human 
red blood cells, which are haemolysed by HOCl in a dose-dependent manner [169-172]. This 
was considered likely to result from membrane and cytoskeletal protein modifications leading 
to destabilisation and lysis [170]. HOBr has been shown to invoke more haemolysis at lower 
concentrations than by HOCl due to the former’s higher reactivity with membrane lipids and 
proteins [170, 173]. Notably, eosinophils were also shown to be more efficient at haemolysis 
than neutrophils [174], most likely due to EPO-dependent HOBr production. The haemolytic 
action of HOSCN has not been demonstrated conclusively. HOSCN has displayed haemolytic 
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properties, but this was only significant under acidic conditions (pH 6.0) [175], where the low 
pKa of HOSCN (pKa 5.3 [45]) favours the protonated form which can pass through the plasma 
membrane. More broadly, haemolysis is not proven to contribute significantly to vascular 
pathology, due to the large number of red blood cells in circulation and high erythrocyte 
turnover rate, but it is still used as a model of cellular damage consequential to direct 
hypohalous acid exposure.  
1.4.2. Vascular cell apoptosis 
In atherosclerosis, endothelial and macrophage death in the arterial wall contributes to the 
development of a necrotic core linked with destabilisation of atherosclerotic plaques which can 
lead to rupturing of the fibrous cap and releasing a plethora of thrombogenic material [176]. 
Exposure of vascular cells to HOCl, HOBr and HOSCN results in extensive cellular 
dysfunction, enzyme inactivation and cell death (reviewed [24]). Direct HOCl exposure (≤ 500 
µM) causes apoptosis of vascular cells, including endothelial cells [23, 177], macrophages [81, 
178, 179], and vascular smooth muscle cells (VSMC) [180] in vitro. Similarly, HOBr induces 
apoptosis in endothelial cells [181], monocytes and macrophages [81]. The action upon VSMC 
has not been reported, although HOBr has been shown to degrade the ECM synthesised by 
VSMC, which can impair cellular function [164]. With regard to relative impacts, it was 
reported that HOBr induced apoptosis to a lesser extent than HOCl in HL-60 (human 
promyelocytic leukaemic) cells, but resulted in greater necrosis than HOCl [182]. 
Interestingly, HOSCN was shown to be more potent than HOCl and HOBr in inducing 
apoptosis in HCAEC and macrophages [23, 81]. This is explicable given that HOSCN induced 
a greater endoplasmic reticular-Ca+ efflux into the cytosol of HCAEC than HOCl [183]. The 
mechanism of Ca2+ efflux was shown to occur through the sarco/endoplasmic reticulum Ca2+-
ATPase (SERCA) Ca2+ pump [183]. SERCA has a high Cys content critical to its ATPase 
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activity, and HOSCN was shown to more effectively oxidise these thiols compared to HOCl 
[183]. This could lead to inactivation of SERCA and increased cytosolic Ca2+, posing a 
plausible mechanism for the difference in potency, with regarding to inducing 
apoptosis/necrosis, between the three oxidants. However, in this study the apoptosis induced 
by HOCl may have been underestimated, as apoptosis was determined by the degree that 
annexin V-binding the ligand of which is the plasma membrane phospholipid, 
phosphatidylserine. Consideration needs to be made given that phosphatidylserine is a target 
of HOCl and HOBr [135, 136]. In contrast, Bozonet et al [184] observed that HOSCN initially 
inhibited apoptosis in HUVEC by disrupting the caspase-dependent apoptotic signalling 
pathway, and suggested HOSCN could play a role in inappropriate survival of damaged cells, 
which could lead to later necrosis. This was in contrast to later findings in HCAEC, which 
observed time- and concentration-dependent apoptosis induced by exposure to HOSCN [23]. 
This discrepancy may be related to phenotypic differences between umbilical vein and adult 
aortic endothelial cells, which have been shown to responded differently to other inflammatory 
stimuli; such examples have been demonstrated between human iliac vein and artery 
endothelial cells [185], as well as HUVEC and HCAEC [186]. 
Reactive halamines can also cause secondary damage to cells. The range of cellular targets 
of reactive chloramines is diverse and includes: halogenation of nucleosides and nucleotides 
[187] and subsequently inhibiting DNA repair [188]; chemical and structural modification of 
proteins leading to inactivation of cellular enzymes [107, 189] and eventually activating cell 
apoptosis [190]. Data on the activity of bromamines is limited, but given the similar chemical 
properties to chloramines, bromamines may have similar effects upon cellular function. 
Although HOBr induced apoptosis in HL-60 cells, amine-free media negated HOBr induced 
apoptosis [182], implicating that bromamines and not HOBr are the main cause of apoptosis. 
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1.4.3. Inflammatory pathway signalling 
In conjunction with, or prior to HOCl inducing apoptosis, HOCl has also been shown to 
activate pro-inflammatory pathways in several mammalian cell types. The extracellular 
signalling-related kinase 1/2 (ERK1/2) and p38 branches of the mitogen-activated protein 
kinase (MAPK) signalling pathway—which are crucial to regulation of cell differentiation, 
proliferation and cell death [191]—were activated in HUVEC and fibroblasts incubated with 
HOCl [192]. The authors also showed that maximum activation in endothelial cells occurred 
rapidly and at sub-lethal concentrations, specifically; 20 μM HOCl for 2 min for maximal 
ERK1/2 stimulation and 15 min for p38 stimulation [192]. Furthermore, inhibition of 
MAPK/ERK1/2 partially prevented HOCl-induced necrosis (but not apoptosis) of HUVEC 
[192], implicating an important role of MAPK activation in regulating appropriate management 
of cell death.  
In J774A.1 macrophages, incubation with 50 μM HOSCN significantly inhibited protein 
tyrosine phosphatases (PTP) together with elevated phosphorylation of MAPK p38 and to a 
lesser extent, ERK1/2 [193]. In the case of PTP1B, this was linked to the selective oxidation 
by HOSCN of the Cys in the active site [193]. HOCl also significantly reduced PTP activity 
[193], which could, at least in part, contribute to the stimulation of p38 and ERK1/2 [192]. 
HOSCN also induced the expression of tissue factor (TF), via activation of NF-κB and 
phosphorylated ERK1/2 MAPK in HUVEC to far greater extent than HOCl or HOBr [194]. 
This was concomitant with an upregulation of endothelial cell adhesion molecules (E-selectin, 
ICAM-1 and VCAM-1) and increased neutrophil adhesion in HUVEC incubated with ≥ 150 
μM HOSCN [195]. This data supports a pro-inflammatory role of HOSCN through promoting 
neutrophil adhesion and extravasation to sites of inflammation. However, this would be better 
modelled on a more relevant cell lineage, such as HCAEC. 
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1.4.4. Cellular antioxidant systems for scavenging 
hypohalous acids 
Although there is strong evidence for cellular damage induced by MPO-derived oxidants, 
evidence is also mounting for hypohalous acids activating cellular antioxidant defence systems. 
As mentioned previously, thiols are major targets for HOCl, HOBr and HOSCN [61, 62, 196]. 
GSH acts as a ubiquitous antioxidant, maintaining redox homeostasis in cells by scavenging 
free radicals and active oxidants. The oxidation of GSH by HOCl, HOBr and HOSCN leads to 
formation of their respective sulfenyl halides and further oxidation of thiols to form GSSG [89, 
196]. Disulfide bonds can also form with GSH and protein-bound Cys residues (R-SSG), 
referred to as S-gluathionylation. 
Over the last two decades, reversible S-glutathionylation has been increasingly recognised 
as a protective mechanism of cellular signalling homeostasis (reviewed [92, 197]). S-
glutathionylation may be protective of further, irreversible Cys oxidation (e.g. sulfonic acid) 
[92] as S-glutathionylation can be reversed by the Sec-containing thioredoxin (Trx) or 
glutaredoxin (Grx) system to form GSSG and the reduced Cys, thus restoring protein function 
(reviewed [56, 198-200]; Figure 1.8). Subsequently, GSSG can be reduced back to GSH by the 
NADPH-dependent glutathione reductase (GR) system to restore GSH levels and thus redox 
homeostasis [201]. Notably, under oxidative stress elements such as GSH depletion by 
hypohalous acids, enzymes involved in GSH synthesis, including GSH synthetase (GS), GR, 
glutamate-cysteine ligase modifier subunit (Gclm) and catalytic subunit (Gclc) are upregulated 
[24]. However, this was demonstrated in vitro and has not been confirmed in the vasculature 
under oxidative stress or atherosclerosis in vivo. 
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Figure 1.8. Antioxidant protection of proteins by GSH, and the glutaredoxin and 
thioredoxin system. Scheme summarises the mechanism of Trx and Grx activity on restoring 
thiols following oxidation by hypohalous acid described in Section 1.4.4. Sources cited in the 
main text. 
Trx and Trx reductase (TrxR) activity are also pertinent to the detoxification of HOSCN 
(reviewed [56]). TrxR is a selenocysteine-containing enzyme responsible for the redox cycling 
of Trx, but can also reduce HOSCN to SCN- [202]. HOSCN can also be scavenged by GR, 
however this is seven-fold slower than the turnover rate with TrxR [202]. Supplementation of 
Sec to mammalian cells—in addition to its antioxidant properties—also improved the 
scavenging of HOCl, HOBr and HOSCN by bolstering the resistance of TrxR to oxidation 
[203]. As well as scavenging of HOSCN produced by peroxidases, this activity by TrxR forms 
an antioxidant defence mechanism for scavenging of HOX by SCN-, independent of MPO-
dependent production of HOSCN (Figure 1.9). 
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Figure 1.9. HOSCN, SCN- and TrxR as an antioxidant defense mechanism (adapted from 
[56]). Respiratory burster by NOX at the cost of NADPH produces O2
•-, wihch dismutates to 
H2O2 for utilisation by MPO to produce HOX. HOX is scavenged by SCN
- to produce HOSCN, 
which is cycled back to SCN- by TrxR at an additional cost of NADPH. 
 Role of MPO in health and disease 
1.5.1. Beneficial role of MPO in the immune system 
The MPO-H2O2-halide system has shown potent antimicrobial activity that contributes to 
host-defence against microbial pathogens, especially in the early phases of infection [29, 204-
206]. Pilot studies by Klebanoff showed that I-, Br- and Cl- ions added to purified MPO and 
H2O2 effectively killed Escherichia coli and Lactobacillus acidophilus in vitro, which was 
prevented with endogenous MPO inhibitors to accentuate the importance of the MPO 
halogenation cycle [22, 207]. Actinobacillius actinomycetemcomitans were also killed with 
MPO-H2O2-Cl
- and I- systems, but remained viable in a MPO-H2O2-SCN
- system [208], while 
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Helicobacter pylori were actually bacteriostatic at early time points and recovery was 
prolonged in a similar LPO-H2O2-SCN
- system [209]. HOCl has been shown to target multiple 
chemical groups to impede bacterial viability, such as iron-sulfur, thioether, haem and 
unsaturated fatty acid groups (reviewed in [118]). In addition to MPO released by 
degranulation, HOCl was also generated in the phagosome to kill ingested bacteria, which was 
demonstrated in vitro with Staphylococcus aureus [210]. 
In contrast to HOCl, HOSCN is bacteriostatic. HOSCN is likely a major product in the oral 
cavity, as SCN- levels are very high (0.5 – 3 mM [211]) and LPO, present in high amounts in 
the oral cavity, has a high affinity for SCN- [212]. HOSCN completely inhibited the sugar-
synthesising enzyme, hexokinase, and partially inhibited glucose 6-phosphate dehydrogenase 
[213]. This was supported by Clem and Klebanoff, who demonstrated that HOSCN, though 
not cytotoxic, inhibited glutamic acid uptake into L. acidophilus [214]. LPO activity and SCN- 
concentrations are also relatively high in the airway and lung epithelia [215-217], which would 
protect the airway in similar fashion to the oral cavity. This is made even more apparent in the 
cases of cystic fibrosis patients who have high susceptibility to lung infections and impaired 
SCN- transport [218, 219]. 
1.5.1.1. MPO deficiency in animal models and 
the clinic 
The contribution of MPO to immune function is underscored in mouse models of MPO 
deficiency, where the mice are healthy under pathogen-free conditions, but exhibit severely 
impaired immune function in eliminating infections. Homozygous mutant MPO deficient-mice 
systemically infected with Candida albicans had significantly higher presence (> 100-fold) of 
C. albicans [220], C. tropicalis, Trichosporon asahii, Pseudomonas aeruginosa [221] and 
Klebsiella pneumoniae [222] compared to their respective wild-type, demonstrating a lack of 
host antibacterial activity in the absence of active MPO. Infection of the lungs with non-viable 
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C. albicans also increased the number of infiltrating neutrophils in MPO-/- mice compared to 
the wild-type, indicating the lack of MPO hindered resolution of the inflammatory response 
[223]. However, S. aureus, Streptococcus pneumoniae, C. glabrate or Cryptococcus 
neoformans infections in MPO-deficient mice were of similar severity to the wild-type [221], 
suggesting that some microbial strains are (i) adapted to MPO activity, and/or are (ii) sensitive 
to MPO-independent immunity. A mechanism independent of MPO halogenating activity has 
been proposed by way of NADPH oxidase activity promoting electron transport into the 
vacuole to form O2
•-, increasing the pH and depolarising the vacuolar membrane of the 
neutrophil, leading to K+ and proton pumping, the latter resulting in activation of neutral 
proteases to digest the pathogen (reviewed [224]). 
Genetic MPO deficiency occurs in between 1:2000 – 1: 4000 people in European and US 
populations [225], and as low as 1:57000 in Japan [226]. Based on the numerous in vitro and 
animal data, MPO deficiency should result in severe impediment to host defence and could 
result in recurrent and frequent infections as described above, however this was not the case in 
humans. A study of 100 people with partial or total MPO deficiency did find higher severity of 
infections compared to a control population, but not higher susceptibility to the onset of 
infection [227]. This is contrasting to chronic granulomatous disease, an immunodeficiency 
disease caused by NOX dysfunction resulting in frequent, severe and sometimes deadly 
infections [228], which strongly supports the role of NOX over MPO in neutrophil-mediated 
microbial killing proposed by Segal et al [224]. Therefore, the author has proposed that MPO 
can actually act as a catalase, by reacting with H2O2 to form compound I then cycling back to 
native MPO through the peroxidase cycle, to protect digestive enzymes inside the vacuolar-
space during microbial killing, but may act as an antimicrobial, halogenating enzyme when 
released into the extracellular space [224]. As studies into the role of MPO in the progression 
of atherosclerosis usually focus on the MPO halogenating activity, this reasoning justifies 
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further investigation into MPO peroxidation activity in atherosclerosis, which is far less 
characterised in vivo. 
1.5.2. MPO, atherosclerosis and cardiovascular 
disease 
Evidence supporting the role of MPO in atherosclerosis is extensive (reviewed [229, 230]). 
Activated MPO is present through all stages of human atherosclerotic lesion development [21]. 
Staining of MPO appeared adjacent to cholesterol deposits in advanced lesions and was 
particularly concentrated near the shoulder region of the atherosclerotic lesions [21]. This is 
significant as MPO-derived HOCl can activate MMPs [231] and deactivate MMP inhibitors 
[232] to promote fibrous cap degradation and destabilise plaques, which often occurs at the 
shoulder regions [4]. Increased MPO activity was supported by the detection of elevated 3-Cl-
Tyr levels in LDL and HDL isolated from atherosclerotic tissue compared to normal aortic 
intima [96, 233]. In agreement with this, HOCl-damaged proteins, as detected using an 
antibody specific for HOCl-modified protein, colocalised with intimal thickening in 
atherosclerotic plaques, together with increased apolipoprotein content [234].  
Blood and lesion MPO levels are a promising predictive biomarker of CVD and in CVD-
related risk stratification. Zhang et al [235] pioneered one of the first studies supporting blood 
and leukocyte MPO levels as an inflammatory marker of atherosclerosis and a risk factor for 
CAD. The EPIC-Norfolk study [236] of 1 138 CAD patients with 2 237 age- and gender-
matched controls supported MPO as a powerful predictor of CAD amongst healthy individuals 
independent of other classic risk markers (smoking, total cholesterol, HDL, hypertension and 
leukocyte count). However, blood MPO levels were not predictive of CVD-related mortality 
[237]. Patients with unstable CAD, characterised by frequent, sporadic symptoms, which can 
occur at rest, had blood MPO levels significantly higher than those of stable CAD patients, 
whose symptoms express at predictable times, e.g. after meals or exercise [238]. CAD patients 
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with elevated MPO levels also had higher risk of developing non-ST segmented-elevated MI 
(patients presenting a MI with ST-segment depression on an electrocardiogram) and other 
major adverse cardiac events [239-241]. MPO has not provided risk-stratification in peripheral 
artery diseases [242], probably as peripheral artery disease has lesser risk of mortality 
compared to CAD except in cases of carotid and cerebral artery diseases, which can lead to 
stroke. 
High levels of MPO are also implicated in acute coronary syndrome (ACS); a spectrum of 
cardiovascular symptoms associated with myocardial ischaemia and a high risk of CHD and 
recurring MI [243, 244]. As stated previously, MPO is not an independent predictor of 
mortality in stable CAD [237], however it may be predictive following non-fatal ST-elevated 
MI (STEMI; patients presenting with ST-segment elevation on an electrocardiogram), as well 
as being predictive of recurring MI [245, 246]. Plasma MPO levels were observed to increase 
significantly soon after MI, followed by depression within 24 h post-MI [245]. This aligns with 
findings of increased neutrophil infiltration at to the onset of MI [247].  
Considering these studies together, the independent predictive capacity of MPO is limited. 
Also, MPO has very low specificity for distinguishing categories of CVD independent of other 
classic markers [248, 249]. Instead, MPO is a useful predictive end-point marker of pre-
diagnosed CVD, but not useful for diagnosis independent of other established markers. 
Furthermore, whether elevated circulating MPO is correlated to increased MPO activity 
contributing to worse outcomes in these studies, or whether the circulating MPO spectates and 
is only an indicator of cardiovascular condition needs to be confirmed. 
Existing clinical studies do have significant limitations. This is due primarily to the fact that 
there is no established normal range of plasma MPO, instead a wide range of MPO plasma 
concentrations have been determined drawing from different patient pools. In addition, heparin, 
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which is used in anti-coagulation therapy in the clinic, is known to liberate MPO from the 
endothelium to circulation [250], consequently elevating plasma MPO levels. Some studies 
declared the use of heparins prior to taking blood samples [244, 248], while others declared 
heparin was not administered [237, 239, 240], but many others did not disclose heparin 
administration information [236, 238, 241, 242, 245, 246, 249, 251]. Therefore, standardised 
protocol to measure plasma MPO levels in the clinic should be devised to allow cross-reference 
between studies and to establish normal ranges of circulating MPO. However, it remains that 
the current clinical evidence supports a role of MPO in the development and progression of 
atherosclerosis and several cardiovascular complications. 
1.5.2.1. Role of SCN- in atherosclerosis 
As described earlier, there is substantial evidence for MPO-derived HOCl in the 
development and progression of CVD. This is less clear for HOSCN. For example, there is still 
debate on the beneficial vs. the detrimental effects of SCN- in atherosclerosis. As previously 
mentioned, smoking is a major risk factor for the early progression of atherosclerosis [13]. A 
prospective study of 34 439 British doctors and their smoking habits over 50 years found that 
life-long smokers had a three-fold increase in mortality risk, which halved upon smoking 
cessation at age 50, and almost completely ameliorated risk upon cessation at age 30 [252]. 
The thoracic and abdominal aorta of male smokers aged 30-34 had evidence of greater 
macrophage infiltration and foam cell formation, which correlated with higher plasma SCN- 
levels although there was no attempt to relate this to another key component of the disease: 
modified (i.e. oxidised) LDL [253]. Whereas, in a similar study by Scanlon et al showed the 
abdominal aortas of young people who smoked had elevated levels of malondialdehyde- and 
4-hydroxynonenal (4-HNE)-modified Lys (markers of lipid peroxidation) in LDL from 
atherosclerotic plaques in people with high serum SCN- versus low serum SCN- concentrations 
[254]. This suggested that elevated levels of SCN-, possibly as a substrate for MPO, promoted 
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LDL oxidation leading to plaque development, although the authors did not observe an increase 
in LDL deposition or plaque area [254].  
Thiol loss was shown to be greater in the plasma from smokers (with approximately three-
fold greater plasma SCN- levels on average) compared to non-smokers when plasma samples 
were incubated with MPO and H2O2, while plasma thiol levels between smokers and non-
smokers were unchanged [42, 55]. This finding supported the hypothesis that elevated SCN- 
levels drive MPO-derived production of HOSCN in the plasma, resulting in loss of thiols.  
 OCN- and its conjugate acid (isocyanic acid; OCNH) can readily react with amino and 
sulfhydryl groups, with the reaction with Lys ε-amines resulting in the formation of 
homocitrulline; a marker of protein carbamylation in renal disease ([255]; Figure 1.10). Protein 
carbamylation can cause alteration of protein function and is a marker linking renal diseases to 
atherosclerosis and MPO [256, 257]. In addition to observing a link between conversion of 
SCN- to OCN- by MPO, to uraemia (pathological elevation of circulating levels of urea) and 
protein (including LDL) carbamylation in renal disease, Wang et al [255] also found protein-
bound homocitrulline levels were a predictive risk factor for CAD, MI, stroke and death [255]. 
HDL isolated from five atherosclerotic lesions were found to be heavily carbamylated, but not 
chlorinated, and in the same study the researchers showed that addition of SCN- to an MPO-
H2O2-Cl
- system promoted apoA-1 carbamylation over chlorination in vitro and that HOCl was 
able to convert urea to OCN- and thus further promote carbamylation [258]. The latter finding 
has adverse implications for patients with uraemia, regardless of receiving haemodialysis, 
particularly as in another study plasma MPO levels were shown to be increased—correlative 
with oxidised LDL—in patients undergoing haemodialysis [259]. CKD and renal failure are 
associated with elevated protein carbamylation. In patients with chronic renal failure, OCN- 
levels in the plasma have been detected at three-fold greater concentration than the control 
group [260]. However, in the context of renal disease without elevated levels of SCN-, uraemia 
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is likely the primary cause of protein carbamylation, due to the equilibrium with OCN- leading 
to a rise in OCN- levels by Le Chatelier principle. SCN- has also been linked to elevated LDL 
carbamylation induced by the MPO-H2O2-SCN
- system in smokers compared to non-smokers 
[255], linking the long-established association between inflammation, smoking and 
atherosclerosis (Figure 1.10). 
 
Figure 1.10. Scheme of MPO-mediated conversion of SCN- to OCN- promoting protein 
carbamylation linked to atherosclerosis (adapted from [255]). Smoking elevates SCN- levels 
in the plasma. MPO utilises H2O2 and SCN
- to OCN- as a minor product besides HOSCN. 
OCN- and OCNH promote protein carbamylation at inflammatory sites.  
While the previous studies support the role of SCN- in CVD and renal disease, there is also 
evidence to support a beneficial role of elevated SCN- in the blood. Human MPO transgenic 
LDLR-/- mice supplemented with SCN- in drinking water for 12 weeks had plaque area reduced 
by 26 % [261]. Although plasma SCN- levels increased three-fold in the plasma compared to 
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the control (and at concentrations similar to human smokers [42]), there was no change in 
circulating cholesterol, thiol, MPO or triglyceride levels [261], implicating a local beneficial 
effect on plaques despite no change to systemic improvement. In addition, a study measuring 
the mortality of post-MI patients (amongst whom were smokers, non-smokers and past 
smokers) found that elevated plasma SCN- levels (categorised as below- and above-median 
levels in the plasma) were beneficial to survival [55]. Post-MI patients with elevated SCN- 
levels had increased survival independent of whether patients had below- or above-median 
MPO levels, compared to the equivalent cohort with below-median SCN- levels [55]. These 
findings were independent of age within each patient group. This was rationalised by the 
proposition that low MPO with high SCN- concentrations shifted the MPO-derived production 
of HOCl to HOSCN [55], limiting the production of HOCl which reacts with a variety of targets 
compared to HOSCN which reacts mainly with thiols [52]. This is supported by the finding 
that smokers had significantly reduced levels of 3-Cl-Tyr, which inversely correlated with 
elevated SCN- concentration in the plasma [120]. However, further work is required to see if 
this is related to alterations in MPO-derived oxidant formation.  
 Role of LDL in atherosclerosis 
1.6.1. Native LDL 
High circulating cholesterol is one of the most well-established predictors of atherosclerosis, 
with LDL-derived lipid accumulation in the artery walls recognised as a hallmark of this 
disease [262-264]. LDL (1.019 < ρ < 1.063 kg•L-1) is synthesised endogenously by the 
hydrolysis of very low-density lipoprotein (VLDL; ρ < 1.019 kg•L-1) in the liver [265, 266]. 
Highlighted by its broad density range, LDL (Figure 1.11) is a complex molecule composed of 
~ 3000 lipid molecules (~ 1 600 cholesterol esters (CE), 600 cholesterol, 700 phospholipids 
and 170 triglycerides [266]), antioxidants (α-tocopherol, Q-tocopherol, carotenoids, 
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oxycaratenoids and ubiquinol-10 [266]), and a single, large 4536 amino acid, approximately 
515 kDa apolipoprotein-B100 (apoB-100; [267]) that binds to the LDL receptor (LDLR). The 
binding of the C-terminal region of apoB-100 to the LDLR facilitates clearance of LDL from 
circulation into cells by endocytosis of the LDL-LDLR complex [268-270]. The main function 
of LDL is to transport cholesterol to cells in the body, to be incorporated into plasma 
membranes and to provide substrate for steroid hormone production, which is essential to the 
viability of cells and cell division [271, 272]. 
1.6.2. Oxidised LDL 
LDL can be modified via different chemical reactions, including oxidation [263], glycation 
[273], carbamylation [274] and acetylation [275]. These modified forms of LDL are no longer 
recognised by the LDLR, but by the scavenger receptors of immune and vascular cells. 
Oxidised LDL binding to the scavenger receptors present on endothelial, mononuclear 
leukocytes and smooth muscle cells is believed to lead to the increased deposition of lipids in 
the vessel wall and inflammation which together drive atherogenesis (reviewed [19, 276, 277]).  
Oxidised LDL has been extensively studied in atherosclerosis. Currently, it is generally 
assumed that the oxidation occurs mostly within the arterial wall, where LDL is sequestered 
from circulating antioxidants [278, 279]. However, as direct identification of the nature of LDL 
modification in vivo is still elusive, there is controversy regarding the source(s) of LDL 
oxidation that are relevant in vivo. LDL modified by different mechanisms generally have 
distinct products that induce different responses in cells (extensively reviewed [280]) and will 
be briefly discussed in this section. 
1.6.2.1. MPO-derived oxidation of LDL 
There has been extensive research into the modification of LDL, particularly the apoB-100 
moiety, by MPO and HOCl [53]. There is robust evidence for an association between LDL, 
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MPO and atherosclerosis with related adverse cardiac events. HOCl-modified LDL are 
demonstrable in atherosclerotic lesions [281], contribute to lesion development [282] and can 
predict the occurrence of CHD [283]. Moreover, MPO and HOCl-modified LDL epitopes are 
colocalised in advanced atherosclerotic lesions [284]. The modification of LDL by MPO and 
HOCl results in a particle with pro-atherogenic properties, including promoting foam cell 
formation and endothelial dysfunction (reviewed [285]). The extent and nature of pro-
atherogenic behaviour is related to the extent of modification observed.  
1.6.2.1.a. MPO binding to LDL 
MPO has a strong binding affinity for LDL, most likely due to the ionic interaction of the 
cationic MPO (pI > 10 [286]) with the anionic apoB-100 (pI ~ 5.4 [287]). Recently, apoB-100 
binding was demonstrated to modulate MPO activity. Delporte et al showed that the presence 
of LDL promoted both halogenation and peroxidation activity of MPO [288], while both 
activities were partially attenuated when MPO was bound to HOCl-modified LDL [288]. 
Sokolov et al tested a number of small oligopeptides matching sequences of apoB-100 
containing anionic residues (i.e. Asp (D) and Glu (E)) to find potential binding sites for MPO 
on LDL [289]. The authors tested peptides 1EEEMLEN7, 53VELEVPQ59 and found that only 
the latter peptide competitively prevented MPO binding to LDL, thus indirectly identifying a 
possible MPO binding domain on LDL. Soon after, Sokolov et al observed that 
445EQIQDDCTGDED456 peptide added to a MPO-H2O2-halide-bound LDL system 
significantly prevented cholesterol accumulation after both 12 and 72 h incubation with 
monocytes/macrophages [290]. This study also found that SCN- added to a MPO-H2O2-halide-
bound LDL system almost completely prevented cholesterol accumulation [290], suggesting 
that a MPO-H2O2-SCN
- system preserves native LDL (at least when MPO is bound to LDL). 
These studies support investigations into a small peptide-based pharmacological approach to 
inhibit MPO activity localised to modifying LDL molecules in vivo. 
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1.6.2.1.b. Apolipoprotein B-100 modification 
by MPO 
LDL modified by HOCl and the MPO-H2O2-Cl
- system has been meticulously characterised 
(reviewed [53]). However, it should be noted that differences in LDL modification may arise 
between a HOCl reagent and MPO enzymatic system [291]. In agreement with reaction kinetics 
(Table 1.1), the order of depletion of apoB-100 residues was Cys >> Lys > Trp when LDL was 
treated with HOCl at 300-fold molar excess [111, 292]. Yang et al identified Met, Cys, Lys, 
Trp and Tyr as targets of HOCl and the MPO-H2O2-Cl
- system [291]. Extensive Met oxidation 
(31 residues), multiple Trp oxidation sites (8 oxidised Trp and 3 di-oxidised Trp), and 3 
chlorinated Tyr residues have recently been detected by rapid resolution LC-MS/MS in LDL 
modified with up to 100 µM HOCl (50:1 HOCl/LDL ratio) [288]. However, this did not match 
an equivalent (up to 100 µM H2O2) MPO-H2O2-Cl
- system, which failed to oxidise 19 Met, 2 
Tyr and all the Trp residues that were able to be oxidised by reagent HOCl [288]. Much greater 
H2O2 concentrations were required (1 250 µM) to reach a similar extent of oxidation as 100 
µM reagent HOCl, showing that the binding of MPO caused targeted oxidation of LDL 
residues [288]. Recently, a more comprehensive analysis has measured the relative reactivities 
of residues in apoB-100 to HOCl in the order of Met ≈ Cys > Lys ≈ Tyr > His ≈ Arg [53]. Trp 
may be elusive targets of an MPO-H2O2-Cl
- system due to their scarcity (only 32 Trp residues 
in the entire 4 536 residue apoB-100 [266]), and possibly because of the hydrophobic indole 
group preferentially burying into the lipid structure of LDL.  
Similarly to Trp, Met is a hydrophobic amino acid and is relatively scant in apoB-100 (78 
residues of 4 536 [266]), yet Met is the prime target of MPO-derived oxidation of apoB-100 
[53, 288]. It has been suggested that Met oxidation could pose a protective mechanism against 
oxidative damage for some proteins [72], especially since MetSO can be repaired by Msr [77]. 
Although MPO binding to LDL increases MPO activity, it may also reduce the capability of 
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MPO to target key residues [288]. Hence, it cannot yet be disregarded that MPO-LDL binding 
may be a mechanism limiting the oxidation of residues that are key to the protein’s function. 
The chlorination products 3-Cl-Tyr and 3,5-diClTyr have been observed in apoB-100 when 
LDL was exposed to HOCl (100-1000 µM) [116] and are present in LDL isolated from human 
atherosclerotic lesions [233, 281]. Unlike 3-Cl-Tyr, 3-Br-Tyr has not been established as a 
biomarker of apoB-100 modification [61, 93]. This is likely due to the low abundance of Br- 
ions in circulation (20 – 100 μM) [38].  
Oxidised amino acid species of LDL can form inter- and intramolecular peptidyl cross-links 
(adducts), leading to changes in secondary to quaternary structure [293]. A characteristic 
mechanism of LDL oxidation is caused by dityrosine formation via tyrosyl radical formation 
mediated by the peroxidation cycle of MPO [121, 122]. LDL isolated from atherosclerotic 
lesions contained up to 100-fold higher concentrations of dityrosine [294]. However, the 
amount of dityrosine generated did not account for the total cross-links formed. Inter- and 
intramolecular sulfenamide, sulfinamide and sulfonamide cross-links have been indicated to 
form between thiols and Lys or Arg residues of HOCl-modified LDL and could contribute to 
further cross-linking [84]. Additionally, HOCl can cause cross-linking of Lys with other ε-
amino groups via Schiff base (-N=C-) formation [293, 295]. 
There are less data regarding HOSCN-modified apoB-100, as there are no specific 
biomarkers of HOSCN activity in vivo. Regardless, more extensive deposits of oxidised LDL 
and macrophage foam cells have been found in young smokers who have elevated SCN- levels 
[253, 254]. Therefore, increased SCN- levels, coupled with increased activation of neutrophils 
in smokers [296, 297], could exacerbate the atherogenic process in smokers. Ismael et al [146] 
have recently found that only 5 µM of HOSCN (1:2.5 ratio of protein: oxidant) was needed for 
complete oxidation of thiol-accessible Cys residues in the apoB-100. Significant oxidation of 
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Trp at higher concentrations of HOSCN (≥250 µM) was also observed [146], though the 
hydrolysis conditions incorporated to measure Trp oxidation result in low pH (≤2) which could 
lead to artefactual oxidation of Trp residues [100]. Additionally, Trp oxidation was not 
different between 30 min and 24 h incubation with HOSCN and was also seen on incubation 
of LDL for 24 h with no oxidant [146]. Other residues of LDL (Met, Lys and Tyr) did not react 
with up to 750 µM HOSCN [146]. This seems in contradiction to Sokolov et al who observed 
near complete prevention of LDL modification with a MPO-H2O2-SCN
- [290]. However, MPO 
binding to LDL in that study would sequester activity near the binding site 
(445EQIQDDCTGDED456) [290] which is not the case with reagent HOSCN. 
1.6.2.1.c. Lipid modification by MPO 
The lipid moieties of LDL are also targets of MPO-derived oxidants, though LDL lipid 
oxidation may be a secondary process mediated by apoB-100-derived chloramines [293]. 
Cholesterol oxidation by HOCl and HOBr yields oxysterols, namely 7-ketocholesterol, as well 
as their corresponding halohydrins and hydroperoxides [93, 298]. Unsaturated phospholipids 
present in LDL (linoleoyl and arachidonoyl fatty acid phosphatidylcholines) form 
chlorohydrins [299]. Jerlich et al [299] also found that these chlorohydrins were formed in 
LDL with the absence of peroxides, hence chlorohydrins rather than peroxides may be the 
major products of LDL phospholipid oxidation by HOCl or the MPO-H2O2-Cl
- system. 
Halohydrins can degrade to yield epoxides [293], however cholesterol chlorohydrins are 
susceptible to epoxidation during gas chromatography-mass spectrometry (GC-MS) analysis, 
and notably, electron spray-mass spectrometry (ES-MS) analysis showed epoxides are not a 
significant secondary product of chlorohydrins [300]. Therefore, the epoxides detected are 
likely an artefact to the methods for analysing the chlorohydrins. 
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HOCl and HOBr, also react with amine groups of phospholipids, particularly with 
phosphatidylethanolamine and phosphatidylserine present in LDL [131]. The reactions of 
HOCl with phosphatidylethanolamine and phosphatidylserine (k ~ 105 M-1•s
-1 [135]) are 
comparable to those of HOCl with many peptidyl side chains. However, reaction rates of HOCl 
with the major phospholipids in LDL, those of phosphatidylcholine and sphingomyelin, are 
slow (k ≤ 10 M-1•s-1 [135]). It has been proposed that phospholipid chloramines may mediate 
lipid peroxidation via nitrogen-centred radical intermediary reactions [301]. HOCl produces 
predominantly chloramines and only chlorohydrins when phospholipid amines were 
completely chlorinated, while HOBr produced both bromamines and bromohydrins 
independently [131]. Given that chlorohydrins are less favoured products than chloramines on 
phospholipids, the presence of chlorohydrins could indicate the severity of MPO-induced 
phospholipid oxidation in vivo. 
HOSCN and the MPO-H2O2-SCN
- system oxidise LDL lipids to produce conjugated dienes 
and lipid hydroperoxides in vitro [144]. The mechanism was suggested to involve reactions of 
SCN- derived radicals (OSCN•- or (SCN)2
•-) formed by MPO utilising SCN- as a peroxidase 
substrate [33, 168]. However, this is thermodynamically unfavourable and evidence has 
emerged displaying a loss of cholesterol and cholesteryl esters (linoleate and arachidonate 
species) in LDL exposed to HOSCN (100 – 750 µM) and an MPO-H2O2-SCN- system (50 – 
200 µM SCN-) [146]. In addition to lipid hydroperoxides, specific products of linoleate and 
arachidonate oxidation, that being 9-hydroxy-10,12-octadecadienoic acid (9-HODE) and F2-
isoprostanes respectively, were also generated both by HOSCN and the MPO-H2O2-SCN
- 
system [146]. This was mitigated by the addition of butylated hydroxytoluene (BHT) [146], 
consistent with a radical-mediated pathway of cholesterol modification, however this still 
warrants verification. 
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1.6.2.2. Other sources of LDL modification 
1.6.2.2.a. Transition metal ions 
Transition metal ion (Cu2+ and Fe2+)-mediated oxidation of LDL has been extensively 
utilised in experiments to contribute to our understanding of LDL oxidation in atherosclerosis. 
Esterbauer et al [302] established a method of Cu2+-mediated oxidation of LDL, to simulate 
biological responses to oxidised LDL in vitro. This method leads to extensive lipid oxidation 
through free radical generation, causing the reduction or depletion of free cholesterol, 
unsaturated fatty acid cholesterol esters and α-tocopherol, the formation of cholesterol ester 
hydroperoxides [303, 304]. This has been shown to induce several proatherogenic effects; 
including uptake by macrophages to produce foam cells leading to caspase-dependent 
apoptosis [305], promotion of ROS production in vascular smooth muscle cells [306], 
enhanced monocyte and leukocyte adhesion to endothelial cells [307, 308]; and reduced 
endothelial nitric oxide synthase (eNOS) expression and NO production in endothelial cells 
[309]. Cu2+-oxidised LDL is also known to induce activation of proinflammatory transcription 
factors in vascular cells; such as nuclear factor-kappa B (NF-κB) [306, 310, 311], activator 
protein-1 (AP-1) [312, 313], hypoxia-inducible factor-1 (HIF-1) [314] and nuclear factor of 
activated T cells (NFAT) [315, 316]. 
There is controversy as to whether the modification of LDL by Cu2+ ions could contribute 
to atherosclerosis in vivo. Wilson disease; a rare hereditary disorder causing Cu2+ ion 
accumulation in vital organs, has not been linked to atherosclerosis in the literature, and cardiac 
events linked to Wilson’s disease are rare [317]. Ceruloplasmin, which binds 95 % of Cu2+ ions 
in a healthy adult [304], has been shown to contribute to LDL modification [318]. A single 
ceruloplasmin can bind to up to seven Cu2+ ions, however the loss of just a single Cu2+ prevents 
ceruloplasmin-derived LDL modification [318]. Furthermore, LDL levels were actually 
43 | P a g e  
 
decreased and LDL oxidisability was not significantly different between Wilsons disease 
patients and the control group [319]. Therefore, the relevance of transition metal ions to LDL 
oxidation and atherosclerosis faces considerable doubt.  
Tissue homogenates from atherosclerotic plaques contain elevated amounts of transition 
metal ions [320], however the process of homogenisation itself can artificially generate 
catalytically active ions [321]. This was addressed in a study by Stadler et al, where elevated 
levels of Cu2+ and iron in advanced human carotid arterial plaque samples (both calcified and 
complex lesions) were measured by EPR and in acid-digested tissues by inductively coupled 
plasma mass spectrometry, which was also correlated to cholesterol accumulation [322]. 
However, the metal ion levels reported (approximately 0.5 nmol Fe and 0.01 nmol Cu per 1 
mg of tissue from advanced atherosclerotic lesions [322]) found in advanced lesions might be 
helpful to indicate range of concentrations seen and how this relates to conditions used to 
oxidise LDL in vitro. Pioneering investigations found epidemiological evidence demonstrating 
a correlation between iron status and atherosclerosis, particularly in males [37, 323, 324]. A 
correlation was found between serum oxidised-LDL/LDL ratio and serum ferritin (an indicator 
or iron levels), but only in males [325]. Despite this, results from a considerable number of 
clinical and animal studies examining iron overload and haemochromatosis genotype in 
atherogenesis do not support iron as an independent risk factor of atherosclerosis and CVD 
[326-332], with a possible exception to the homozygous haemochromatosis genotype H63D 
[330]. Thus, there is not enough evidence to support a role of transition metal ions in driving 
in vivo LDL oxidation during the initial stages of atherosclerosis or development of CVD. 
1.6.2.2.b. Lipoxygenase 
The lipoxygenase class proteins are (non-haem) iron-containing enzymes that catalyse the 
oxidation of polyunsaturated fatty acids [333]. Elevated lipoxygenase activity has been 
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implicated in a variety of diseases including atherosclerosis, carcinogenesis, diabetes, 
metabolic syndrome, neurodegeneration, stroke and various infectious disease (reviewed 
[334]). Of interest to LDL modification in atherosclerosis is the activity of 12- and 15-
lipoxygenase. Both Lipoxygenase-12 and -15 were observed to oxidise linoleic acid, 
arachidonic acid and the arachidonate- and linoleate-esterised cholesterol moieties of LDL to 
form hydroxy fatty acids and carbonyl derivatives which alter the electronegativity of apoB-
100 [335, 336]. The mRNA and protein of 15-lipoxygenase and its derived epitope of oxidised 
LDL has been colocalised in human atherosclerotic lesions, supporting a proatherogenic role 
of lipoxygenase-mediated lipid oxidation [337]. It should be noted that 12- and 15-
lipoxygenase are both encoded by the ALOX15 gene, the specificity of each isoform is 
determined by various single amino acid substitutions at crucial binding sites [338, 339]. 
Evidence shows that 12-lipoxygenase contributes to cholesterol accumulation and fatty acid 
oxidation in macrophages, while 15-lipoxygenase activity in endothelial cells mediates fatty 
acid oxidation in LDL [340, 341]. While this could aid in cholesterol clearance from circulation 
mediated by endothelial cells, it also led to foam cell formation in macrophages if LDL 
deposition into the vessel wall was left unchecked. One study showed that inhibiting 15-
lipoxygenase with 5,8,11,14-eicosatetraynoic acid (EYTA) in endothelial and macrophage 
cells did not inhibit LDL oxidation in vitro [342], but the LDL was incubated in Ham’s F10 
media contains transition metals at levels that can oxidise LDL [343]. The knowledge of the 
biological relevance of 12- and 15-lipoxygenase in atherosclerosis is still limited and not fully 
evaluated [334]. 
1.6.2.2.c. Glucose 
It has been proposed that hyperglycaemia in people with diabetes mellitus (DM) may 
promote metal ion-mediated glycation of LDL to yield advanced glycation end-products (AGE) 
[344, 345] and there is evidence for increased formation of AGE adducts on plasma proteins 
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(including apoB-100) from people with DM [346, 347]. However, the role for AGE-modified 
LDL in atherosclerosis is not well established. One study found that LDL isolated from DM 
patients was more susceptible to oxidation than from the control group, but LDL was not 
glycated [348]. Interestingly, α-tocopherol levels were not reduced in LDL from DM patients 
compared control groups [348], which further implicated transition metal ions were not 
involved. Intracellular cholesterol levels in macrophages, endothelial and smooth muscle cells 
were not significantly altered when treated with glucose-treated LDL, but accumulation was 
seen in macrophages treated with methylglyoxal- and glycolaldehyde-treated LDL [349], 
which react more rapidly than glucose [350]. This implies a DM-related mechanism of LDL 
modification leading to foam cell formation dependent on hyperglycaemia and inflammation, 
but the relevance of this to the elevated risk of cardiovascular morbidities in DM patients 
remains unclear.  
1.6.2.2.d. Nitrogen species 
NO derived from nitric oxide synthases (NOS), and O2
•- can react together to form a potent 
oxidant peroxynitrite (ONOO-). The high reactivity of ONOO- can potentiate nitration, 
nitrosylation and nitroxidation of biomolecules [351-353], such as nitration of Tyr residues to 
form 3-nitrotyrosine (3-nitroTyr) on apoB-100 [354]. 3-nitroTyr has also been detected in 
human atherosclerotic lesions but not in plasma, implying a role in plaque progression [354, 
355]. ONOO- can also oxidise the lipid fraction of LDL to produce lipid hydroperoxides and 
increase LDL uptake by macrophages [356-358]. Interestingly, MPO can utilise nitrite (NO2
-) 
to form inflammatory oxidants NO2
• and NO2Cl, which also nitrate Tyr residues [359]. 
Additionally, an MPO-H2O2-NO2
- system can induce LDL lipid peroxidation, which converts 
LDL into an high-uptake atherogenic form [360, 361] and produce 7α- and 7β-
hydroxycholesterol, which were cytotoxic to HUVEC [362]. 
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1.6.2.3. Prevention of LDL modification 
1.6.2.3.a.  α-tocopherol and ascorbate 
Ascorbate (Vitamin C) and α-tocopherol (Vitamin E) have been shown to prevent LDL 
cholesterol oxidation under exposure to atmospheric oxygen [363]. Ascorbate is also 
sacrificially oxidised to preserve LDL-sourced α-tocopherol levels [363], making it an 
attractive anti-atherogenic pharmacological antioxidant. Also, ascorbate can react quite rapidly 
with MPO compound I (1.1 × 106 M-1•s
-1) and compound II (1.1 × 104 M-1•s
-1) by the 
peroxidation cycle [364], which has been shown to prevent MPO-mediated consumption of 
NO [365], forming the ascorbate radical which can be recycled, while preventing hypohalous 
acid production. Alpha-tocopherol reacts with HOCl (1.3 × 103 M-1•s
-1), but supplementation 
with α-tocopherol did not prevent apoB-100 oxidation [366]. 
In addition to these in vitro studies, lipid oxidation products are detected in LDL associated 
with reduced antioxidants ascorbate and α-tocopherol in atherosclerotic lesions [367-369] 
(reviewed [370]). Based on this evidence, high interest was garnered on the efficacy of lipid-
antioxidant supplementation on the outcome of atherosclerosis. A large body of 
epidemiological evidence showed that supplementation with α-tocopherol, but not ascorbate 
was linked to significant risk reduction in adverse cardiovascular outcomes (reviewed [371]). 
Unfortunately, overall on comparison of multiple studies, supplementation with antioxidants, 
such as α-tocopherol, ascorbate, or beta-carotene did not prove successful in reducing 
atherosclerosis and CVD in clinical trials. A large study of 29 133 Finnish male smokers aged 
50 – 69 found that supplementation with α-tocopherol, β-carotene or both did not reduce 
cardiovascular mortality [372]. This was later supported by randomised, controlled and blinded 
studies, involving collaboration between the Primary Prevention Project and the Vitamin E 
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Atherosclerosis Prevention Study (VEAPS), that found no reduction in cardiovascular 
mortality with α-tocopherol within a 4-year follow-up [373, 374].  
1.6.2.3.b.  Flavonoids/Phenolic compounds 
 Other dietary antioxidants have also been trialled in preventing CVD associated 
morbidity/mortality. Hydroxyl (OH•), alkoxyl (RO•) and peroxyl (ROO•) radicals are formed 
by transition metal ions reacting with H2O2 and other peroxide compounds present on LDL, 
including lipids and α-tocopherol [375-377]. Flavonoids are effective scavengers of potent 
oxidants of OH•, RO• and ROO• radicals (reviewed [378]), as well as NO and ONOO- [379]. 
Wine-derived phenolics were more effective than α-tocopherol in inhibiting conjugated diene 
formation in LDL [376]. Similarly, isolated catechins, which are enriched in green tea, 
accumulated in LDL and protected it from oxidation in the plasma in a small study of 19 healthy 
subjects given green tea extract [380]. Therefore, flavonoids may be beneficial sacrificial 
antioxidants.  
Epidemiological evidence showed that flavonoids and corresponding phenolic compounds 
are beneficial to preventing CHD (reviewed [381]). Increasing dietary intake of catechin-rich 
green tea was correlated with reduced aortic atherosclerosis [382]. Similarly, red wine which 
is rich in flavonoids may exert the same benefit [383]. Caution is required however, given the 
previously described elevation of MPO levels in people at risk of CVD. The reason being that 
MPO can catalyse the formation of highly reactive phenolic species which can react with 
proteins [384]. MPO compound I can redox cycle phenolic compounds, which lead to phenoyl 
radical formation and severe reduction in available thiols in HL-60 cells [385]. This was also 
observed in HL-60 cells with apigenin, accompanied by elevated apoptosis and necrosis [386]. 
Therefore, flavonoids and phenolic compounds act as MPO inhibitors by diverting MPO 
activity from halogenation to peroxidation, but conversely a high presence of active 
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peroxidases may cycle the production of phenoxyl radicals which propagate oxidative stress in 
inflammatory situations, despite the flavonoid antioxidant properties. 
1.6.2.4.  MPO halogenation activity inhibitors 
1.6.2.4.a. Azide and aryl hydroxamic acids 
The prevention of MPO-mediated damage by administering MPO inhibitors may be an 
effective means of pharmacological intervention in atherosclerosis and significant effort has 
been placed on the development of agents to inhibit MPO in vivo (reviewed [33]). Cyanide is 
able to inhibit MPO in vitro [387], but along with its high toxicity, cyanide undergoes rapid 
endogenous detoxification by mitochondrial rhodanase enzymes to form SCN- [388] and 
together these considerations don’t support its therapeutic use. Two early studies demonstrated 
that two aryl hydroxamic acids, salicylhydroxamic acid (SHA) and benzohydroxamic acid 
(BHA), significantly inhibited MPO compound II formation by competing with the haem-H2O2 
binding domain with inhibition of MPO by SHA occurred at three orders of magnitude lower 
concentration than BHA [389, 390]. Further, SHA, BHA, azide and p-hydroxy benzoic acid 
hydrazide (pHBAH) inhibited oxidation of apoB-100 by the MPO-H2O2-Cl
- system in vitro, as 
assessed by the loss of Trp residues [391]. This same study showed that pHBAH most 
effectively inhibited MPO-mediated damage of LDL Trp residues compared to azide, BHA 
and SHA [391]. 4-aminobenzoic acid hydrazide (ABAH) also competes with halogenation 
substrates and irreversibly inhibit MPO [392]. These studies provide a class of compounds with 
high efficacy for inhibiting MPO, however a lack of pharmacokinetic data has hindered 
investigating their effectiveness in preventing MPO-mediated damage in vivo.  
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1.6.2.4.b.  Paracetamol 
Paracetamol is a common over-the-counter analgaesic/antipyretic drug [393] that was also 
shown to inhibit MPO halogenation activity [394]. Although not strictly an inhibitor, 
paracetamol acts as a substrate for compound I to form compound II, then reacts with 
compound II to reform the native MPO [394], allowing MPO to react with more H2O2
 to reform 
compound I. This infers that paracetamol can convert the MPO catalytic cycle into a more 
catalase-like form without halogenation activity. This was supported by studies showing 
paracetamol competes with Cl- and Br- for reactivity with compound I to reduce the 
corresponding hypohalous acid production at therapeutic concentrations [395-397]. 
Paracetamol has been shown to inhibit MPO-H2O2-nitrite-mediated damage of LDL [398] and 
partially inhibited lipid peroxidation in LDL from hypercholesterolaemic rabbits [399]. 
However, this is contraindicated by the finding that phenoxyl radicals formed by MPO catalyse 
lipid oxidation of LDL [400]. The formation of acetaminophen free radicals by MPO [394], 
which can rapidly polymerise and lose their function as an MPO substrate [401], and the 
hepatotoxicity of long-term paracetamol administration [402] likely makes paracetamol 
inefficacious in ablating MPO-mediated damage in vivo.  
1.6.2.4.c. Nitroxides 
Nitroxides (TEMPOL-derived compounds), which can oxidise to form stable nitroxide 
radical groups, have been shown to exhibit oxidant-scavenging properties in inflammation 
models in animals (reviewed [403]). More recently, TEMPOL was shown to inhibit MPO-
dependent Tyr nitration by reacting with compound I and II at favourable rates (3.5 × 105 M-
1
•s
-1 and 2.1 × 104 M-1•s
-1, respectively [404]) to promote peroxidation cycling [404, 405]. H2O2 
consumption by MPO and HOCl production by the MPO-H2O2-Cl
- system was also inhibited 
with a range of nitroxide compounds, 4-aminoTEMPO being the most potent [406]. Thus 
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nitroxide compounds may act as safe and efficacious pharmacological inhibitors of MPO, but 
the beneficial effects of nitroxides may likely be due to antioxidant activity in vivo [403], while 
inhibiting halogenation activity of MPO may be a minor pleiotropic benefit. 
 Vascular dysfunction and oxidised LDL in 
atherosclerosis 
LDL exposed to MPO and its oxidants affects the different tissues of the vasculature in 
variety of ways that promote inflammation and propagate atherosclerosis. HOCl-modified 
LDL epitopes are found in atherosclerotic lesions [281, 284], linking to multiple cellular 
disruptions. While the most characterised pathological process of atherosclerosis is the 
formation of foam cells [407, 408], endothelial dysfunction is also an important atherogenic 
process which promotes localised inflammation at the site of lesions [407]. Vascular smooth 
muscle cell (VSMC) functions are also significantly altered which can manifest in physical 
alterations such as arterial wall thickening and calcification, leading to the formation of 
complex lesions [409, 410]. These processes will be described in this section. 
1.7.1. Macrophage “foam cell” formation 
One of the earliest hallmarks of atherosclerosis is the deposition of lipids within the arterial 
wall. Macrophages are present in few numbers in normal arterial intima [411]. However, 
lipoproteins that embed in the vascular wall are prone to modification into high-uptake forms 
that are recognised by scavenger receptors, leading, and amongst other things, to the 
accumulation of lipids in these macrophages to form “foam cells” [275]. The scavenger 
receptors: class A (SR-A1 and 2), class B (SR-B1 and SR-B2, otherwise known as CD36) and 
lectin-like oxidised LDL receptor-1 (LOX-1): are the most characterised scavenger receptors 
responsible for unregulated uptake of oxidised LDL in macrophages (reviewed [412]). 
Scavenger receptor recognition of oxidised LDL leads to multiple proinflammatory signalling 
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processes, including PKC, NF-κB and MAPK activation, in turn leading to cytokine production 
[412]. The release of cytokines, such as monocyte chemoattractant protein-1 (MCP-1) and 
tumour necrosis factor-alpha (TNF-α) leads to activation and chemotaxis of circulating 
monocytes/macrophages to inflamed vessel walls, which take up oxidised LDL and apoptotic 
bodies to form foam cells [413, 414]. 
Uptake of LDL modified by HOCl in macrophages is greater than that for native LDL in 
vitro, leading to intracellular accumulation of cholesterol/cholesteryl esters [292]. MPO-
modified LDL induced caspase-dependent apoptosis in THP-1 monocytes and TNF-α 
production [415], however when differentiated to macrophages, these cells were resistant to 
apoptosis [305]. HOSCN-modified LDL did induce foam cell formation in macrophages, but 
not to the same extent as HOCl-modified LDL [146]. However, HOSCN-modified LDL 
contains significant levels of 9-HODE [146] (as a result of HOSCN-derived modification of 
cholesteryl esters present in LDL), an endogenous stimulus of peroxisome proliferator-
activated receptor gamma (PPARγ). This suggests HOSCN-modified LDL could have other 
effects on lipid metabolism as PPARγ regulates cellular lipid uptake and upregulated the 
expression of scavenger receptors on macrophages [416, 417]. Oxidised LDL-induced 
activation of PPARγ also resulted in C-C chemokine receptor type 2 (CCR2) downregulation 
to reduce response to MCP-1-mediated chemotaxis [418]. These effects are capable of 
prolonging macrophage survival and enhancing oxidised LDL uptake with the effect of 
enhancing atherogenesis. 
1.7.2. Endothelial dysfunction 
Endothelial cells regulate vascular relaxation via NO signalling. However more recently 
endothelial cells have been acknowledged as playing key regulatory roles in vascular 
inflammation. Damage to vascular endothelial cells by proinflammatory stimuli is commonly 
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termed “endothelial dysfunction.” Endothelial dysfunction refers to the reduced endothelium-
derived vasodilation and enhanced leukocyte adhesion to facilitate leukocyte infiltration into 
the arterial wall; a hallmark characteristic of atherosclerotic lesions [247]. Scavenger receptors 
SR-B1, SR-B2 and LOX-1 are expressed by endothelial cells providing a possible mode of the 
pro-atherogenic activity of oxidised LDL [419-421].  
1.7.2.1. Leukocyte adhesion cascade 
During inflammation, endothelial cells residing in inflamed regions will upregulate the 
expression of adhesion molecules (ICAM-1; intercellular adhesion molecule-1, VCAM-1; 
vascular cell adhesion molecule 1, and E-selectin) to mediate the attachment and extravasation 
of leukocytes to the damage site [422]. This process is typically simplified to a three-step 
leukocyte adhesion cascade; (1) rolling, (2) adhesion, and (3) diapedesis [423]. E-selectin binds 
to leukocytes expressing P-selectin glycoprotein ligand-1 (PSGL-1) to facilitate leukocyte 
rolling [424, 425] to extend transit time across the inflamed tissue. VCAM-1 and ICAM-1 on 
endothelial cells then bind to very late antigen-4 (VLA-4) and lymphocyte function-associated 
antigen-1 (LFA-1) on neutrophils, respectively, to both facilitate slower rolling along and 
subsequent arrest onto the endothelium, and ICAM-1 also facilitates diapedesis [426-431]. 
Thus, in inflammatory disorders like atherosclerosis, adhesion molecule expression 
sequesters MPO-rich leukocytes to the inflamed vessel, making them strong candidates in 
contributing to atherosclerosis and perpetuating vascular damage. Uptake of unmodified LDL 
by HCAEC can increase VCAM-1 and E-selectin via an LDLR-related pathway [432], but this 
only reached approximately 14 % of the magnitude of TNF-α stimulated HCAEC. Cu2+-
oxidised LDL has been shown to upregulate ICAM-1, VCAM-1 and in some cases, E-selectin 
in endothelial cells to promote adhesion of neutrophils [307, 433-435]. Cu2+-oxidised LDL also 
promotes the release of MCP-1 from endothelial cells to promote chemotaxis and adhesion of 
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monocytes [436]. One study had observed VCAM-1 mRNA expression in proximal tube 
endothelial cells was induced in response to LDL heavily modified by HOCl (400:1 molar ratio 
of HOCl to apoB-100) [437]. However, prospective changes to the expressions of ICAM-1 and 
E-selectin is currently lacking and requires investigation. HOCl-modified LDL incubated with 
endothelial cells lead to enhanced adhesion of RAW 264.7 murine macrophages in vitro, which 
was prevented by a CD36 antibody [438]. The effects of HOSCN-modified LDL in endothelial 
dysfunction has not yet been characterised. Additionally, reactive oxygen species generation, 
degranulation and adhesion to HUVEC was stimulated in neutrophils incubated with HOCl-
modified LDL, but not native LDL or Cu2+-modified LDL [439]. 
1.7.2.2. Endothelial nitric oxide synthase 
function and dysfunction 
Under physiological conditions, endothelial cells produce NO using the homodimeric eNOS 
enzyme. NO is a potent messenger molecule, which ligates to guanylyl cyclases, a lyase 
enzyme that converts guanidine monophosphate (GMP) to cyclic GMP (cGMP), activating the 
protein kinase G (PKG) signal cascade leading to the upregulation of transcription factors, 
cytosolic calcium ion efflux and smooth muscle cell relaxation, and consequently vasodilation. 
NADPH is oxidised to NADP+ in the reductase domain of eNOS to donate an electron, which 
is transported via calmodulin-regulated flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN) reduction chain to reduce ferric (Fe3+) haem to ferrous (Fe2+) haem, 
allowing oxygen binding to the haem (Figure 1.12) [440, 441]. Fe2+-haem binds to cofactor 
5,6,7,8-tetrahydrobiopterin (BH4, or alternatively THB) and L-Arg. BH4 and a zinc ion bound 
tetrahedrally to a CXXXXC motif from each eNOS monomer (referred to as a zinc-sulfur (Zn-
S) cluster) is needed to stabilise the homodimeric structure of eNOS [442, 443]. L-Arg is then 
catabolised to form NO in the oxygenase domain of the opposite monomer, releasing L-
citrulline (L-Cit) as a by-product. 
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Figure 1.11. Catalytic scheme of NO production by eNOS dimer. NADPH donates an 
electron which is shuttled through the reductase domain by FAD and FMN and reduces the 
Fe(III)-haem to Fe(II)-haem. O2 binds to haem and BH4 facilitates catalysis of L-Arg to L-Cit 
in the oxygenase domain of the opposite monomer of the eNOS dimer, liberating NO. The zinc-
sulfur cluster (Zn(CXXXXC)2) stabilises the eNOS dimer. Sources cited in the accompanying 
text. 
Endothelial dysfunction is defined by reduced NO bioavailability, leading to the promotion 
of coagulation and reduced arterial distensibility [407]. This occurs by altered function of 
eNOS switching from NO to O2
•- production, conventionally referred to as uncoupling [441, 
444]. Briefly, uncoupled eNOS is no longer stabilised by the Zn-S cluster, so cannot bind haem 
or BH4 and functions as a monomer [445]. Under these circumstances, electron transport 
through the reductase domain cannot transfer electrons to haem, but rather to O2 directly to 
form O2
•- (Figure 1.13B). O2
•- and NO can combine to produce the potent oxidant peroxynitrite 
(ONOO-) which can cause cell stress by nitration, nitrosylation and nitroxidation of 
biomolecules as well as potentiating further reducing NO bioavailability. This will manifest as 
the impairment of endothelium-mediated vessel dilation characteristic of atherosclerosis [351]. 
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Figure 1.12. Catalytic scheme of NO production by coupled eNOS and O2•- by uncoupled 
eNOS. (A) eNOS dimer as described in Figure 1.9. (B) Uncoupled eNOS exists as a monomer, 
where the electron is shuttled as in coupled eNOS, but not haem is reduced, instead the electron 
is scavenged by O2 to form O2
•-. 
Two comparable studies demonstrated that for HOCl and HOSCN exposure to purified 
HUVEC and HCAEC-derived eNOS resulted in cleavage of the eNOS dimer, oxidation of the 
Zn-S cluster and overall reduced NOx levels (indicative of NO production), all indicative of 
eNOS uncoupling [446, 447]. HOCl-modified LDL induced delocalisation of eNOS from 
caveolin-1 in HUVEC, which may leave eNOS vulnerable to uncoupling [448]. Yet, evidence 
has not been obtained for the comparative effect of HOSCN-modified LDL on in situ 
endothelial eNOS activity and expression. Recently, oxidative stress-induced S-
glutathionylation of conserved Cys residues in the reductase domain has been shown to 
“switch” eNOS activity, by compromising the reductase FAD- and FMN-binding domains to 
produce O2
•- [449]. This novel mechanism of eNOS uncoupling, its regulation and relative 
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contribution to endothelial dysfunction still needs to be elucidated. However, the specificity of 
HOSCN with Cys could have implications with this glutathionylation-dependent signalling 
mechanism. 
In rabbits fed a high cholesterol diet to produce hypercholesterolaemia, there was increased 
endothelial O2
•- production and impaired aortic endothelium-dependent vasodilation [450], 
which was attributed to receptor recognition of LDL [451]. This was later experimentally 
verified in rabbit aortic [452] and femoral artery vasorelaxation [453], which was shown to be 
impaired by oxidised LDL. In the porcine coronary artery, oxidised LDL but not native LDL 
impaired endothelium-dependent vasodilation [454]. A similar finding was also observed with 
oxidised LDL-, but not native LDL-treated porcine coronary arterioles, which exhibited 
impaired pressure gradient- and adenosine-mediated vasodilation (both endothelium-
dependent) [455], which was supported by another study, with exception of bradykinin-
induced vasodilation which was unaffected by oxidised LDL [456]. However, these studies 
utilised Cu2+- or cell-mediated LDL oxidation and no studies have been published to date 
describing the effects of MPO-modified LDL. 
1.7.2.3. Unfolded Protein Response 
The unfolded protein response (UPR) is the pathway involved in the regulation of proteins 
that are activated when newly synthesised proteins become misfolded and inactive due to 
endoplasmic reticular (ER) stress (reviewed [457]). Briefly, the role of the UPR is to inhibit 
the synthesis of proteins, repair protein folding and reverse ER stress [457] (Figure 1.14). The 
UPR has three distinct branches mediated by inositol requiring kinase-1 (IRE1), activating 
transcription protein-6 (ATF6) and RNA-activating protein kinase-like ER kinase (PERK) 
[457]. IRE1 activation leads to splicing of X-box binding protein (XBP1, also the spliced 
variant; sXBP1), ATF6 activation leads to proteolytic cleavage and translocation to the nucleus 
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and PERK activation leads to eukaryotic translation initiation factor 2 alpha subunit (eIF2α) 
phosphorylation; these pathways lead to ER-associated protein degradation and induction of 
protein folding chaperones [457]. Hence, either the endoplasmic reticulum gets repaired and 
the cell is rescued, or apoptosis is activated through activation of C/EBP homologous protein 
(CHOP) through the PERK and/or ATF6 pathway [458]. 
There is increasing evidence that the accumulation of unfolded proteins is not required for 
UPR activation [459-461]. This included the induction of UPR by a number of endogenous 
upstream sources, such as free fatty acids, glucose, homocysteine, angiotensin II and modified 
LDL (reviewed [462]). Endothelial cells exposed to Cu2+-oxidised LDL activated all three 
branches of the UPR and induced CHOP and sXBP1 expression, resulting in apoptosis in 
human microvascular endothelial cells [463, 464]. OxPAPC (a constituent of oxidised 
phospholipids similar to oxidised LDL) induced the expression of inflammatory markers such 
as MCP-1, IL-6 and IL-8, which was ablated by genetic silencing of ATF4 and XBP1, 
indicating that UPR is a regulatory mediator of endothelial inflammation [465]. Whether LDL 
modified by MPO-derived oxidants induces the UPR in endothelial cells has not been 
previously demonstrated.
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Figure 1.13. Three branches of the UPR. Scheme summarises the downstream activation of 
UPR pathways as described in Section 1.7.2.1. Sources cited in the main text. 
1.7.3. Vascular smooth muscle cells 
Vascular smooth muscle cells (VSMC) are the effectors of arterial relaxation via both 
endothelium-dependent and independent mechanisms. The dysfunction of smooth muscle cell 
relaxation is the cause of high blood pressure linked to atherosclerosis and CVD through 
several pathways including the renin-angiotensin-aldosterone system, proliferation and 
calcification at lesion sites [4]. These pathways have also shown to be caused by oxidised LDL 
in vitro (reviewed [466]). Cu2+-oxidised LDL induced NF-κB [311] and AP-1 [313] activation 
in VSMC, thus promoting pro-inflammatory response to oxidised LDL. Additionally, oxidised 
LDL also induced phosphoinositide 3-kinase (PI3K)/epithelial growth factor receptor (EGFR)-
mediated proliferation in VSMC [467]; a response which is associated with SMC hypertrophy 
in atherosclerotic lesions [409]. The response of smooth muscle cells to atherogenic stimuli is 
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complex and displays both pro- and anti-atherogenic properties, which is attributed to the 
phenotypic plasticity of vascular smooth muscle cells described below.  
1.7.3.1. Vascular smooth muscle cell phenotypes 
With regard to phenotype, VSMC are highly plastic cells. During angiogenesis (new blood 
vessel formation from pre-existing vessels) and vasculogenesis (construction of new blood 
vessels where there are no pre-existing vessels), VSMC are highly migratory and proliferative, 
and rapidly synthesise ECM components including collagen, elastin and proteoglycans [468]. 
This stage is also crucial for the development of gap junctions with endothelial cells [469], 
such as through connexins which are necessary for NO signalling [470]. Contrastingly, 
migration, proliferation and ECM deposition are slow in established VSMC, signifying their 
function is solely towards vessel contractility, often termed the “contractile phenotype” [468]. 
In the event of vascular injury and the resultant inflammation, VSMC can significantly alter 
their phenotype to aid in vascular repair, termed “synthetic phenotype” [468].  
It is beyond doubt that residing VSMC at the sites of vascular injury aid in the repair of the 
vasculature by altering their phenotype to a highly replicative, migratory and synthetic state 
[468]. SMC differentiation has strong implications for the development of atherosclerosis. 
SMC are responsive to inflammatory stimulation and promote inflammation (reviewed [471]). 
Given that VSMC hyperplasia caused by proliferation and migration is a characteristic of 
atherosclerotic lesions [4], often termed “remodelling”, VSMC phenotypic changes could be 
integral to vascular repair and be key to monitoring plaque progression and possibly plaque 
(in)stability. Although referred to as two distinct synthetic and contractile phenotypes, in reality 
the SMC phenotype will be expressed as a spectrum within the two. 
Some studies have shown a causal role of oxidised LDL in the (de)differentiation of VSMC 
in vitro. One study found that VSMC subpopulations responded differently to Cu2+-oxidised 
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LDL, showing that the “spindle-like” cells had increased liposomal protease activity and 
accumulated lipids from oxidised LDL, which was not the case with “epithelioid-like” cells, 
thus indicating phenotypic modulation of SMC in response to oxidised LDL [472]. Cu2+-
oxidised LDL also promoted the proliferation and migration of human coronary artery SMC 
by upregulation of OPN and released matrix metalloprotein-9 (MMP-9) [473], which is also 
known to promote pro-inflammatory NF-κB and ERK1/2 signalling [474]. Further, oxidised 
LDL prevented bone marrow-derived SM progenitor cells from differentiation to VSMC by 
PDGF, shown by reduced gene expression of α-smooth muscle actin (α-SMA) and myocardin, 
whilst increasing LOX-1 expression, lipid uptake and accumulation [475]. This supports a role 
for oxidised LDL as a pro-atherogenic stimulus for SMC differentiation. However, the 
contribution of LDL modified by MPO-derived oxidants in SMC differentiation has not been 
previously reported. 
 Project Outline 
Although MPO plays a critical role in the innate immune response to combat pathogens, its 
misplaced activation and inappropriate generation of oxidants in the vasculature is strongly 
linked with the development of atherosclerosis. Abundant evidence supports the role of MPO 
and MPO-derived HOCl in the proatherogenic modification of LDL [53, 476]. HOSCN is also 
a major product of MPO, yet its role in LDL modification in atherosclerosis is largely 
unexplored. The reaction of HOSCN and the MPO-H2O2-SCN
- system, with LDL modification 
is of particular relevance to smokers, whom simultaneously exhibit elevated circulating MPO 
levels [296], SCN- levels [42, 43], LDL levels [477], and have a greater risk of cardiovascular 
complications [13, 478] compared to equivalent non-smokers. 
Whereas the role of MPO-modified LDL in macrophage “foam cell” formation has been 
characterised previously [146, 284, 292], considerably less is known on the effects of MPO-
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modified LDL on endothelial cells and smooth muscle cells. Similarly, no information is 
available on LDL modified by HOSCN or the MPO-H2O2-SCN
- system in inducing endothelial 
dysfunction or smooth muscle cell differentiation. The objective of this project therefore is to 
characterise the physiological effects LDL modified by the MPO-derived oxidants HOCl and 
HOSCN on endothelial and vascular smooth muscle cells. This is intended to gain a better 
understanding of the role of SCN- in the development of atherosclerosis. 
 Hypothesis 
 That LDL modified by MPO-derived oxidants, HOCl and HOSCN, induces vascular cell 
dysfunction, which will exacerbate inflammation and accelerate inflammatory atherogenesis. 
 Aims 
The specific project aims are to: 
1. Characterise the ability of HOSCN to induce structural modifications to the apoB-
100 component of LDL. 
2. Determine the cellular uptake of MPO oxidant-modified LDL associated lipids and 
investigate the effects on inflammatory pathway expression in human endothelial 
cells. 
3. Examine whether each MPO oxidant-modified LDL induces eNOS-dependent 
endothelial dysfunction in HCAEC in vitro and in rat aortic ring segments ex vivo. 
4. To determine the extent of uptake and cellular reactivity of MPO oxidant-modified 
LDL with vascular smooth muscle cells.
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 Materials and Reagents 
All Chemicals were of analytical or higher grade and were purchased from Sigma-Aldrich 
(Missouri, USA) unless stated otherwise. All aqueous reagents were prepared with nanopure 
water from a four stage-filtered Milli-Q water system. Phosphate-Buffered Saline (PBS; 
Amresco; Solon, Ohio) for incubating low-density lipoprotein (LDL; refer to Section 2.3) was 
treated with Chelex-100 resin (Bio-Rad; Hercules, California) for at least 2 h to remove metal 
ions, filtered to remove the chelex resin, and then adjusted to pH 7.4 with HCl.  
 Generation of myeloperoxidase-derived oxidants 
2.2.1. HOCl quantification 
HOCl was prepared by diluting a NaOCl stock solution (original concentration of 12.5 % 
w/v; BDH; Poole, Dorset) with chelated PBS. The concentration of the stock NaOCl was 
quantified by measuring the absorbance of the stock at pH 11 at 292 nm (ε = 350 M-1∙cm-1) 
[479]. Stock NaOCl was diluted with chelex-treated PBS immediately prior to use. 
2.2.2. HOSCN generation and quantification 
HOSCN was produced enzymatically using bovine milk lactoperoxidase (LPO; 
Calbiochem; San Diego, California) [64, 480]. Briefly, LPO (1.5 – 2 μM) was incubated with 
7.5 mM NaSCN in 10 mM potassium phosphate buffer (pH 6.6) and 3.75 μM H2O2 was added 
in five aliquots, 1 minute apart, with a total incubation time of 15 min on ice. Catalase (from 
bovine liver; 10 µg) was then added to the solution to quench unreacted H2O2 and the 
preparation was incubated for a further 5 min on ice. The preparation was then filtered through 
a 10 kDa molecular mass cut-off filter (Pall Life Sciences, New York, New York) for 5 min at 
10 000 g at 4 °C to remove the LPO and catalase. 
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HOSCN was quantified by 5-thio-2-nitrobenzoic acid (TNB) assay [481]. Briefly, Stock 
TNB solution was freshly prepared by alkaline hydrolysis of 2 – 2.4 mg DTNB (5,5-dithio-bis-
(nitrobenzoic acid)) in 50 mM NaOH. The TNB reagent was then made up by 1:50 dilution of 
the DTNB stock in chelex-treated 0.1 M sodium phosphate buffer (pH 7.4). Five µL of HOSCN 
was added to 995 µL of TNB reagent in triplicate and the concentration was determined using 
the specific molar absorption coefficient of TNB at 412 nm (ε = 14150 M-1• cm-1) [481]. The 
stock HOSCN was then diluted with chelex-treated PBS before incubating with LDL. 
 Isolation and oxidation of LDL from plasma 
Human blood was taken by a qualified phlebotomist with the donor’s consent and under 
ethics approval (Sydney Local Health District, protocol X12-0375) in accordance with the 
Declaration of Helsinki, 2000 of the World Medical Association. The collected blood was 
stored in tubes containing 0.01 mM EDTA (Astral Scientific; Taren Point, NSW), a 1:200 
dilution of stock aprotinin from bovine lung (3 – 7 trypsin inhibitor unit/mg protein), 0.04 µM 
PPACK (a potent, irreversible thrombin inhibitor) and 20 µg•mL
-1 soybean trypsin inhibitor. 
The plasma was then isolated from whole blood by centrifugation at 3 000 g for 20 min at 10 
°C. If blood cells were still visible in the plasma, the plasma was replaced into clean tubes and 
centrifuged again. The plasma was isolated and the density adjusted to 1.24 kg•L
-1 by adding 
0.3816 g of KBr per 1 mL of plasma. Density solutions (1.0247, 1.0538, 1.063 and 1.085 kg•L
-
1) were freshly made by combining different volumes of two stock density solutions (1.006 and 
1.346 kg•L
-1) as described in Table 2.1. The final densities were checked gravimetrically and 
adjusted as appropriate, then degassed under nitrogen. Centrifuged tubes (39.2 mL, Quick-
Seal®, 25 × 89 mm polypropylene tubes; Beckman-Coulter, Los Angeles, California) were 
prepared with 9 mL of each density solution and underlaid with the plasma added in increasing 
order of density. LDL (ρ 1.019 – 1.050 kg•L-1) was isolated using density gradient 
ultracentrifugation (Optima™ XPN from Beckman-Coulter) using a VTi50 rotor (Beckman, 
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Palo Alto, California) for 2.5 h at 206 000 g at 10 °C [349, 482]. The LDL was then dispensed 
into new centrifuge tubes, mixed with 1.063 kg•L
-1 density solution and separated from other 
lipoproteins that may be present in the isolate by a second ultracentrifugation using a Ti70 rotor 
(Beckman) at 184 000 g for 20 h at 10 °C. The LDL was then removed from the centrifuge 
tubes and dialysed four times for at least 2 h each dialysis in PBS with 1 g•L
-1 EDTA and 0.1 
mg•L
-1 chloramphenicol to remove the KBr. The LDL was sterilised through a 0.45 µm filter 
(Pall Life Sciences) under aseptic conditions and the protein content was measured by 
bicinchoninic acid (BCA) assay as described in Section 2.5. The LDL was stored in the dark at 
4 °C and used within 4 weeks. 
Table 2.1. Making density solutions for density gradient ultracentrifugation of LDL from 
plasma. Solution A and Solution B are stock density solutions of 1.346 and 1.006 kg•L
-1, 
respectively. 
 
 
 
 
 
 
 
 
2.3.1. LDL oxidation 
Before oxidation, LDL was desalted through a PD-10 column (GE Healthcare; Barrington, 
Illinois) to remove the chloramphenicol and EDTA. Apolipoprotein-B100 (apoB-100) 
concentration was determined using the BCA assay with absorbance read at 562 nm, as detailed 
in Section 2.5. LDL was diluted in chelated PBS to a concentration of 1.0 mg•mL
-1 apoB-100 
 Volume (mL) 
ρ (kg•L-1) Solution A Solution B 
1.0247 5 85.9 
1.0538 12.5 76.37 
1.063 10 46.2 
1.085 20 66 
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(equal to approximately 2 µM apoB-100) prior to incubation with 100 or 250 μM HOSCN or 
HOCl (equivalent to a 50:1 and 125:1 molar ratio of oxidant: LDL), prepared as described in 
Section 2.2, at 37 °C and 5 % CO2 for 24 h, with a control LDL sample incubated under the 
same conditions without oxidant (control LDL). After incubation, LDL samples were purified 
through an Amicon (Merck-Millipore; Darmstadt, Hesse) 10 kDa exclusion spin column 
following the manufacturer’s protocol and the protein concentration was remeasured by BCA 
assay to account for any loss of LDL during the purification step, prior to characterisation or 
addition to cells as described in Section 2.4 and 2.6, respectively. 
  Characterisation of LDL oxidation 
2.4.1. ApoB-100 aggregation and fragmentation 
assessed by SDS-PAGE 
The extent of LDL oxidation induced by varying concentrations of HOSCN (0-250 µM) and 
HOCl (0-250 µM) added to LDL (1.0 mg•mL
-1) for 24 h was analysed by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a NuPAGE 3-8 % w/v Tris-
acetate gel, according to the manufacturer’s instructions (Life Technologies; Camarillo, 
California). Briefly, samples were prepared by adding 2.5 µL of NuPAGE lithium dodecyl 
sulfate (LDS) buffer and 7.5 µL of nanopure water (or 1 µL of 500 mM DTT in 6.5 µL 
nanopure water for reduced samples) to a final LDL concentration of 10-20 µg in 20 µL. 
Samples were left to rest at 21 °C for 30 min before 20 µL of each sample was loaded into a 
SDS-PAGE gel well. A HiMark 40 – 500 kDa unstained molecular weight ladder (Life 
Technologies) was run at the same time. Electrophoresis was performed using an Invitrogen 
XCell SureLock Electrophoresis cell, containing 1X NuPAGE tris-acetate SDS running buffer 
with running conditions of 80 V for 5 min followed by 120 V for 1.5 h. Gels were stained with 
Coomassie Brilliant Blue (0.1 % w/v Brilliant Blue G, 40 % v/v ethanol and 10 % v/v acetic 
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acid) for at least 2 h, then placed in a destain solution (25 % v/v methanol and 10 % v/v acetic 
acid in nanopure water) under gentle agitation until the gels were adequately destained to allow 
protein band visualisation. Images of SDS-PAGE gels were then scanned and imaged with 
SilverFast software (Sarasota, Florida). 
2.4.1.1. Silver Stain method 
The apoB-100 was separated through SDS-PAGE as described in Section 2.4.1. The gels 
were submerged in a solution of 50 % methanol and 10 % acetic acid (v/v) for 30 min, then in 
5 % (v/v) methanol for 15 min. The gels were then washed three times in deionised water for 
5 min each, before incubating with freshly prepared 0.2 g•L
-1 sodium thiosulfate solution. 
Excess sodium thiosulfate was washed out for 2 min with deionised, then incubated with 2 g•L
-
1 silver nitrate for 25 min. Excess silver nitrate was washed out for 5 min with deionised water. 
A development solution of 30 g•L
-1 sodium carbonate, 4 mg•L
-1 sodium thiosulfate and 37 % 
(v/v) formaldehyde was then added until appropriate colour development (1 – 2 min). 14 g•L-1 
EDTA was added and incubated for 10 min to chelate the silver to stop colour development. 
The gels were then scanned and imaged using SilverFast software. 
2.4.2. Electrophoretic mobility of LDL through 
agarose gel 
The change in electric charge of LDL was assessed empirically by agarose gel 
electrophoresis and measuring the migration across the gel relative to that of control LDL (i.e. 
relative electrophoretic mobility; REM). Ten µg of LDL, HOSCN-modified LDL or HOCl-
modified LDL were added in 5 separate aliquots to wells in a pre-cast 1 % w/v agarose gels 
(Helena Laboratories, Mt Waverley, Victoria). The agarose gels were fitted to Ciba Corning 
gel apparatus containing barbitone buffer (100 mM sodium barbitone, 27 mM barbituric acid 
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and 12.6 mM EDTA; pH 8.6) at 90 V per gel for 45 min [350]. The REM was measured as the 
distance migrated by the modified LDL relative to the control LDL.  
2.4.3. De novo sequencing of apoB-100 fragments 
by HOSCN-induced oxidation by HOSCN using 
mass spectrometry 
After incubation of LDL with 250 µM HOSCN for 24 h, HOSCN-modified LDL was run 
through all lanes of a 3-8 % Tris-acetate gel by SDS-PAGE separation, followed up with 
Coomassie staining and destaining, as described in Section 2.4.1. The subsequent methods for 
analysing apoB-100 fragmentation by HOSCN described in this section is schematically 
depicted in Figure 2.1. 
2.4.3.1. Trypsin in-gel digestion 
The peptide band detected at ~ 97 kDa according to the molecular weight ladder from all 
sample lanes was pooled together, excised from the gel, diced into approximately 1 mm3 pieces 
with a sterile scalpel blade on a glass plate and cleaned with 70 % v/v ethanol. Gel pieces were 
then transferred to a 2 mL Eppendorf tubes and destained at least three times with 200 µL of 
50 % v/v acetonitrile/ 50 % v/v 100 mM ammonium bicarbonate for 10 min each. After the last 
destain, the liquid was removed and the gel pieces dehydrated with 200 µL of 100 % 
acetonitrile for 10 min. This was repeated until gel pieces were shrunken and opaque. Cysteines 
in the peptide were reduced and alkylated to prevent artefactual modification with 5 mM 
tributylphosphine and 20 mM acrylamide in 100 mM ammonium bicarbonate for 90 min at 21 
°C. The liquid was removed and the gel pieces were washed with 100 mM ammonium 
bicarbonate for 5 min, then three times with 50 % v/v acetonitrile/ 50 % ammonium bicarbonate 
for 5 min each. The gel pieces were then dehydrated again with 100 % acetonitrile. Acetonitrile 
was removed, then a 1:80 dilution of 1 µg•mL
-1 mass spectrometry-grade trypsin (Promega; 
69 | P a g e  
 
Fitchburg, Wisconsin) in 100 mM ammonium bicarbonate was incubated with the gel at 4 °C 
for 30 min for infiltration of trypsin through the gel before trypsin auto-digestion. The gel 
pieces were then topped up with 100 mM ammonium bicarbonate and digested overnight at 37 
°C. The tubes were then sonicated for 10 min, centrifuged briefly and the liquid transferred to 
a clean 0.65 mL Eppendorf tube. A solution of 50 % v/v acetonitrile and 2 % v/v formic acid 
was added to the gels, after which the samples were vortexed and sonicated again for 10 min 
to extract more peptide digests from the gel. This supernatant was then added to the initial 
digest solution. The volume of peptide solution was concentrated, under vacuum, to 
approximately 15 µL using a Speedvac Concentrator (John Morris Scientific; Sydney, NSW), 
and the concentrate was transferred to an autosampler vial and immediately analysed by LC-
MS/MS, or otherwise stored at -20 °C. 
2.4.3.2. Reductive dimethylation tagging of 
primary amines 
Reductive dimethylation was performed to tag N-terminal primary amines to identify 
cleavage sites of HOSCN-induced apoB-100 fragmentation [483]. Experimental conditions 
and procedures were performed as described in Section 2.4.3.1. However, following the 
reduction and alkylation step, the gel pieces were dried with 100 % acetonitrile, then incubated 
with 40 mM formaldehyde and 20 mM of freshly prepared cyanoborohydride in water for 1 h 
at 37 °C. Excess solution was then removed and 100 mM ammonium bicarbonate was added 
for 5 min to quench the remaining formaldehyde. The ammonium bicarbonate was then 
removed and the gel pieces were desiccated with 100 % acetonitrile for 5 min. Once dry, trypsin 
digestion, sample recovery and sample concentration was performed as described in Section 
2.4.3.1. 
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Figure 2.1. Schematic for preparation of HOSCN-modified LDL samples for LC-MS/MS peptide sequencing and N-terminal 
dimethylation analysis. Blue arrows indicate pathway for peptide sequencing analysis. Red arrows indicate additional steps for N-terminal 
dimethylation using 20 mM cyanoborohydride (NaBH3CN) and 40 mM formaldehyde (CH3C(O)H). CH3CN; acetonitrile, NH4HCO3; ammonium 
bicarbonate, TBP; tributylphosphine.
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2.4.3.3. LC-MS/MS 
Ten µL of sample was loaded at 20 µL•min
-1 with MS loading solvent (2 % v/v acetonitrile 
and 0.2 % v/v trifluoroacetic acid) onto a C8 trap column (Michrom Biosciences, Auburn, 
California) using an Eksigent AS-1 autosampler connected to a Tempo nanoLC system 
(Eksigent, Dublin, California). The traps were washed for 3 min before the peptides were 
washed off the trap at 300 nL•min
-1 onto a PicoFrit column (75 µm × 100 mm) containing 
Magic C18AQ resin (Michrom Biosciences). The peptides were then eluted into the QSTAR 
Elite hybrid quadrupole-time-of-flight mass spectrometer (Applied Biosystems, Foster City, 
California). MS solvent A (2 % v/v acetonitrile and 0.2 % v/v formic acid) and MS buffer B 
(98 % v/v acetonitrile and 0.2 % v/v formic acid) were used for the elution gradient of each 
sample as described in Table 2.1. The eluting peptides were ionised with a 75 µm ID emitter 
that tapered to 15 µm at 2300 V. An Intelligent Data Acquisition (IDA) analysis was performed, 
with a mass range of 375 – 1500 Da continuously scanned for peptides of charge state 2+ - 5+ 
with an intensity of more than 30 s-1. The detected peptides were fragmented and the ion 
products masses were measured over a mass range of 100 – 1500 Da. The precursor peptide 
masses were then excluded for 15 s. 
Table 2.2. Elution gradient for the peptide sequencing analysis of HOSCN-modified LDL 
fragment. 
Time (min) MS solvent A (%) MS solvent B (%) 
0 95 5 
8 50 50 
13 20 80 
15 20 80 
18 95 5 
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2.4.3.4. Data analysis 
MS/MS data files were searched with the Mascot Daemon program through the LudwigNR 
database (consisting of the UniProt, plasmoDB and Ensembl databases; vQ111. 16,818,973 
sequences; 5,891,363,821 residues). The following settings were applied; 
• Fixed modification: none.  
• Variable modifications: deamidated, propionamide, oxidised methionine.  
• Enzyme: semi-trypsin.  
• Number of allowed missed cleavages: 3.  
• Peptide mass tolerance: ± 100 ppm.  
• Fragment mass tolerance: ± 0.2 Da.  
• Charge state: 2+ and 3+.  
The results of the database search were only included if protein hits with at least one unique 
peptide were detected. Peptide hits with p-value > 0.05 were excluded.  
2.4.3.5.  Inhibition of HOSCN-induced cleavage 
of apoB-100 with BHT and desferrioxamine 
To determine a possible chemical mechanism for HOSCN-induced cleavage of apoB-100, 
LDL was incubated with 250 µM HOSCN as described in section 2.3.1 in the absence or 
presence of 200 µM butylated hydroxytoluene (BHT) or 50 µM desferrioxamine (DFO). BHT 
is an effective scavenger of chemical radicals [484] and can prevent peptide cleavage by 
HOSCN if it is free radical mediated. DFO is a high-affinity free iron chelator [485] which was 
added to chelate any haem-derived iron released from LPO during HOSCN-synthesis (as 
described in Section 2.2.2). As millimolar levels of HOSCN were being generated by LPO in 
this system, it was a concern that this could potentially cause iron release similar to that 
reported for HOCl [486]. Such iron cannot be filtered out by a 10 kDa cut-off and if present in 
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the sample could lead to oxidation of the peptide backbone and amino acid side chains [487]. 
After incubation, the samples were processed and analysed as described in Section 2.4.1. The 
band densitometry was analysed using ImageJ software (National Institute of Health open-
sourced software). 
 Determination of protein concentration by 
bicinchoninic acid assay 
Protein concentration was determined using the bicinchoninic acid (BCA) assay which 
relies upon protein-mediated stoichiometric conversion of Cu+ into Cu2+ ions [488]. Diluted 
samples were compared to a bovine serum albumin (BSA) standard ranging from 0.1 – 1 
mg•mL
-1 in a 96 well tissue culture plate (Corning, New York, New York). The BCA reagent 
(1 % w/v sodium bicinchoninate, 2 % w/v sodium carbonate, 0.16 % w/v sodium tartrate, 0.4 
% w/v sodium hydroxide and 0.95 % w/v sodium bicarbonate) and 4 % w/v cupric sulfate 
solution at a 50:1 ratio. 200 µL of working reagent was transferred to standards and samples, 
then the plate was incubated at 60 °C for at least 30 min. The absorbance was measured using 
a plate reader (Sunrise Tecan; Mannedorf, Zurich) at 562 nm and the protein concentration of 
each sample was determined from the BSA standard curve. 
 Cell culture 
Human coronary artery endothelial cells (HCAEC) and Human coronary artery smooth 
muscle cells (HCASMC) were grown in MesoEndo Endothelial Cell Growth Media (Cell 
Applications; San Diego, California) or Smooth Muscle Growth Media-2 (Lonza; Basel, Basel) 
respectively; and used from passages 4-6. To prepare suspensions of cells, HCAEC and 
HCASMC were dissociated with 0.1 % w/v trypsin-EDTA for 1 min at 37 °C and 5 % CO2 and 
then trypsin was deactivated with growth media. Cells were pelleted by centrifuge for 5 min at 
~232 g, aspirated, resuspended in their respective growth media and a small aliquot of cells 
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was counted with a haemocytometer. HCAEC (0.5 × 105 cells•mL
-1) and HCASMC (1.0 × 105 
cells•mL
-1) were seeded overnight in their respective growth media. Culture plate wells were 
then washed twice with PBS before incubation with the different LDL conditions at a 
concentration of 0.1 mg•mL
-1 apoB-100 protein in sterile-filtered serum-free defined medium 
(Cell Applications) supplemented with 5 % v/v foetal bovine serum (FBS) as treatment medium 
for HCAEC, or basal medium supplemented with 5 % FBS and insulin as treatment medium 
for HCASMC. At least 3 independent HCAEC and HCASMC donors were used for all 
experiments. 
  Cell viability and activity determination 
HCAEC and HCASMC were plated in 12-well plates overnight prior to incubation with 
LDL, HOSCN-modified LDL or HOCl-modified LDL for 24 h in triplicate. The supernatant 
was then removed and the cells were washed twice with heat-treated PBS. The cells were lysed 
with 0.1 % v/v Triton X-100. Cell viability was determined by the lactate dehydrogenase 
(LDH) kinetic assay. 10 µL of each lysate and supernatant was added separately (after 
centrifuging at 353 g to pellet cell debris) to a 200 µL LDH assay solution of 2.5 mM sodium 
pyruvate and 0.15 mg•mL
-1 of reduced nicotinamide adenine dinucleotide (NADH) 
respectively, in triplicate before recording the change in absorbance at 340 nm (ΔA340). Ten µL 
of 0.1 % v/v Triton X-100 or cell media in 200 µL of LDH assay solution were used as blanks 
for the lysate activity and supernatant activity, respectively. Non-viable cells leak LDH into 
the cell media [489], hence the viability was calculated by comparing the intracellular (lysate) 
and extracellular (supernatant) LDH activity by measuring the loss of NADH every 5 min over 
7 cycles and read with a Tecan Sunrise plate reader. Cell viability was calculated as a fraction 
of intracellular activity over total activity (i.e. % viability = 100 × ΔA340 [intracellular activity]/ 
ΔA340 [intracellular + extracellular activity]). 
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Metabolic activity measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. HCAEC and HCASMC were plated in 96-well plates and treated under 
identical conditions as described in Section 2.6. The cells were then washed twice with heat-
treated PBS before 10 µL of MTT (Biotium; Fremont, California), reconstituted in 110 µL of 
treatment media, was added to the wells and the cells were re-incubated for 4 h at 37 °C and 5 
% CO2 in the dark. The media was then removed and cells washed twice with heat-treated PBS 
before dissolving the insoluble formazan (formed from the metabolism of MTT by 
mitochondrial oxidoreductase) in dimethyl sulfoxide (DMSO). The absorbance of the product 
was then measured at 570 nm with a reference set at 630 nm. Activity within treated cells was 
expressed as a percentage of the activity present in control cells. 
 Assessment of endothelial migration rate by 
scratch assay 
HCAEC were seeded on a 12-well plate as described in Section 2.6. After allowing the cells 
to adhere for 6 h, a vertical and horizontal scratch was made on the wells with a p200 pipette 
tip, the debris was washed out with PBS and the cells were treated with control LDL, HOSCN- 
or HOCl-modified LDL for up to 24 h. Images were taken at the intersection of the vertical and 
horizontal scratch and the scratch width was measured at the start of treatment (0 h) and at 
intervals up to 24 h treatment. The cellular migration rate was measured as half the speed of 
scratch closure rate, as the cells migrate from two sides, doubling the apparent migration rate. 
 Quantification of LDL-sourced lipid uptake in 
endothelial and smooth muscle cells measured by 
high-performance liquid chromatography (HPLC) 
The cellular composition of cholesterol and specific cholesteryl esters (arachidonate, 
docosahexanoate, linoleate, oleate, palmitate and stearate) was quantified after treatment with 
LDL as described in Section 2.6. After treatment for 24 or 48 h, cells were washed and lysed 
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in 1 mL of deionised water, scraped and transferred to glass vials containing 10 µL of 200 mM 
EDTA and 10 µL of butylated hydroxytoluene (BHT; in ethanol). The cholesterol and 
cholesterol esters were then separated from apoB-100 by liquid-liquid extraction with 2.5 mL 
methanol and 5 mL hexane. Each tube was vortexed vigorously and stored at -80 °C. Samples 
were not stored longer than 4 weeks. Before quantification, the tubes were vortexed again, 
allowed to fractionate and 4 mL of the hexane (organic) layer was individually transferred to 
clean glass tubes. The hexane was completely evaporated in a Speedvac Concentrator for 1 h, 
then the lipid pellet was reconstituted in 200 µL of HPLC mobile phase buffer (HPLC-grade 
70 % v/v isopropanol and 30 % v/v acetonitrile; solvent; Merck-Millipore) [490]. 
Cholesterol and cholesteryl ester standards were used for quantification. One hundred and 
fifty µL of standard and samples were transferred to individual HPLC vials with inserts for 
HPLC analysis. Response factors for the cholesterol and cholesteryl esters were formulated to 
quantify the amounts of cholesterol and cholesteryl esters in each sample against the standards. 
The samples were run through a Supelco Supercosil LC-18, 25 cm × 4.6 mm × 5 µm HPLC 
column in a Shimadzu LC-10AT liquid chromatograph system (Kyoto, Japan). The flow rate 
was set at 1 mL•min
-1 at 25 °C and the constituents were detected by UV absorption at 205 nm 
(Figure 2.2) [349]. 
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Figure 2.2. Representative HPLC trace of retention peaks of cholesterol and cholesteryl 
esters. Representative HPLC trace from 10 µL of 1.0 mg•mL
-1 LDL. Cholesterol and each 
cholesteryl ester species can be sufficiently eluted apart for independent or total lipid 
quantification. 
2.9.1. Lysosomal activity in cells assessed by 
cysteine-dependent cathepsin enzyme activity  
The cysteine-dependent cathepsins (cathepsin B and L enzymes) are known to aid in the 
digestion of proteins in the lysosome from endocytosed proteins and particles, including LDL 
[491, 492]. Cells were scraped and lysed in PBS and the suspension was centrifuged at 376 g 
for 5 min at 21 °C to pellet cell debris. Each lysate supernatant was transferred to a clean tube 
and 25 µL of lysate were added to wells of a 96-well plate. Cathepsin B buffer (100 mM 
potassium phosphate, 2.5 mM EDTA and 0.005 % v/v Brij35, pH 5.5) or cathepsin L buffer 
(100 mM monobasic potassium phosphate, 2.5 mM EDTA and 0.005 % v/v Brij35, pH 6) was 
added to sample wells at 180 µL with the respective fluorescent substrates; 10 µM Z-Arg-Arg-
AMC hydrochloride for cathepsin B assay or 10 µM Z-Phe-Arg-AMC hydrochloride for 
cathepsin L assay (Bachem, Bulbendorf, Switzerland). Cathepsin activity was determined by 
measuring the fluorescence of the liberated AMC species over 40 min at 1 min intervals using 
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a SpectraMax M2 fluorescent plate reader (Molecular Devices, Sunnyvale, California) at λex 
360 nm and λem 460 nm. The cathepsin enzyme kinetics was measured in the linear phase of 
enzyme activity. 
 RNA isolation and PCR 
HCAEC and HCASMC were plated in 12-well plates overnight prior to the addition of LDL 
or modified LDL (0.1 mg•mL
-1) and further incubated for 3 or 24 hours. Each well was washed 
twice with warm PBS before being lysed using 250 µL of BL lysis buffer with thioglycerol 
(Promega). The lysates were processed and analysed immediately or following storage at -80 
°C. RNA extraction was performed using the Promega Reliaprep RNA Miniprep Kit (which 
supplied all the wash solutions and DNase 1 enzyme) as prescribed by the manufacturer with 
some alterations, as described below. 
2.10.1. RNA isolation 
Eighty-five µL of isopropanol was added to fresh or thawed lysates and mixed thoroughly 
by repeated up-and-down pipetting. Samples were then transferred to spin cartridges supplied 
with the kit and centrifuged at 14 000 g for 30 s. Samples were washed once with 500 µL of 
RNA wash buffer and centrifuged at 14 000 g for 30 s before incubating with 30 µL of DNase 
solution (24 µL Yellow Core buffer + 3 µL 0.09 M MnCl2 + 3 µL DNase I) for 45 min at room 
temperature. Samples were then washed with the 200 µL column wash buffer and centrifuged 
at 14 000 g for 30 s. The cartridge was washed with 500 µL of RNA wash buffer and 
centrifuged at 14 000 g for 30 s before washing again with 300 µL of RNA wash buffer and 
centrifuging at max speed for 2 min to dry the cartridge. Twenty-two µL of RNase-free water 
was added to the dry spin cartridge and centrifuged at 14 000 g for 1 min to extract the RNA 
into individual microcentrifuge tubes. The concentration of RNA obtained was then measured 
using a Nanodrop 2000C spectrophotometer (Thermo Scientific; Waltham, Massachusetts) to 
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measure RNA concentration. The concentration of RNA was normalised to 5 – 10 µg/mL of 
RNA per sample. Reverse transcription of total cellular RNA was performed using a iScript 
cDNA synthesis kit under the following conditions; (1) binding of reverse transcriptase to RNA 
at 25 °C for 5 min, (2) reverse transcription of RNA to cDNA template at 42 °C for 30 min, 
and (3) denaturing and inactivation of reverse transcriptase at 95 °C for 5 min, using an 
Eppendorf Mastercycler system (Hamburg, Germany). Non-RT controls were used to test for 
cDNA contamination. The RNA extraction from cDNA was considered satisfactory if non-RT 
controls were amplified >10 cycles later than the PCR samples (1/210 or 1/1024-fold) by RT-
qPCR (Section 2.9.2). cDNA samples were stored at 4 °C. 
2.10.2. Real-time quantitative polymerase chain 
reaction (qPCR) analysis 
Quantification of mRNA expression was performed using qPCR with the primer sequences 
listed in Table 2.2. Each analysis was performed in triplicate with 2 μL of cDNA sample, 1 μL 
each of 10 µM forward and reverse primer and the iQ SYBR Green supermix (Bio-Rad) as per 
the manufacturers’ instructions. An initial DNA polymerase activation step was carried out by 
heating samples to 95 °C for 3 min, followed by denaturation at 95 °C for 30 s, annealing at 60 
°C for 30 s and extension at 72 °C for 30 s over 40-50 cycles, followed by denaturing at 95 °C 
for 2 min. This was performed using either a Bio-Rad CFX96 or CFX384 real-time system 
with CFX manager 3 software to obtain sample Ct values. For all primer sets tested, a standard 
curve was generated using serially diluted cDNA to obtain the PCR efficiency. The relative 
mRNA concentrations in each sample was derived from the Ct values plotted against the 
standard curve. To verify that only a single product was amplified by PCR, a dissociation curve 
ranging from 65 – 95 °C with 0.5 °C intervals was generated at the end of the amplification 
cycle. The genes of interest were calculated based on the Pfaffl method (Equation 1) [493], 
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with comparison to the 18S ribosomal RNA (18S) and β2-microglobulin (β2M) housekeeping 
products. 
(1) Ratio=
E
∆Ct(target)
E
∆Ct(ref)  
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Table 2.3. The forward and reverse primer sequences for qPCR. All primers were designed using NCBI primer design software and synthesised 
by GeneWorks (Adelaide, SA). 
Name Abbreviation Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) 
Intracellular adhesion molecule 1 ICAM-1 GGCTGGAGCTGTTTGAGAAC ACTGTGGGGTTCAACCTCTG 
Vascular cell adhesion molecule 1 VCAM-1 CAGACAGGAAGTCCCTGGAA TTCTTGCAGCTTTGTGGATG 
E-Selectin  GGCAGTTCCGGGAAAGATCA GTGGGAGCTTCACAGGTAGG 
Endothelial nitric oxide synthase eNOS CCGGGTCCTGTGTATGGATG AGTGGGTCTGAGCAGGAGAT 
Nuclear factor (erythroid-derived 2)-like 2 Nrf2 GAGCAAGTTTGGGAGGAGCT GGTTGGGGTCTTCTGTGGAG 
Superoxide dismutase 1 SOD-1 AAAGATGGTGTGGCCGATGT CAAGCCAAACGACTTCCAGC 
Haem oxygenase 1  HO-1 TTCAAGCAGCTCTACCGCTC GGGGCAGAATCTTGCACTTT 
Glutamate-cysteine ligase catalytic subunit Gclc TCCAGGTGACATTCCAAGCC GAAATCACTCCCCAGCGACA 
Glutamine synthetase GS CCCTAGCCGGTTTGTGCTAA CCAAAGATGCCCAGCTCTGA 
Monocyte chemotactic protein 1 MCP-1 AGCCACCTTCATTCCCCAAG TTGGGTTTGCTTGTCCAGGT 
Interleukin 6 IL-6 CCAGAGCTGTGCAGATGAGT AGCTGCGCAGAATGAGATGA 
18S ribosomal subunit 18S GAGGATGAGGTGGAACGTGT TCTTCAGTCGCTCCAGGTCT 
β2 microglobulin β2M AGATGAGTATGCCTGCCGTG GCGGCATCTTCAAACCTCCA 
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CCAAT enhancer-binding protein 
homologous protein 
CHOP GGAGCTGGAAGCCTGGTATG GCAGGGTCAAGAGTGGTGAAG 
Activating transcription factor 4 ATF4 CTTCACCTTCTTACAACCTCTTC GTAGTCTGGCTTCCTATCTCC 
Activating transcription factor 6 ATF6 GTATCAGCAGGAACTCAGG GTCTTGTGGTCTTGTTATGG 
78 kDa glucose-regulated protein GRP78 TGTTCAACCAATTATCAGCAAAC TTCTGCTGTATCCTCTTCACCAG 
Spliced x-box binding protein 1 sXBP1 GCTGCGTCCGCAGCAGGT GTCCAGAATGCCCAACAGG 
Low-density lipoprotein receptor LDLR TACAAGTGGGTCTGCGATGG TGAAGTCCCCGGATTTGCAG-3’ 
Scavenger receptor expressed by 
endothelial cell 1 
SREC-1 ATAGAGACAGGGTTTCACCAT GTTA ATCACCTACAATCTCATCTTC CAGA 
Scavenger receptor class A1 SR-A1 TGGACCAAAAGGCCAGAA ACTTCCCAGCGATCGTCA 
Scavenger receptor class B1 SR-B1 CTGTGGGTGAGATCATGTGG GCCAGAAGTCAACCTTGCTC 
Scavenger receptor class B2 SR-B2 GAACCTATTGATGGATTAAA CCC TCCAGTTACTTGACTTCTG AAC 
Lectin-like oxidised low-density lipoprotein 
receptor 1 
LOX-1 GAGAGTAGCAAATTGTTCAGC 
TCCTT 
GCCCGAGGAAAATAGGTAAC AGT 
α-smooth muscle actin α-SMA CATTGTCCACCGCAAATGCT GGCCAACGCAAGAAGTTACC 
Osteopontin OPN AGGCATCACCTGTGCCATAC GGCCACAGCATCTGGGTATT 
S100 calcium-binding protein A4 S100A4 TCTTGGTTTGATCCTGACTGCT ACTTGTCACCCTCTTTGCCC 
Connexin 43 Cx43 TCTTCATGCTGGTGGTGTCC ACCACTGGTCGCATGGTAAG 
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Decorin  TGCTTTCTGTTGCAGGTTGG GTGGGGGTCTTGCTTTTTGG 
Olfactomedin-like 3 Olfml3 GGACACACCATGTCCCAGAG 
  
GTTATAGCGGAGGCTGGCAT 
Collagen type 1  ACAAGGCATTCGTGGCGATA ACCATGGTGACCAGCGATAC 
Osteocalcin  AGGGAACAATCCCAGCCTTG CCCTGTTCTAGCCAGTCAGC 
Runt-related transcription factor 2 Runx2 CCGGAATGCCTCTGCTGTTA TGTCTGTGCCTTCTGGGTTC 
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 Cytokine release from HCAEC by enzyme-
linked immunosorbent assay 
The release of the cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6) and monocyte 
chemotactic protein-1 (MCP-1) from HCAEC (after 24 h treatment with LDL as described in 
Section 2.6) was measured by enzyme-linked immunosorbent assay (ELISA). ELISA kits, 
including buffers and antibodies for each cytokine, were purchased from PeproTech (Rocky 
Hill, New Jersey) and performed per the manufacturer’s instructions for IL-1β (catalogue 
number 900-TM95), IL-6 (catalogue number 900-M16) and MCP-1 (catalogue number 900-
M31). 
The MCP-1 and IL-6 capture antibodies were diluted to 250 ng•mL
-1 and the IL-1β capture 
antibody was diluted to 1 µg•mL
-1 with PBS, then 100 µL per well of capture antibody was 
incubated in ELISA microplates (Corning) overnight at 21 °C. The wells were then aspirated 
and washed four times with 300 µL of wash buffer (0.1 % v/v Tween-20 in PBS), then 
incubated with 300 µL of fresh block buffer (1 % w/v BSA in PBS) for 1 h at 21 °C. The wells 
were again washed four times, then 100 µL of cell media sample were incubated at 21 °C for 
2 h in triplicate. One hundred µL of standards for IL-1β (0 – 750 pg•mL-1), IL-6 (0 – 1.5 ng•mL-
1) and MCP-1 (0 – 1 ng•mL-1) were also incubated in duplicates. The wells were washed again 
four times and incubated with 100 µL of Streptavidin-HRP (75 ng•mL
-1) for IL-1β, or Avidin-
HRP (1:2000 dilution) for 30 min at 21 °C. The wells were washed again four times and 100 
µL of substrate solution (3,3ʹ,5,5ʹ-trimethylbenzidine for IL-1β and 2,2ʹ-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) for IL-6 and MCP-1) was added to each well. Colour was 
developed over 20 min incubation at 21 °C, then the absorbance was measured immediately at 
450 nm with wavelength correction at 620 nm for IL-1β, or 405 nm with wavelength correction 
at 650 nm for IL-6 and MCP-1. 
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 Protein analysis by immunoblot (Western blot) 
2.12.1. Preparation of HCAEC lysates for whole 
cell immunoblot analysis 
HCAEC were treated as stated in Section 2.4 and then lysed with radioimmunoprecipitation 
assay (RIPA) buffer for immunoblot analysis. The protein content of whole cell lysates was 
measured by BCA assay and normalised to 10-20 µg protein per sample in LDS sample buffer 
and reducing agent (Life Technologies). The samples were then heat-denatured for 10 min at 
70 °C and separated by SDS-PAGE as described in Section 2.8.3. 
2.12.2. Preparation of HCAEC lysates for co-
immunoprecipitation and immunoblot 
The coimmunoprecipitation method was adapted from the manufacturer’s protocol for 
Dynabeads® protein G and used the corresponding immunoprecipitation kit (Life 
Technologies). HCAEC were lysed with 0.1 % v/v Triton X-100 in tris-buffered saline (TBS) 
and sonicated for 10 min in iced-water for coimmunoprecipitation experiments to preserve 
protein-protein interactions. For immunoprecipitation of eNOS, 30 mg of Dynabeads® were 
magnetically separated from solution, then resuspended in 200 µL solution of PBS, 0.02 % v/v 
Tween-20 and 1 µg of eNOS antibody (BD Bioscience; San Jose, California; cat. # 610297) 
for 20 min at 21°C with rotation before each experiment. The beads were magnetically removed 
from the solution and resuspended with PBS and Tween-20 solution. The beads were 
magnetically removed from solution and incubated with 100 µL of whole cell lysate for 20 min 
at 21 °C with rotation to allow binding to the Dynabead®-antibody complex. The leftover 
unbound lysates (supernatant) were transferred to a clean tube for further analysis with the 
coimmunoprecipitate. The Dynabead®-antibody-eNOS complex (D-Ab-eNOS) was washed 3 
times with 200 µL washing buffer. When the final wash solution was removed, 100 µL of wash 
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buffer was added and the beads transferred to a clean tube to avoid elution of proteins bound 
to the tube wall. The solution was removed and the D-Ab-eNOS complex was eluted with a 
solution of 20 µL elution buffer, 9 µL LDS sample buffer and 1 µL sample reducing agent. 
Samples were then heat-denatured for 10 min at 70 °C and separated by SDS-PAGE as 
described in Section 2.9.3. 
2.12.3. SDS-PAGE separation and 
immunoblotting of whole cell lysates and eNOS 
coimmunoprecipitates 
Whole cell lysates and eNOS-coimmunoprecipitates were resolved by SDS-PAGE using a 
4-15 % Mini-Protean TGX precast gel in an electrophoresis cell (Bio-Rad). Electrophoresis 
was performed at 120 V for approximately 1.5 h. For eNOS dimerization, electrophoresis was 
performed in an ice bath at 4 °C to prevent thermal uncoupling of eNOS. The proteins were 
transferred to a PVDF membrane over 5.5 min at 20 V using an iBlot 2 system (Life 
Technologies). The immunoblot membranes were blocked with 5 % w/v bovine serum albumin 
in TBS with 0.1 % v/v Tween-20 overnight at 4 °C. Blots were incubated with 1:1000 dilution 
of antibodies for eNOS, p-S1177-eNOS, cav-1 (BD biosciences), LDLR, LOX-1 (Abcam; 
Cambridge) or β-actin (Santa Cruz; Santa Cruz, California), 1:2000 SR-B1 (Abcam), or 1:500 
SR-B2 (BD biosciences) for 2 h at 21 °C. For whole cell and supernatant Western blot, 1:2000 
dilution of anti-IgG-HRP-conjugated antibody (Cell Signalling Technology; Beverly, 
Massachusetts) of the appropriate isotype was incubated for 1 h at 21 °C. For eNOS 
immunoprecipitation, 1:1000 TrueBlot® Ultra anti-mouse IgG-HRP-conjugated antibody 
(Rockland; Limerick, Pennsylvania) was used to prevent binding to eluted unbound IgG heavy 
and light chains. Information on the antibodies used are listed in Table 2.3. Chemiluminescence 
was induced with the enhanced chemiluminescence substrate (Perkin Elmer; Waltham, 
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Massachusetts), imaged with a ChemiDoc MP (Bio-Rad) imaging system. Band densitometry 
was ascertained using ImageLab software (Bio-Rad). 
Table 2.4. Primary and Secondary antibodies used for immunoblot analysis of HCAEC 
lysates. Target antigen, isotype, company and catalogue information of antibodies used for 
Immunoblot analysis. 
Antigen Isotype Antibody company Catalogue number 
eNOS Mouse BD biosciences 610297 
pS1177-eNOS Mouse BD biosciences 612393 
Cav-1 Mouse BD biosciences 610406 
β-actin Mouse Santa Cruz Sc-47778 
SR-B1 Rabbit Abcam ab52629 
SR-B2 Mouse BD biosciences 555453 
LDLR Mouse Abcam ab204941 
LOX-1 Mouse Abcam ab53202 
Mouse IgG Horse Cell Signaling Technology 7076 
Rabbit IgG Goat Cell Signaling Technology 7074 
Mouse IgG (H&L)* Rat Rockland 18-8817-33 
* Mouse IgG (H&L) only recognises complete IgG, not unbound light or heavy chains. 
 Measurement of eNOS activity  
2.13.1. Scintillation counting of 3[H]L-Citrulline 
converted from 3[H]L-Arginine 
The specific activity of eNOS in HCAEC was determined by measuring the total conversion 
of [3H]-L-Arginine to [3H]-L-Citrulline using a commercial kit (Cayman Chemical, catalogue 
number 781001, Ann Arbor, Michigan). HCAEC were cultured in 60 mm2 petri dishes as 
described in Section 2.6 for 24 h. Cells were then washed and incubated for 5 min in PBS with 
1 mM EDTA, then lightly scraped to non-enzymatically detach cells from the plate. Trypsin 
was not used to detach cells as eNOS can be bound to the plasma membrane and be deactivated 
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by trypsin. The detached cells were then centrifuged at 300 g for 5 min, the PBS with EDTA 
was removed and the pellet was lysed in 50 µL homogenisation buffer supplied in the kit. The 
lysates were stored on ice and the protein content of the lysates were measured by BCA assay 
as described in Section 2.5. The protein concentrations were normalised to 0.5 mg•mL
-1
 for 
each sample assay. A 50 µL reaction assay mix for each sample was prepared fresh containing 
50 mM Tris/HCl (pH 7.4), 1 mM NADPH, 6 µM BH4, 2 µM FAD, 2 µM FMN, 750 µM CaCl2, 
0.2 µM calmodulin and 1 µL (1 µCi•µL) L-[1,2,3,4-
3H]-arginine monohydrochloride (Perkin 
Elmer) and incubated for 1 h at 21 °C. The reaction was stopped by the addition of 400 µL of 
stop buffer for each reaction. The [3H]-L-citrulline was separated from the unconverted [3H]-
L-arginine using an equilibrated resin, 100 µL of resin was added to each reaction. The [3H]-
L-citrulline was then eluted from the resin-bound [3H]-L-arginine through spin cups by 
centrifugation at 20 000 g for 30 s. 
Two hundred µL of each sample was added to scintillation vials and thoroughly mixed with 
5 mL of Ultima Gold scintillation fluid (Perkin Elmer). The radioactivity in each sample was 
quantified as counts per minute (cpm) averaged over 5 min using a Tri-Carb liquid scintillation 
counter (Perkin Elmer). A total count (cpm of the reaction mix with stop buffer) and a 
background count (cpm of reaction mix with stop buffer and equilibrated resin eluted through 
spin cups) control were used in each experiment. The percentage conversion was calculated by 
background cpm subtracted from sample cpm compared to the total cpm (Equation 2). 
(2) % conversion= 
(cpmreaction - cpmbackground)
cpmtotal
 ×100  
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2.13.2. Spin trapping of NO and measurement by 
electron paramagnetic resonance (EPR) 
spectroscopy 
Electron paramagnetic resonance (EPR) spectroscopy is a powerful technique for the 
sensitive and specific measurement of biological free radicals. The Fe(II)-MGD (N-methyl-D-
glucamine dithiocarbamate) method was used to spin trap to trap and directly measure NO 
released by HCAEC using a modified protocol [494]. HCAEC were cultured and treated for 
24 h with LDL treatments as described in Section 2.6. Cells were also treated with LDL that 
was freshly desalted through a PD-10 column, but not incubated for 24 h at 37 °C and 5 % 
CO2, as an additional control. The cells were then washed in PBS and were incubated with the 
Fe(II)-MGD spin trap (21 μL Fe(II)SO4 + 210 μL MGD + 189 μL PBS with Ca and Mg) at 37 
°C and 5 % CO2 for 36 min. Immediately after incubation, the resulting solution containing the 
spin trap was then placed in a clean flat cell and the EPR signal was measured. A negative 
control was performed by incubating the cells in treatment media with 100 µM of the eNOS 
inhibitor N5-(1-iminoethyl)-L-ornithine (L-NIO); for 1 h prior to, and during, spin trapping. 
The EPR signals were acquired by using an EMXplus EPR spectrometer (Bruker) and Xenon 
software with the following parameters: frequency: 9.8 GHz; centre field: 3420 G; modulation 
amplitude: 6 G; sweep width: 100 G; gain: 40 dB; power: 25 mW; scans: 15; sweep time: 30 
s; and time constant: 20 s. Signal intensity was quantified by double-integration of the signal 
from 3387 – 3452 G (Figure 2.3). 
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Figure 2.3. Structure and binding of Fe-(MGD)2 spin trap to NO (above) and EPR signal 
of Fe-(MGD)2-bound NO (below). 
2.13.3. Intracellular NO measured by fluorescence 
of DAF-FM by flow cytometry 
The diaminofluorescein probe, 4-amino-5-methylamino-2’,7’-difluorofluorescein (DAF-
FM) is effective at measuring relative intracellular NO detection. DAF-FM is natively non-
fluorescent and cell permeable and is activated by intracellular esterases to a NO-reactive form 
[495, 496]. DAF-FM then reacts with NO to form the fluorescent benzotriazole derivative with 
excitation/emission maxima at 494/515 nm. After treating HCAEC for 24 h with oxidised LDL 
in 12- well plates as described in Section 2.6, HCAEC were washed twice with HBSS 
supplemented with Ca and Mg. HCAEC were then incubated with 1 μM of DAF-FM in HBSS 
supplemented with Ca and Mg for 30 min at 37 °C and 5 % CO2. As DAF-FM is light-sensitive, 
tissue culture plates were wrapped in foil during incubation and flow cytometry was performed 
in darkness. HCAEC were then washed twice and incubated with 0.5 mL PBS containing 1 
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mM EDTA for 5 min before lightly scraping to liberate HCAEC from the plate. The suspension 
was transferred to a tube to be analysed using the FACSVerse flow cytometer (BD Biosciences) 
using the FITC laser settings. The FACSVerse was cleaned and quality control was performed 
before each experiment. 
2.13.4. Measurement of cellular O2•- by DHE 
oxidation and fluorescence 
 
2.13.4.1.  Solutions and preparation of HPLC 
standards 
HPLC-grade acetonitrile (Thermo Scientific) was used to make mobile phase buffers in 
deionised water from a four stage-filtered Milli-Q system (Merck Millipore). Mobile phase A 
(10 % v/v acetonitrile in 25 % v/v 0.2 M potassium phosphate buffer pH 2.6) and mobile phase 
B (60 % v/v acetonitrile in 25 % v/v 0.2 M potassium phosphate buffer pH 2.6) were filtered 
through a 0.2 µm HPLC filter system. 
Stock solutions of 20 mM dihydroethidium (DHE) were prepared in the dark and stored in 
degassed DMSO at -80 °C. Ethidium bromide (EtBr) and 2-hydroxyethidium (2-OH-E+; 
Noxygen, Elzach, Germany) stock were bought commercially and standards were prepared 
fresh for each experiment. The stock of DHE was diluted to approximately 50 µM in potassium 
phosphate buffer (pH 7.4) containing 200 µM diethylenetriaminepentaacetic acid (DTPA) and 
the UV-Vis spectrum was scanned from 200-600 nm in quartz cuvettes to assess the purity and 
true 2-OH-E+ concentration. The true concentration of DHE was calculated using the extinction 
coefficient at 265 nm (ε = 1.8 × 104 M-1•cm-1 [497]) and 345 nm (ε = 9.75 × 103 M-1•cm-1 [497]) 
and diluted to 5 µM in mobile phase A. The concentration of 2-OH-E+ and E+ were prepared 
the same and determined using the extinction coefficient at 470 nm (ε = 9.4 × 103 M-1•cm-1 
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[497]) and 480 nm (ε = 5.8 × 103 M-1•cm-1 [498]), respectively, and each diluted to 5 µM in 
mobile phase A. A standard curve was formulated from 1 – 5 µM for each product. 
2.13.4.2.  HPLC sample preparation 
After treatment of HCAEC, the supernatant was replaced with fresh treatment media with 
50 μM DHE and incubated for 30 min at 37 °C and 5 % CO2. As DHE is light-sensitive, tissue 
culture plates were wrapped in foil during incubation and storage. A 30 min treatment with 50 
μM menadione (2.5 mM stock prepared in the dark and stored in degassed DMSO at -80 °C) 
before incubation with DHE was used as a positive control for O2
•- production [499]. The cells 
were washed and lightly scraped in 1 mL cold PBS and centrifuged (1000 g for 5 min), the 
supernatant removed, then the pellet was stored at -80°C for no longer than 1 week before 
analysis. The samples were lysed with 150 µL of ice-cold PBS with 0.1 % v/v Triton X-100, 
drawn through a 1 mL syringe ten times. Cell debris were pelleted by centrifugation at 1 000 g 
for 5 min at 4 °C, then 100 µL of supernatant was transferred to a tube containing 100 µL of 
0.2 M HClO4 in methanol, vortexed, and allowed to precipitate on ice for 2 h. Meanwhile, 2 
µL of each sample was transferred to 200 µL of Bradford reagent (Brilliant Blue G in 
phosphoric acid and methanol from Sigma-Aldrich) in a 96-well plate for 20 min at 21 °C with 
BSA standards from 0.5 – 5 mg•mL-1 to determine the protein concentration. The absorbance 
for the Bradford assay was measured at 595 nm [500]. After incubation, the protein precipitate 
was pelleted by centrifugation at 20 000 g for 30 min at 4 °C. One-hundred µL of the 
supernatant was transferred to tubes containing 100 µL of 1 M phosphate buffer pH 2.6 and 
vortexed for 5 s. The excess buffer and resultant potassium perchlorate precipitate were 
pelleted by centrifugation at 20 000 g for 15 min at 4 °C. One hundred and fifty µL of each 
sample was then transferred to HPLC vials with 200 µL conical glass inserts and analysed by 
HPLC immediately. 
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2.13.4.3. HPLC separation and fluorescence 
detection of O2•- products 
The samples (50 µL) were separated after injection through a Synergi Polar RP C18 column 
(250 × 4.6 mm, 4 µM, 80 Å; Phenomenex, Torrance, California), equilibrated with 60 % mobile 
phase A and 40 % mobile phase B using a Shimadzu LC-10AT liquid chromatograph system 
with a fluorescence detector (RF-20A XS, Shimadzu). Separation of 2-OH-E+ and ethidium 
(E+) was performed by a linear increase to 100% mobile phase B over 63 min (see Table 2.4) 
at a flow rate of 0.5 mL•min
-1. Products were quantified by fluorescence (DHE; λex 358 nm, 
λem 440 nm, and 2-OH-E+ and E+; λex 490 nm, λem 565 nm). The concentration of 2-OH-E+ was 
calculated by peak integration and interpolated from a standard curve, then normalised to cell 
protein concentration.  
Table 2.5. Elution gradient for the analysis of DHE, E+ and 2-OH-E+ by HPLC and 
fluorescence detection. 
Time (min) Mobile phase A (%) Mobile phase B (%) 
0 60 40 
30 0 100 
40 0 100 
45 60 40 
63 60 40 
 
2.13.5. eNOS and caveolin-1 localisation in 
endothelial cells observed by fluorescence 
microscopy 
HCAEC (200 µL of 0.5 × 105 cells•mL
-1) were seeded onto pre-coated 8-well microscope 
slides before treating with LDL treatments for 24 h as described in Section 2.6. After treatment, 
the wells were spiked with 200 µL of 1 % w/v paraformaldehyde (PFA) in PBS for 2 min. The 
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wells were then aspirated and the cells were fixed to the microscope slide by cross-linking with 
1 % PFA for 10 min at 21 °C. The wells were then aspirated and washed with PBS and 
incubated with 0.1 % Triton X-100 for 5 min to permeabilise the cells. The wells were then 
washed twice with PBS and then incubated (in a humidified chamber) with 10 % v/v goat 
serum in PBS for 1 h at 21 °C to block the cells. The wells were then washed twice with PBS 
for 5 min each, then incubated overnight at 4 °C with 1:200 dilution of primary antibodies in 
PBS, rabbit monoclonal anti-eNOS (Cell Signalling Technology, catalogue number 9586) and 
mouse polyclonal anti-cav-1 (BD bioscience, catalogue number 610406) in the humidified 
chamber. The wells were then aspirated and washed twice with PBS with 0.1 % v/v Tween-20 
(PBST) for 5 min each, to wash off excess and non-specific antibody binding. The cells were 
then incubated with 1:250 dilution of secondary fluorophore-conjugated antibodies, anti-rabbit 
IgG-AF594 (Abcam, catalogue number ab150080) and anti-mouse IgG-AF488 (Invitrogen, 
catalogue number A10667, Carlsbad, California) for 30 min at 21 °C in the dark in the 
humidified chamber. The cells were washed twice with PBST and counterstained with 1 
µg•mL
-1 of 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) for 20 min at 21 °C in the 
dark in the humidified chamber. The wells were then washed twice with PBS, aspirated and 
air-dried, then the coverslip was overlaid with Dako S3023 fluorescence mounting media 
(Agilent Technologies, Santa Clare, California). 
The microscope wells were imaged with an Axio Imager.Z2 microscope (Zeiss, 
Oberkochen, Germany) at 40× magnification. The following excitation/emission spectra for 
each fluorophore were; DAPI (372/465), AF488 (488/519), AF594 (552/565). The 
fluorescence of eNOS (AF594) and cav-1 (AF488) were overlayed to visualise the localisation 
of eNOS and caveolin, with DAPI fluorescence to view cell nuclei.  
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 Measurement of intracellular calcium levels in 
endothelial cells 
The intracellular calcium levels were measured by utilising the cell permeant, calcium-
binding fluorophore, Fluo-4AM (excitation/emission = 494/516 nm [501]). HCAEC were 
plated onto 6-well plates in triplicate for each 1 h and 24 h treatment with LDL as described in 
Section 2.6. Ca2+- and Mg2+-free HBSS was used in these experiments. After treatment, cells 
were washed with HBSS and incubated with 2.5 µM Fluo-4AM for 45 min at 37 °C and 5 % 
CO2 in the dark. The wells were then aspirated, washed with HBSS and lightly scraped in 500 
µL HBSS to be analysed immediately using the FACSVerse flow cytometer (BD bioscience) 
with FITC laser settings (excitation/emission = 494/520). 
 Neutrophil adhesion to endothelial cells in vitro 
2.15.1. Isolation and labelling of leukocytes 
Human blood (up to 15 mL into a EDTA-coated vacutainer) was taken on the day of the 
experiment by a qualified phlebotomist with the donor’s consent and under ethics approval 
(Sydney Local Health District, protocol X12-0375) in accordance with the Declaration of 
Helsinki, 2000 of the World Medical Association. Equal volumes of blood were carefully 
overlaid on 4.5 mL of Polymorphprep (Axis-Shield, Oslo, Norway) in two 15 mL Falcon tubes, 
ensuring whole blood did not mix with the gradient solution. The tubes were centrifuged at 500 
g for 30 min at 21 °C with no deceleration so as not to disturb the cell bands, and the neutrophil 
layer were collected into a fresh 15 mL Falcon tube. An equal volume of 0.45 % v/v NaCl 
saline was mixed with the neutrophils to restore normal osmolality, then the tubes were topped 
up to 12 mL with 0.1 % v/v NaCl saline and mixed. The tube was centrifuged at 400 g for 10 
min at 21 °C with maximum deceleration. The supernatant was discarded, then the cells were 
gently resuspended in 2 mL of red cell lysis buffer and incubated for 15 min at 21 °C in the 
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dark. The tubes were topped up to 12 mL with HBSS (containing Ca2+ and Mg2+) and 
centrifuged at 400 g for 10 min at 21 °C. Red cell lysis was repeated until no further red cells 
were seen in the neutrophil pellet.  Then, the supernatant was removed, cells resuspended in 12 
mL of HBSS and centrifuged again at 400 g for 10 min at 21 °C. The supernatant (with excess 
lysis buffer) was removed and the cells were resuspended in 2 mL HBSS. 
For analysis of neutrophil adhesion to endothelial cells using fluorescence spectroscopy and 
microscopy, the leukocytes were labelled with 1 µM of calcein for 20 min at 37 °C and 5 % 
CO2, then centrifuged at 400 g for 10 min at 21 °C. The supernatant was then discarded to 
remove excess calcein. 
2.15.2. Adhesion assay 
HCAEC were plated onto 96-well plates, then treated with LDL for 24 h as described in 
section 2.6. The cells were then washed with HBSS, aspirated, and 100 µL of neutrophils (106 
cells•mL
-1) stained with calcein were added to the cells and incubated for 20 min at 37 °C and 
5 % CO2. The total neutrophil fluorescence (without washing) and adherent neutrophil 
fluorescence (neutrophils remaining after washing the cells five times with HBSS) were 
measured in the 96-well plate by fluorescence spectroscopy with an excitation/emission 
spectrum of 492/515 nm and the percentage was calculated by the difference between the total 
and adherent neutrophil fluorescence compared to the total fluorescence (Equation 3). The 
adherence of neutrophils was also qualitatively studied by fluorescence microscopy of the 96-
well plates for comparison. 
(3)  % adherence = 
(ftotal - fadherent)
ftotal
 ×100  
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 Vasodilation of rat aortic segments ex vivo 
The physiological consequence of LDL, HOSCN-modified LDL and HOCl-modified LDL 
was investigated by ex vivo treatment of rat aortic segments with 0.1 mg•mL
-1 of each LDL 
treatment for 1 h in HBSS, or for 24 h in endothelial cell treatment media. The rats used for 
this study were the control animals sacrificed for other experiments unrelated to this study 
(Ethics Protocols 2014-020 and 2014-030). This was conducted in accordance with the 
ARRIVE guidelines, the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes (MSW – Animal Research Act 1985) and certified by the National Health 
and Medical Research Council of Australia (NHMRC). Rats were acclimatised in cages located 
at the Heart Research Institute Biological Facilities Centre under environmental enrichment, 
maintained at 25 ± 2 °C and 40 – 60 % humidity, with access to food and water ad libitum.  
The thoracic aortae were harvested from eight male Sprague-Dawley rats (weight; 250 – 
450 g, 1 h: n = 5, 24 h: n = 3) and rapidly cleaned and stripped of fat and adhered tissue in 
warm HBSS. The thoracic aorta was cut into four ~ 4 mm length segments and placed in warm 
HBSS. Each of the four segments were mounted with two pins in 7 mL myograph chambers 
(Danish Myo Technology, Aarhus, Denmark) maintained at 37 °C and pH 7.4 by continuous 
bubbling with 95 % O2 and 5 % CO2. Myography was recorded and analysed using LabChart 
8 software (ADInstruments, Dunedin, New Zealand). Aortic segments were equilibrated to a 
resting tension of ~15 mN for approximately 15 min, with washout and addition of fresh HBSS. 
Aortic segments were then washed out and treated with 0.1 mg•mL
-1 LDL or LDL oxidised 
with either 250 µM HOSCN or HOCl in 7 mL of warm HBSS for 1 h. Untreated ring segments 
were maintained in HBSS without any added LDL as a control. Rat aortic segments treated for 
24 h in endothelial cell treatment media were subject to an initial pre-tension force of 2 mN 
until equilibrated, then pre-tension force was increased to 4 mN and allowed to equilibrate 
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again. This was due to the vessels being sensitive to pressure-induced tone (spontaneous 
periodic contractions which may indicate mechanical vessel injury) when subject to tension 
forces similar to the 1 h treatment vessels. The treatments were then washed out and replaced 
with HBSS. A vasoconstrictive dose-response to norepinephrine (NE; 10-9 to 10
-5 M) was 
measured for each experiment, and a submaximal dose (0.5 - 1 µM NE) was used for 
preconstriction before performing endothelium-dependent acetylcholine (ACh; 10-9 - 10-3 M) 
and endothelium-independent sodium nitroprusside (SNP; 10-11 - 10-5 M; a NO generator) 
induced vasodilation experiments. The cumulative dose response curves were generated with 
four-parameter logistic regression analysis. The EC50 and maximum vasodilatory response 
were analysed between each LDL treatment. 
 Statistics 
Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, San 
Diego, California) with p < 0.05 taken for statistical significance. Specific statistics and post-
hoc tests used in experiments are provided in the Figure legends in the respective Results 
sections.
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 Characterisation of LDL modified by 
HOSCN and HOCl   
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 Introduction 
Oxidation of the apoB-100 moiety of LDL is a major post-translational modification linked 
to the development of atherosclerosis [234, 502]. Many different initiators of LDL oxidation 
have been implicated in atherosclerotic lesion development, including transition metal ions, 
lipoxygenase, reactive oxygen and nitrogen species, glucose and MPO-derived oxidants, 
particularly, in the case of the latter: HOCl (see reviews [53, 263, 264, 273, 278, 280, 304, 321, 
476, 503, 504]). Transition metal ions, particularly copper, are the most widely utilised agent 
for the preparation of oxidised LDL used extensively in in vitro experiments [303, 304, 318, 
375, 505-508]. This type of oxidised LDL is characterised by extensive lipid modifications, 
such as the loss of polyunsaturated cholesteryl esters and formation of fatty acid 
hydroperoxides, with the depletion of antioxidants such as α-tocopherol to give free radical 
intermediates that can potentiate apoB-100 modification [303, 304]. However, it has been 
questioned as to whether this is a valid model of LDL oxidation, due to the lack of causative 
evidence of transition metal ion-mediated LDL oxidation in atherosclerotic lesions in vivo, 
where these ions are only present in advanced calcified and complex lesions and at levels lower 
than that used commonly to modify LDL in vitro [322].  
Iron ions have also been implicated in atherosclerotic development and shown to potentiate 
LDL lipid oxidation similar to copper ion-mediated LDL oxidation, albeit at a reduced 
reactivity compared to copper (Cu2+) ions [323, 375]. In cholesterol-fed rabbits, iron overload 
did not affect atherosclerotic lesion size [509], while dietary supplementation of copper ions 
paradoxically decreased atherosclerosis [510, 511]. Contrastingly, atherosclerosis-prone apoE-
/- mice with iron overload showed a reduction in atherosclerotic lesion size [327], while C57B 
mice with copper deficiency showed an exacerbated atherosclerotic state [512]. The majority 
of studies of people with haemochromatosis and cardiovascular risk have found no significant 
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association between iron stores (i.e. ferritin, transferrin) [513]. Further, patients with Wilson’s 
disease had reduced LDL levels and no change in LDL oxidisability compared to the control 
group [319]. This raises further questions as to the relevance of the transition metal ion pathway 
of LDL oxidation in vivo. 
In contrast to transition metal ions, the MPO-derived oxidant HOCl predominantly reacts 
with the apoB-100 moiety of LDL and displays little reactivity with cholesteryl esters or LDL-
bound antioxidants at physiologically-relevant concentrations [53]. HOCl reacts directly with 
apoB-100, which results in the oxidation of a variety of amino acid residues and phospholipid 
groups including, in order of reactivity: Met > Cys > His ~ N-terminal amine > 
phosphatidylserine and phosphatidylethanolamine head groups > Trp > Lys > > Tyr > Arg [58, 
111, 135, 292]. HOCl-modified epitopes of LDL and 3-Cl-Tyr on LDL have also been detected 
immunologically in human atherosclerotic lesions [233, 281]. Treatment of LDL with the 
MPO-H2O2-Cl
- system results in extensive modification of Tyr and Trp to form 3-Cl-Tyr and 
di-oxidised Trp in apoB-100 in the presence of high H2O2 concentration of 1 mM, in contrast 
to reagent HOCl which oxidised predominately Met residues [288]. These data demonstrate 
that the MPO-H2O2-Cl
- system can react in a site-specific manner with apoB-100 due to MPO 
binding directly to LDL [288]. 
In contrast, less is known about the modification of LDL by the other major MPO-derived 
oxidant, HOSCN. Studies of LDL incubated with the MPO-H2O2-SCN
- system provided 
evidence for LDL conjugated diene and lipid hydroperoxide formation [144]. This was 
supported by Ismael et al, who showed some reactivity of reagent and MPO-derived HOSCN 
with polyunsaturated cholesteryl arachidonate and linoleate components to produce lipid 
hydroperoxides, 9-HODE and F2-isoprostanes [146]. Further, the latter study also showed 
evidence of apoB-100 modification by HOSCN, which differed in reactivity compared to HOCl 
and cyanate (OCN-; a decomposition product of HOSCN) with apoB-100. In this study, 
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evidence was also obtained for the cleavage of apoB-100 by HOSCN in a site-specific manner, 
though the mechanism of fragmentation and the cleavage site were not identified [146]. 
 Aims 
The aim of the studies in this Chapter was to examine the mechanism and define the 
cleavage site(s) of HOSCN-induced apoB-100 fragmentation. This is important as 
identification of a novel HOSCN-derived apoB-100 peptide/protein fragments might be useful 
as a biomarker to assess the role of HOSCN formation during lesion development in vivo. 
 Results 
3.3.1. Charge modification of LDL 
Initial studies were performed to assess the extent of LDL modification by relative 
electrophoretic mobility (REM); a function of charge modification of LDL measured by the 
distance travelled through an agarose gel under constant voltage. LDL (1.0 mg•mL
-1) was 
incubated with 250 µM HOSCN or HOCl for 24 h at 37 °C, and compared to LDL oxidised by 
incubation with 5 µM CuSO4, which is commonly used in in vitro cell function studies [307-
309, 313, 419, 473, 507, 514-530]. The REM was normalised to LDL incubated under identical 
conditions in the absence of oxidant (referred to as control LDL from hereafter). The REM of 
LDL incubated with HOSCN was not significantly different to the control LDL (Figure 3.1). 
In contrast, HOCl-modified LDL migrated significantly further than both control LDL and 
HOSCN-modified LDL (approximately 183 % versus control LDL). Similarly, Cu2+-modified 
LDL charge was extensively modified and had an REM of approximately 330 % compared to 
the control LDL (Figure 3.1). These results reflect differences in the ability of HOCl and 
HOSCN to modify charged amino acid side chains, including Lys, Arg and His, as unlike 
HOCl, HOSCN is highly selective towards Cys residues [90, 135, 146, 292, 531]. Meanwhile, 
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Cu2+ ions can react with most LDL constituents, including amino acid residues, lipids and the 
backbone polypeptides [303, 375, 532]. 
 
Figure 3.1. Relative Electrophoretic Mobility (REM) of LDL modified by MPO-derived 
oxidants and CuSO4. LDL (1.0 mg•mL
-1) was incubated with 250 µM HOSCN, 250 µM HOCl 
or 5 µM CuSO4 for 24 h at 37 °C. (A) Representative REM gel of two independent LDL 
experiments run through an agarose gel simultaneously. (B) REM of control LDL compared to 
oxidised LDL species. Migration distance was measured from the origin (dashed line) away 
from the anode (-) and normalised to control LDL. Bars represent the mean ± SD (n = 4; from 
two LDL donors). Statistical analysis was performed using one-way ANOVA with Dunnett’s 
multiple comparison test. *** and **** represent significant difference with p < 0.001 and 
0.0001, respectively compared to control LDL. 
3.3.2. Structural modifications of apoB-100 
The charge modification studies were extended to examine the ability of HOSCN and HOCl 
to induce structural modifications of apoB-100, such as aggregation and fragmentation of the 
protein structure. These modifications were examined by SDS-PAGE experiments under 
reduced and non-reduced conditions after 24 h incubation of LDL with up to 250 µM HOSCN 
or HOCl or LDL exposed to 5 µM CuSO4. The exposure of LDL to HOSCN or HOCl led to 
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different types and extents of modification upon comparison of the two oxidants (Figure 3.2). 
ApoB-100 aggregation (indicated by the bracket in lane 2 and 3, respectively) was observed 
upon exposure of LDL to both 100 µM or 250 µM HOSCN as seen by the bands appearing 
above the parent apoB-100 band. This aggregation was also present, but to a lesser extent in 
the control LDL, most likely due to the mild oxidation seen as a result of the incubation 
conditions alone. Evidence was also obtained for fragmentation of apoB-100 with HOSCN-
modified LDL, indicated by the band stained at approximately 90 kDa (highlighted by the red 
box). In contrast, LDL modified by 100 or 250 µM HOCl (lanes 4 and 5, respectively) appeared 
more extensively modified, with visible loss of the parent apoB-100 band, formation of darker, 
higher molecular mass aggregate bands, and more extensive low molecular-mass bands 
consistent with protein fragmentation. In some experiments, it was possible to see the 90 kDa 
fragment evidence with LDL exposure to HOSCN, within the analogous experiments with 
HOCl, but the visualisation of this band was only seen at 100 µM HOCl doses, and not 
consistently. This may suggest that HOCl can fragment apoB-100 at the same site as HOSCN, 
but can further fragment the resultant peptide. Consistent with previously published data [375], 
LDL exposed to CuSO4 is extensively modified, with the parent apoB-100 protein totally 
displaced in the gel (lane 6). Cu2+-modified LDL perhaps modified to the extent that Coomassie 
Blue cannot adequately stain the aggregates or fragments of apoB-100.  
To ascertain whether the apoB-100 aggregation upon exposure to HOSCN and HOCl is 
associated with the formation of disulfide bridging between two Cys residues, identical 
experiments were performed with samples run under reducing conditions, with the LDL 
samples pre-treated with 50 µM DTT before running SDS-PAGE in order to break the disulfide 
bonds. Under reduced conditions, considerable aggregation of the apoB-100 protein was still 
apparent with treatment of LDL with HOCl and HOSCN, suggesting that aggregation was not 
dependent on the formation of disulfide bonds and instead involving cross-linking between 
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other amino acid residues [66, 84, 122]. Likewise, the HOSCN-specific band at approximately 
90 kDa was still present (Figure 3.3) [293]. Additionally, in both Figures 3.2 and 3.3, a band 
just below the parent apoB-100 band appeared (indicated by white arrows) together with the 
appearance of the HOSCN-modified apoB-100 specific fragment, which was likely the 
remaining major apoB-100 fragment after cleavage of the peptide by HOSCN. 
 
Figure 3.2. Separation of apoB-100 parent, fragment and aggregate peptides by SDS-
PAGE from HOSCN- and HOCl-modified LDL under non-reducing conditions. LDL (1.0 
mg•mL
-1) was incubated with 100 µM or 250 µM HOSCN or HOCl, or 5 µM CuSO4 for 24 h 
at 37 °C. 10 µg LDL was added to each lane of the 3 – 8 % Tris-acetate SDS-PAGE gel in each 
experiment. The peptide bands were stained with Coomassie Blue. A molecular mass ladder is 
displayed in kDa. LDL was incubated with; Lane 1: no oxidant, lane 2: 100 µM HOSCN, Lane 
3: 250 µM HOSCN, Lane 4: 100 µM HOCl, Lane 5: 250 µM HOCl, Lane 6: 5 µM CuSO4. The 
red box highlights bands specific to HOSCN-modified LDL. Gel is representative of three 
independent experiments. 
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Figure 3.3. Visualisation of apoB-100 parent, fragments and aggregates under non-
reduced and reduced conditions by Coomassie staining. LDL (1.0 mg•mL
-1) was incubated 
with 100 µM or 250 µM HOSCN or HOCl, or 5 µM CuSO4 for 24 h at 37 °C. 10 µg LDL was 
added to each lane of the 3 – 8 % Tris-acetate SDS-PAGE gel in each experiment under (A) 
non-reduced conditions, or (B) under reduced conditions with the addition of 50 mM DTT. 
LDL was incubated with; Lane 1: no oxidant, lane 2: 100 µM HOSCN, lane 3: 250 µM 
HOSCN, lane 4: 100 µM HOCl, lane 5: 250 µM HOCl, and lane 6: 5 µM CuSO4. Gels are 
representative of three independent experiments. 
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In order to improve the visualisation and resolution of the HOSCN-induced apoB-100 
fragment bands, a silver staining protocol was utilised [533]. The silver stain signal can be 
amplified by extending the exposure of the developing solution to silver ions captured by the 
peptides to increase sensitivity, while Coomassie blue is a colloid and the stain intensity is 
dependent on the protein concentration. This results in the silver stain being up to 100-fold 
more sensitive than Coomassie blue stain [534].  
Using the silver staining approach, the smaller fragments of apoB-100 were more easily 
visualised and the formation of the HOSCN-modified LDL specific fragment at approximately 
90 kDa was more clearly distinguished (Figure 3.4 A and B). This fragment band is observed 
under both reducing and non-reducing conditions, suggesting that site-specific fragmentation 
is not related to disulfide bond cleavage. Further, this band appears to be a doublet, suggesting 
the presence of two protein fragments of similar size. These data also showed that this fragment 
intensity is dependent on HOSCN concentration, while it is not present with the control (Figure 
3.4 C). The HOSCN-modified LDL fragment band (indicated by the red box) was also apparent 
in experiments with 100 µM HOCl-modified LDL (lane 4), but not with 250 µM HOCl-
modified LDL (lane 5; Figure 3.3). This is due to a larger number of fragmentation events of 
apoB-100 with higher concentrations of HOCl, producing more fragments.
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Figure 3.4. Sensitive visualisation of apoB-100 parent, fragments and aggregates under 
non-reduced and reduced conditions by silver staining. LDL (1.0 mg•mL
-1) was incubated 
with 100 µM or 250 µM HOSCN or HOCl, or 5 µM CuSO4 for 24 h at 37 °C. 10 µg LDL was 
added to each lane of the 3 – 8 % Tris-acetate SDS-PAGE gel in each experiment under (A) 
non-reduced conditions, or under (B) reduced conditions with the addition of 50 mM DTT. 
LDL was incubated with; Lane 1: no oxidant, lane 2: 100 µM HOSCN, lane 3: 250 µM 
HOSCN, lane 4: 100 µM HOCl, lane 5: 250 µM HOCl, and lane 6: 5 µM CuSO4. (C) 
densitometry of apoB-100 fragment (red box):parent ratio. Bars represent the mean ± SD (n = 
4). Statistical analysis was performed with one-way ANOVA with Dunnett’s multiple 
comparison test. * represents significance level p < 0.05 compared to control LDL.  
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3.3.3. HOSCN-modified LDL fragmentation 
characterisation 
It has been shown previously that HOSCN-induced oxidation of LDL associated cholesterol 
and cholesteryl esters occurred via radical-mediated pathway, and was influenced by the 
presence of trace transition metal ions [146]. Since the apoB-100 fragmentation by HOSCN 
was not observed to the same extent as HOCl, which itself may indicate a specific reaction with 
HOSCN, further experiments were designed to elucidate the chemical mechanism involved in 
this HOSCN-mediated fragmentation of LDL. This was attained by exposing LDL to 250 μM 
HOSCN in the presence of a free radical-scavenging compound (BHT) and an iron-chelator 
(DFO) for 24 h before SDS-PAGE and Coomassie stain analysis (Figure 3.5A). The addition 
of 50 μM DFO did not reduce the fragmentation of apoB-100 upon HOSCN exposure to LDL, 
however 200 μM BHT significantly, though not completely, reduced the formation of the 
fragment band, as shown by the densitometry ratio of the fragment band to the parent band 
(Figure 3.5B). From these data, free radical-mediated chemistry may be involved in the 
cleavage of apoB-100 when oxidised by HOSCN. 
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Figure 3.5. LDL incubated with HOSCN and the iron-chelator desferrioxamine (DFO) or 
the free radical scavenger butylated-hydroxytoluene (BHT). 1.0 mg•mL
-1 Control LDL 
(lane 1) or LDL modified by 250 µM HOSCN in the absence (lane 2) or presence of 50 µM 
DFO (lane 3) or 200 µM BHT (lane 4) for 24 h at 37 °C. (A) Gels were stained with Coomassie 
Blue. The red box highlights bands specific to HOSCN-modified LDL. (B) Densitometry of the 
fragment: parent apoB-100 ratio between treatments. Bar represents the mean ± SD (n = 4). 
One-way ANOVA with Dunnett’s multiple comparison test. # represents p < 0.05 compared to 
LDL incubated with HOSCN only. 
3.3.3.1.a. Sequence of HOSCN-derived apoB-
100 fragments 
Next, the nature of the cleavage site responsible for the HOSCN-induced apoB-100 cleavage 
site was examined using a proteomic approach. The proteomics experiments were performed 
in collaboration with Dr Matthew Padula and Iain Berry at the Proteomics Core Facility at the 
University of Technology Sydney, who assisted with the experimental design, ran the samples 
through the LC-MS, and provided guidance regarding data analysis. LDL at 1.0 mg•mL
-1 was 
exposed to 250 µM HOSCN for 24 h at 37 °C before separation of the parent protein and 
fragments by SDS-PAGE. The fragment bands were excised from the gel, free Cys residues 
were blocked by reduction and alkylation with acrylamide, the fragments were digested using 
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trypsin and analysed using triple quadrupole time-of-flight LC-MS/MS as described in Section 
2.4.3. The peptides were matched to the apoB-100 amino acid sequence through the Mascot 
Daemon program using the LudwigNR database, as shown in Figure 3.6. Data show that the 
peptides from the HOSCN-induced fragment band matched two regions of the apoB-100 
sequence at the N-terminal (amino acid 1 – 819) and C-terminal (amino acid 3725 – 4563), 
which were thus named the N-fragment and C-fragment, respectively. The detection of 
significant peptide sequences was highlighted red in the sequence, while non-significant 
peptide sequences were highlighted blue.  
On comparison of replicate experiments, peptide fragments were detected further in the 
apoB-100 sequence, up to residue 960 at the N-terminal and up to 3167 at the C-terminal 
(Figure 3.6). The high scoring peptide sequences (950TEVIPPLIENR960 and 3167QSFDLSVK-
3174), although statistically significant, needed to be scrutinised in the analysis as there was a 
large gap in the sequence to the next detected de novo peptide, where there were several 
potential de novo tryptic digestion sites possible. The potential tryptic site residues were Lys822, 
859, 863 ,876, 918, 921, 923, 930 and Arg895, 941 for the N-fragment, and Lys3778, 3779, 3781, 3202, 3210, 3227, 3229, 
3232, 3234, 3237, 3314, 3321, 3344, 3380, 3390, 3524, 3531, 3537, 3568, 3586, 3626, 3630, 3656, 3689 and Arg3138, 3206, 3244, 3386, 
3389, 3391, 3437, 3507, 3527, 3632, 3638, 3670, 3698, 3699, which were not detected in any replicates. 
Furthermore, the calculated molecular mass of these apoB-100 fragments from residues 1 – 
960 and 3617 – 4563, was approximately 106.8 and 160.5 kDa, respectively, which is far 
greater than the predicted molecular mass of each fragment and the mass difference between 
the apoB-100 fragments according to the Figures 3.3, 3.4 and 3.5. The next significant peptide 
detected in all three replicates for the N-terminal apoB-100 fragment was 
805TLQGIPQMIGEVIRK819 (score: 44) and the C-terminal apoB-100 fragment was 
3725VLADKFIIPGLK3736 (score: 63). The estimated molecular mass of the N- and C-terminal 
LDL fragments up to these residues are approximately 91.7 and 96.6 kDa, respectively; which 
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was in greater agreement with the SDS-PAGE analysis and predicted molecular mass, and in 
the observed molecular mass difference between the two fragments by SDS-PAGE and silver-
stained gels.
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1 MDPPRPALLA LLALPALLLL LLAGARAEEE MLENVSLVCP KDATRFKHLR 
51 KYTYNYEAES SSGVPGTADS RSATRINCKV ELEVPQLCSF ILKTSQCTLK 
101 EVYGFNPEGK ALLKKTKNSE EFAAAMSRYE LKLAIPEGKQ VFLYPEKDEP 
151 TYILNIKRGI ISALLVPPET EEAKQVLFLD TVYGNCSTHF TVKTRKGNVA 
201 TEISTERDLG QCDRFKPIRT GISPLALIKG MTRPLSTLIS SSQSCQYTLD 
251 AKRKHVAEAI CKEQHLFLPF SYKNKYGMVA QVTQTLKLED TPKINSRFFG 
301 EGTKKMGLAF ESTKSTSPPK QAEAVLKTLQ ELKKLTISEQ NIQRANLFNK 
351 LVTELRGLSD EAVTSLLPQL IEVSSPITLQ ALVQCGQPQC STHILQWLKR 
401 VHANPLLIDV VTYLVALIPE PSAQQLREIF NMARDQRSRA TLYALSHAVN 
451 NYHKTNPTGT QELLDIANYL MEQIQDDCTG DEDYTYLILR VIGNMGQTME 
501 QLTPELKSSI LKCVQSTKPS LMIQKAAIQA LRKMEPKDKD QEVLLQTFLD 
551 DASPGDKRLA AYLMLMRSPS QADINKIVQI LPWEQNEQVK NFVASHIANI 
601 LNSEELDIQD LKKLVKEALK ESQLPTVMDF RKFSRNYQLY KSVSLPSLDP 
651 ASAKIEGNLI FDPNNYLPKE SMLKTTLTAF GFASADLIEI GLEGKGFEPT 
701 LEALFGKQGF FPDSVNKALY WVNGQVPDGV SKVLVDHFGY TKDDKHEQDM 
751 VNGIMLSVEK LIKDLKSKEV PEARAYLRIL GEELGFASLH DLQLLGKLLL 
801 MGARTLQGIP QMIGEVIRKG SKNDFFLHYI FMENAFELPT GAGLQLQISS 
851 SGVIAPGAKA GVKLEVANMQ AELVAKPSVS VEFVTNMGII IPDFARSGVQ 
901 MNTNFFHESG LEAHVALKAG KLKFIIPSPK RPVKLLSGGN TLHLVSTTKT 
951 EVIPPLIENR QSWSVCKQVF PGLNYCTSGA YSNASSTDSA SYYPLTGDTR 
1001 LELELRPTGE IEQYSVSATY ELQREDRALV DTLKFVTQAE GAKQTEATMT 
1051 FKYNRQSMTL SSEVQIPDFD VDLGTILRVN DESTEGKTSY RLTLDIQNKK 
1101 ITEVALMGHL SCDTKEERKI KGVISIPRLQ AEARSEILAH WSPAKLLLQM 
1151 DSSATAYGST VSKRVAWHYD EEKIEFEWNT GTNVDTKKMT SNFPVDLSDY 
1201 PKSLHMYANR LLDHRVPQTD MTFRHVGSKL IVAMSSWLQK ASGSLPYTQT 
1251 LQDHLNSLKE FNLQNMGLPD FHIPENLFLK SDGRVKYTLN KNSLKIEIPL 
1301 PFGGKSSRDL KMLETVRTPA LHFKSVGFHL PSREFQVPTF TIPKLYQLQV 
1351 PLLGVLDLST NVYSNLYNWS ASYSGGNTST DHFSLRARYH MKADSVVDLL 
1401 SYNVQGSGET TYDHKNTFTL SYDGSLRHKF LDSNIKFSHV EKLGNNPVSK 
1451 GLLIFDASSS WGPQMSASVH LDSKKKQHLF VKEVKIDGQF RVSSFYAKGT 
1501 YGLSCQRDPN TGRLNGESNL RFNSSYLQGT NQITGRYEDG TLSLTSTSDL 
1551 QSGIIKNTAS LKYENYELTL KSDTNGKYKN FATSNKMDMT FSKQNALLRS 
1601 EYQADYESLR FFSLLSGSLN SHGLELNADI LGTDKINSGA HKATLRIGQD 
1651 GISTSATTNL KCSLLVLENE LNAELGLSGA SMKLTTNGRF REHNAKFSLD 
1701 GKAALTELSL GSAYQAMILG VDSKNIFNFK VSQEGLKLSN DMMGSYAEMK 
1751 FDHTNSLNIA GLSLDFSSKL DNIYSSDKFY KQTVNLQLQP YSLVTTLNSD 
1801 LKYNALDLTN NGKLRLEPLK LHVAGNLKGA YQNNEIKHIY AISSAALSAS 
1851 YKADTVAKVQ GVEFSHRLNT DIAGLASAID MSTNYNSDSL HFSNVFRSVM 
1901 APFTMTIDAH TNGNGKLALW GEHTGQLYSK FLLKAEPLAF TFSHDYKGST 
1951 SHHLVSRKSI SAALEHKVSA LLTPAEQTGT WKLKTQFNNN EYSQDLDAYN 
2001 TKDKIGVELT GRTLADLTLL DSPIKVPLLL SEPINIIDAL EMRDAVEKPQ 
2051 EFTIVAFVKY DKNQDVHSIN LPFFETLQEY FERNRQTIIV VLENVQRNLK 
2101 HINIDQFVRK YRAALGKLPQ QANDYLNSFN WERQVSHAKE KLTALTKKYR 
2151 ITENDIQIAL DDAKINFNEK LSQLQTYMIQ FDQYIKDSYD LHDLKIAIAN 
2201 IIDEIIEKLK SLDEHYHIRV NLVKTIHDLH LFIENIDFNK SGSSTASWIQ 
2251 NVDTKYQIRI QIQEKLQQLK RHIQNIDIQH LAGKLKQHIE AIDVRVLLDQ 
2301 LGTTISFERI NDILEHVKHF VINLIGDFEV AEKINAFRAK VHELIERYEV 
2351 DQQIQVLMDK LVELAHQYKL KETIQKLSNV LQQVKIKDYF EKLVGFIDDA 
2401 VKKLNELSFK TFIEDVNKFL DMLIKKLKSF DYHQFVDETN DKIREVTQRL 
2451 NGEIQALELP QKAEALKLFL EETKATVAVY LESLQDTKIT LIINWLQEAL 
2501 SSASLAHMKA KFRETLEDTR DRMYQMDIQQ ELQRYLSLVG QVYSTLVTYI 
2551 SDWWTLAAKN LTDFAEQYSI QDWAKRMKAL VEQGFTVPEI KTILGTMPAF 
2601 EVSLQALQKA TFQTPDFIVP LTDLRIPSVQ INFKDLKNIK IPSRFSTPEF 
2651 TILNTFHIPS FTIDFVEMKV KIIRTIDQML NSELQWPVPD IYLRDLKVED 
2701 IPLARITLPD FRLPEIAIPE FIIPTLNLND FQVPDLHIPE FQLPHISHTI 
2751 EVPTFGKLYS ILKIQSPLFT LDANADIGNG TTSANEAGIA ASITAKGESK 
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Start – End De novo Peptide sequence Score 
N-terminal 805 – 819 TLQGIPQMIGEVIRK 44 
C-terminal 3725 – 3736 VLADKFIIPGLK 63 
Figure 3.6. De novo tryptic sequence of apoB-100 fragments following HOSCN 
modification. (Top) Entire peptide sequence of apoB-100 with detected de novo fragments 
highlighted red/blue and undetected residues within the fragment sequence highlighted black. 
Red highlighted fragments had a significant score (E value < 0.05) while blue highlighted 
fragments had a non-significant score (E value ≥ 0.05). (Bottom) Proposed peptide sequence 
closest to the true peptide cleavage site. This experiment was replicated three times. 
2801 LEVLNFDFQA NAQLSNPKIN PLALKESVKF SSKYLRTEHG SEMLFFGNAI 
2851 EGKSNTVASL HTEKNTLELS NGVIVKINNQ LTLDSNTKYF HKLNIPKLDF 
2901 SSQADLRNEI KTLLKAGHIA WTSSGKGSWK WACPRFSDEG THESQISFTI 
2951 EGPLTSFGLS NKINSKHLRV NQNLVYESGS LNFSKLEIQS QVDSQHVGHS 
3001 VLTAKGMALF GEGKAEFTGR HDAHLNGKVI GTLKNSLFFS AQPFEITAST 
3051 NNEGNLKVRF PLRLTGKIDF LNNYALFLSP SAQQASWQVS ARFNQYKYNQ 
3101 NFSAGNNENI MEAHVGINGE ANLDFLNIPL TIPEMRLPYT IITTPPLKDF 
3151 SLWEKTGLKE FLKTTKQSFD LSVKAQYKKN KHRHSITNPL AVLCEFISQS 
3201 IKSFDRHFEK NRNNALDFVT KSYNETKIKF DKYKAEKSHD ELPRTFQIPG 
3251 YTVPVVNVEV SPFTIEMSAF GYVFPKAVSM PSFSILGSDV RVPSYTLILP 
3301 SLELPVLHVP RNLKLSLPDF KELCTISHIF IPAMGNITYD FSFKSSVITL 
3351 NTNAELFNQS DIVAHLLSSS SSVIDALQYK LEGTTRLTRK RGLKLATALS 
3401 LSNKFVEGSH NSTVSLTTKN MEVSVATTTK AQIPILRMNF KQELNGNTKS 
3451 KPTVSSSMEF KYDFNSSMLY STAKGAVDHK LSLESLTSYF SIESSTKGDV 
3501 KGSVLSREYS GTIASEANTY LNSKSTRSSV KLQGTSKIDD IWNLEVKENF 
3551 AGEATLQRIY SLWEHSTKNH LQLEGLFFTN GEHTSKATLE LSPWQMSALV 
3601 QVHASQPSSF HDFPDLGQEV ALNANTKNQK IRWKNEVRIH SGSFQSQVEL 
3651 SNDQEKAHLD IAGSLEGHLR FLKNIILPVY DKSLWDFLKL DVTTSIGRRQ 
3701 HLRVSTAFVY TKNPNGYSFS IPVKVLADKF IIPGLKLNDL NSVLVMPTFH 
3751 VPFTDLQVPS CKLDFREIQI YKKLRTSSFA LNLPTLPEVK FPEVDVLTKY 
3801 SQPEDSLIPF FEITVPESQL TVSQFTLPKS VSDGIAALDL NAVANKIADF 
3851 ELPTIIVPEQ TIEIPSIKFS VPAGIVIPSF QALTARFEVD SPVYNATWSA 
3901 SLKNKADYVE TVLDSTCSST VQFLEYELNV LGTHKIEDGT LASKTKGTFA 
3951 HRDFSAEYEE DGKYEGLQEW EGKAHLNIKS PAFTDLHLRY QKDKKGISTS 
4001 AASPAVGTVG MDMDEDDDFS KWNFYYSPQS SPDKKLTIFK TELRVRESDE 
4051 ETQIKVNWEE EAASGLLTSL KDNVPKATGV LYDYVNKYHW EHTGLTLREV 
4101 SSKLRRNLQN NAEWVYQGAI RQIDDIDVRF QKAASGTTGT YQEWKDKAQN 
4151 LYQELLTQEG QASFQGLKDN VFDGLVRVTQ EFHMKVKHLI DSLIDFLNFP 
4201 RFQFPGKPGI YTREELCTMF IREVGTVLSQ VYSKVHNGSE ILFSYFQDLV 
4251 ITLPFELRKH KLIDVISMYR ELLKDLSKEA QEVFKAIQSL KTTEVLRNLQ 
4301 DLLQFIFQLI EDNIKQLKEM KFTYLINYIQ DEINTIFSDY IPYVFKLLKE 
4351 NLCLNLHKFN EFIQNELQEA SQELQQIHQY IMALREEYFD PSIVGWTVKY 
4401 YELEEKIVSL IKNLLVALKD FHSEYIVSAS NFTSQLSSQV EQFLHRNIQE 
4451 YLSILTDPDG KGKEKIAELS ATAQEIIKSQ AIATKKIISD YHQQFRYKLQ 
4501 DFSDQLSDYY EKFIAESKRL IDLSIQNYHT FLIYITELLK KLQSTTVMNP 
4551 YMKLAPGELT IIL    
115 | P a g e  
 
3.3.3.2. Labelling the N-terminal fragment site 
by reductive dimethylation 
Peptide mapping did not reveal the exact cleavage site, owing to incomplete sequence 
coverage. Therefore, an in-gel reductive dimethylation labelling of the N-terminal amines was 
performed, prior to excision, improve the identification of the HOSCN-modified apoB-100 
cleavage site. This method can be used to determine the cleavage site of the C-fragment, which 
leaves its N-terminus exposed to dimethylation. As per the fragment sequencing experiment, 
the same exposure of LDL to HOSCN, separation by SDS-PAGE and in-gel reduction and 
alkylation was applied. Afterwards, the peptides were exposed to 20 mM cyanoborohydride 
and 40 mM formaldehyde to dimethylate primary amines as described in Section 2.4.3.1, before 
trypsin digestion, LC-MS/MS and peptide sequencing. Compared to the sequencing following 
trypsin digestion, the yields of peptides were significantly reduced following in-gel reductive 
dimethylation and only ten unique fragments were detected (Table 3.1). Of the ten unique 
fragments, the last seven fragments in order of apoB-100 sequence were of the C-fragment. 
Fragment 3767 – 3790 was closest to the suspected fragmentation site, but this fragment was 
not significant (Score: 44, p < 0.05). Regardless, only Lys ε-amine dimethylation and no N-
terminal dimethylation of other residues was detected. The likely cause for the reduced 
fragment yield could be the reduced efficiency of trypsin to digest Lys residues following 
dimethylation, as the trypsin recognises the positively charged ε-amine group to digest the 
peptide backbone. This may have left peptides that were too large to exit the gel or be 
sequenced by the mass spectrometer. The reduced efficacy of trypsin digestion is evidenced by 
the presence of Lys residues within the fragments 3767 – 3790, 4202 – 4213, 4497 – 4519 and 
4552 – 4563 where trypsin did not further fragment the peptides at those Lys sites. 
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Table 3.1. De novo Peptide sequences of N-fragment and C-fragment peptides following 
reductive dimethylation of N-terminal and primary amines. Dimethylated Lys are 
highlighted in red. 
 
 Discussion 
The current study has shown that HOSCN reacts selectively with the apoB-100 moiety of 
LDL. This was demonstrated by SDS-PAGE, which showed a novel peptide band appearing in 
LDL samples incubated with HOSCN, indicating selective cleavage of apoB-100 by this 
oxidant. The formation of this fragment is likely to be free-radical mediated due to the 
inhibition by the radical scavenger BHT. Peptide sequencing and mapping by LC-MS/MS then 
revealed this band to be two fragments of similar molecular mass from the terminal ends of 
apoB-100. The cleavage site of the C-fragment, however, was not resolved by a reductive 
dimethylation and trypsin digestion approach. This mechanism of selective apoB-100 
modification by HOSCN may be of physiological importance in cases of high SCN- levels in 
the plasma leading to elevated HOSCN production by MPO. The modification of the apoB-
100 moiety of LDL leads to a reduced ability of cells to recognise LDL by the LDLR and 
altered increased uptake of the modified particle through scavenger receptors (including 
scavenger receptor class A type 1 (SR-A1), class B type 1 and 2 (SR-B1 and SR-B2), lectin-
like oxidised LDL receptor 1 (LOX-1) and SR for endothelial cell type 1 (SREC-1)), which are 
present on macrophages and endothelial cells, leading to foam cell formation and endothelial 
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dysfunction, respectively (reviewed [535]) [19, 276, 277, 421]. Additionally, the recognition 
of modified LDL by these scavenger receptors often leads to activation of pro-inflammatory 
responses such as MAPK and NF-κB, followed by the consequent release of pro-inflammatory 
cytokines such as TNF-α and IL-6 [282, 536, 537], leukocyte adhesion molecule expression 
[538] and caspase 3- and 9-dependent apoptosis [523]. 
The oxidant concentrations of HOSCN and HOCl incubated with LDL in the experiments 
of this project are based on calculations of circulating oxidant concentrations in vivo. 
Calculation of these oxidant concentrations were based on, (i) normal levels of circulating 
neutrophils (5 × 106 cells•mL
-1) produce a range of 150 – 425 µM/h HOCl [38, 539], and (ii) 
that at physiological pH, MPO converts approximately equal proportion of the consumed H2O2 
to HOSCN and HOCl [39]. In vitro exposure of LDL to HOCl and HOSCN led to aggregation 
and fragmentation of the parent apoB-100 protein, with HOCl also shown to induce significant 
change in the overall net charge of LDL producing a more negatively charged LDL species. In 
contrast, no significant change in REM was seen with HOSCN, which agrees with previous 
data [146]. This can be rationalised by the difference in selectivity of HOSCN and HOCl, with 
HOSCN targeting free thiols from Cys [145]: whereas the significant change in LDL charge 
induced by HOCl is likely due to the modification of positively charged apoB-100 residues 
such as Lys [104, 146, 292, 531, 540], His, another charged amino acid, would likely be another 
significant target for HOCl reactivity [58].  
The difference in the mechanism of apoB-100 modification by hypohalous acids compared 
to Cu2+ were apparent in this study. Modification of LDL by Cu2+ significantly altered the 
charge of LDL compared to the control (similar to previously reported cases [375, 541]) and 
oxidised LDL to a greater extent than HOCl. Unlike LDL modified by HOSCN or HOCl, which 
showed distinct parent, fragment and aggregate bands of apoB-100 by SDS-PAGE, the parent 
apoB-100 band was shifted to a higher molecular mass and there was no distinguishable 
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aggregate or fragment band of apoB-100 that could be seen by Cu2+-oxidised LDL. It is likely 
that technical issues in analysing peptide structure by SDS-PAGE gel arise due to the extent of 
backbone modification of LDL by Cu2+. The lack of resolved silver and Coomassie staining of 
apoB-100 is likely caused by the universal peptide backbone oxidation by Cu2+ [488]. 
Coomassie blue is a colloidal molecule that binds to basic amino acids (Arg, Lys and His) and 
to a lesser extent the aromatic amino acids (Phe, Tyr and Trp) [542], which may be modified 
by Cu2+ and impair affinity for Coomassie blue to these residues and prevent binding [304]. 
3.4.1. Site-specific fragmentation of apoB-100 by 
HOSCN 
A specific fragment band seen at approximately 90 kDa by SDS-PAGE was produced 
following exposure of LDL to HOSCN, as previously reported by Ismael et al [146]. Peptide 
sequences from the LC-MS/MS study were consistent with the formation of two independent 
fragments of similar estimated molecular mass (ca. 91 to 97 kDa), resulting in the cleavage of 
a N-fragment and C-fragment. Results also indicated that HOSCN-dependent cleavage of 
apoB-100 may be free radical-mediated, specifically the inhibition of fragmentation when LDL 
was exposed to HOSCN in the presence of BHT. Ismael et al also demonstrated that the 
fragment band was not formed when LDL was exposed to OCN-, indicating that HOSCN 
degradation did not mediate apoB-100 fragmentation [146]. As the resultant LDL 
fragmentation from HOSCN was consistent with the formation of a specific N- and C-fragment 
(as analysed by SDS-PAGE and LC-MS), it was important to determine the amino acid residues 
located on either side of the fragmentation site as this can help determine the mechanism and 
peptide environment mediating the specific peptide fragmentation by HOSCN.  
The cleavage site could not be determined from the sequence coverage following tryptic 
digestion as this varied between experiments. Therefore, a reductive dimethylation protocol 
(adapted from [483]) was utilised to dimethylate the N-terminus of the C-fragment as a non-
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physiological tag of the residue at the fragmentation site. This method of terminal amine 
isotopic labelling of substrates (TAILS) involves the formation of a Schiff base by the reaction 
of formaldehyde with the amine, which is then reduced by cyanoborohydride to produce the 
dimethylamine in a very fast reaction, which has no significant side products and does not 
impact MS/MS peptide sequencing [543], making it a reliable and accurate method of peptide 
tagging. This approach has applications in differential protein expression, assessing post-
translational modifications and protein interactions (reviewed [544]) and has successfully been 
used to discover substrates of eukaryotic proteases, such as caspases [545], cathepsins [546] 
and matrix metalloproteins [547, 548], by detecting the loss of the native N-termini. This made 
it an appropriate approach for identification of fragmentation sites.  
In this study, there was a significantly reduced yield of trypsin-digested apoB-100 peptides. 
Of the peptides detected, Lys ε-dimethylamine groups were detected but no N-terminal 
dimethylation was observed. As trypsin activity is localised at positively-charged Lys (and 
Arg) residues of peptides and reductive dimethylation is also known to dimethylate (and 
neutralise the positive charge of) the Lys ε-amine group [483], it is likely that trypsin was 
unable to recognise these Lys sites and thus fail to cleave the peptide. Indeed, this has been 
experimentally verified [549, 550]. This would restrict tryptic digestion at Arg sites and 
severely impair the capability of obtaining yields of peptides detectable by MS. Using different 
methods of peptide digestion, such as endoproteinase GluC to cleave Glu sites [551] (and to a 
lesser extent, Asp [552]) may overcome this limitations of dimethylation tagging, as Glu and 
Asp sites are not targets of HOSCN reactivity [168] and were not methylated in the peptides 
we were able to obtain in our experiments. 
Other than thiols, HOSCN has previously shown reactivity towards Trp residues [100]. 
Previously, a study showed that HOSCN was more reactive towards Trp in non-Cys-containing 
myoglobin (containing haem) compared to apomyoglobin (haem-deficient), but HOSCN did 
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not react with free Trp or Trp in model peptides (Gly-Trp-Gly or Gly-Lys-Arg-Trp-Gly) [64]. 
In the current study, neither Cys or Trp can be found near the suspected cleavage site and both 
residues are of low abundance on apoB-100 [267, 553], the involvement of these residues in 
formation of the fragments was difficult to determine. However, HOSCN was also found to 
modify the haem-group of myoglobin [64], which may lead to haem degradation and iron 
release. This implied that HOSCN reactivity may be altered or modulated by the presence of 
free iron ions. Ismael et al used a free radical scavenger (BHT) and iron chelator (DFO) to 
examine HOSCN-induced lipid peroxidation of LDL [146]. In this case, DFO partially, yet 
significantly inhibited lipid hydroperoxide and 9-HODE formation in LDL incubated with 250 
µM HOSCN, while BHT completely inhibited the formation of these lipid peroxides and F2-
isoprostane, indicating that lipid peroxidation was via free radical-mediated [146]. Results in 
this Chapter also demonstrate that BHT, but not DFO, significantly reduce apoB-100 
fragmentation, which supports a free radical-mediated mechanism. It should be noted that DFO 
also exhibits free radical-scavenging properties, sometimes leading to the formation of a less 
reactive DFO radical [554, 555]. This could explain the partial prevention of lipid oxidation 
products in HOSCN-modified LDL samples and the relatively large variability in fragment: 
parent apoB-100 ratio when HOSCN-modified LDL was treated with DFO. Nevertheless, 
together this evidence also confirmed the specific fragmentation of apoB-100 is due to its 
reactivity with HOSCN. 
The inhibition of lipid peroxidation [146] and reduced presence of the specific fragment 
formed from HOSCN modified LDL by BHT indicates that one-electron, radical-mediated 
lipid peroxidation is secondary to apoB-100 oxidation and decomposition of peptidyl radicals. 
This is supported by the detection of apoB-100 modifications before the detection of lipid 
oxidation products [146] and the distinct lack of products formed between HOSCN and isolated 
lipids [556]. Unfortunately, the inhibition by BHT is not indicative of a specific radical-
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mediated mechanism. HOSCN reactivity with thiol groups has not been previously reported to 
propagate peptide backbone cleavage. It is still uncertain whether this specific fragmentation 
of apoB-100 is attributed to the thiol (Cys)-selectivity of HOSCN, though the presence of this 
specific fragment was verified under thiol-reducing and non-reducing conditions in this study 
and previously [146]. However, the reaction between HOSCN and thiols can yield RS-SCN 
intermediates [83], which could decompose to generate thiyl radicals (RS•) analogous to RS-
Cl to promote lipid oxidation, particularly in the presence of trace transition metal ions. RS• 
derived from RS-SCN has not been experimentally verified, as RS-SCN has been shown to 
hydrolyse to RS-OH rather than decomposing via RS• formation [83]. Studies to determine the 
pathway responsible for radical formation in apoB-100 and LDL lipid species by HOSCN are 
still required.  
Overall, the marked difference in reactivity of HOSCN and HOCl on proteins, as shown 
with apoB-100, are evident. HOCl exhibits more diverse reactivity with apoB-100 residues, 
resulting in a higher negative charge, aggregate and fragmentation. In contrast, the thiol-
specific oxidant HOSCN, reacts mildly and selectively towards apoB-100, preserving charged 
amino acid residues while forming distinct fragments. By the aforementioned-results, the 
chemical and physical modification of apoB-100 by both HOCl and HOSCN form the basis for 
investigation into the effect these modified LDL species have on cell function and LDL- and 
scavenger receptor binding. In the next Chapter, the effect of LDL modification by HOSCN 
and HOCl on endothelial cell processing and inflammatory response is investigated.
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 Endothelial uptake and response to LDL 
modified by HOSCN or HOCl  
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 Introduction 
The accumulation of LDL within the intima of the artery wall leads to the formation of 
plaques; which is a hallmark of atherosclerosis [262]. This atherosclerotic lesion formation 
caused by retention of LDL-sourced lipids leads to injury of the endothelium, which 
consequentially promotes chemotaxis and adhesion of neutrophils and monocytes both through 
the release of chemokines and cytokines into the vasculature and by the expression of leukocyte 
adhesion molecules on the endothelium [557, 558]. It has been shown that human 
atherosclerotic plaques elevated expression of adhesion molecules VCAM-1, ICAM-1 and E-
selectin, over lipid-enriched regions of the lesion [557]. As part of the immune response, 
infiltrating neutrophils release MPO at the site of the atherosclerotic lesion [21], the actions of 
which can oxidatively modify LDL accumulated in the arterial intima. Indeed, the presence of 
oxidised LDL in human atherosclerotic lesions has been demonstrated [559] and importantly, 
HOCl-modified LDL is present at these sites of injury [281, 284, 502]. Additionally, Cu2+-
oxidised LDL has been shown to activate NF-κB signalling in endothelial cells [311] to induce 
neutrophil and monocyte/macrophage adhesion to the endothelium [307, 436, 560]; which is 
mediated by the expression of ICAM-1, VCAM-1 and E-selectin [307, 433-435]. There is, 
however, a lack of data on whether LDL modified by MPO-derived oxidants induces adhesion 
molecule expression on endothelial cells.  
Upon invocation of endothelial dysfunction, cells within the vasculature, including 
endothelial cells, release inflammatory cytokines to facilitate further migration of circulating 
monocytes/macrophages. One of the most important regulators of this chemotactic process is 
monocyte chemotactic protein-1 (MCP-1), which is upregulated by endothelial cells to attract 
monocytes to injury sites and activate them into macrophage differentiation which occur in a 
MCP-1 concentration-dependent manner [561]. Additionally, it has been shown that the release 
124 | P a g e  
 
of MCP-1 is induced upon exposure of endothelial cells to minimally-modified and Cu2+-
oxidised LDL, promoting chemotaxis and adhesion of circulating monocytes [560, 562], 
independent of leukocyte adhesion molecule expression [560]. Furthermore, interleukin-6 (IL-
6) can also be released by endothelial cells, switching the immune response from the early 
phase of primarily neutrophil adhesion and infiltration to recruitment and subsequent activation 
of monocytes at inflamed sites [563]. Notably, IL-6 binding to soluble IL-6 receptor (sIL-6R) 
has also been shown to synergistically promote MCP-1 secretion from endothelial cells pre-
treated with oxidised LDL [564]. Given the involvement of MPO and LDL in the progression 
of atherosclerotic lesions [21, 281], the effect of LDL modified by the MPO oxidants HOSCN 
and HOCl, on endothelial cell-leukocyte adhesion and cytokine secretion was investigated. 
Endothelial dysfunction, in turn, activates a range of response pathways designed to limit 
cellular damage and restore homeostasis. For example, endoplasmic reticulum (ER) stress 
initiates the unfolded protein response (UPR) which has previously been shown to be activated 
in human arterial endothelial cells incubated with Cu2+-oxidised LDL [463-465, 565]. Upon 
exposure to Cu2+-oxidised LDL, the protein chaperone GRP78 is induced via XBP1 splicing 
mediated through IRE1 branch activation [464], while an associated oxidised phospholipid, 
oxPAPC activated both PERK and ATF6 branches of the UPR [566]. Over longer incubation 
times, the activation of both the IRE1 and PERK branches progressed endothelial cells towards 
apoptosis in response to Cu2+-oxidised LDL [463, 464, 565]. Activation of the UPR can also 
lead to the promotion of antioxidant response element (ARE) pathways mediated by nuclear 
factor (erythroid-derived 2) like-2 (Nrf2) [567, 568]. Upon activation, Nrf2 is cleaved from 
keap1 and translocates to the nucleus to promote the gene expression of antioxidant response 
genes, such as haem oxygenase-1 (HO-1) and glutamate-cysteine ligase (Gcl) [569-571]. HO-
1 is an inducible haem enzyme that degrades haemoglobin to biliverdin with the release of 
carbon monoxide (CO) and ferrous iron (Fe2+) [572]. HO-1 activity can be closely coupled 
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with eNOS activity to preserve eNOS in the coupled state [573], while the CO released by HO-
1 is regarded to have anti-atherogenic properties analogous to NO [574, 575]. Furthermore, 
Gcl ligates Glu and Cys to form L-γ-Glu-L-Cys in the first and rate-limiting step, followed by 
GSH synthetase (GS) activation, resulting in the synthesis of GSH; a constitutively active 
cellular antioxidant involved in signalling and redox homeostasis [576]. Together, the 
components of the ARE pathway work to protect the cell from oxidative injury and preserve 
endothelial function. 
 Aims 
The aim of the studies in this Chapter was to assess the degree of cellular uptake of HOSCN- 
and HOCl-modified LDL associated lipids and the impact of HOSCN- and HOCl-modified 
LDL upon inflammatory and stress-related signalling pathways, including the UPR and Nrf2, 
and the alteration of leukocyte adhesion molecule, IL-6 and MCP-1 expression. 
 Results 
4.3.1. Cell viability and metabolic activity of 
HCAEC 
The extent of endothelial cell viability was initially determined following exposure of 
HCAEC to modified LDL (1.0 mg•mL
-1 LDL treated with 0 µM oxidant, or either 250 µM 
HOSCN or HOCl for 24 h). HCAEC were exposed to 0.1 mg•mL
-1 of each modified LDL 
species for both 24 h and 48 h in serum free-defined media with 5 % v/v FBS, before using the 
lactate dehydrogenase (LDH) assay for cell viability, or the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay for cell metabolic activity (as described in Section 
2.7). The LDH assay was used to measure the activity of LDH released into the media 
compared to the LDH remaining in the cell lysate as an indicator of the proportion of viable 
(intact) cells [489]. These results were compared to data from the MTT assay, which involves 
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measuring the conversion of the yellow, soluble MTT substrate to the purple, water-insoluble 
formazan product by the mitochondria of living cells, which is used as a measure of cellular 
metabolic activity [577]. 
No loss in viability was seen when HCAEC were incubated with or without each oxidised 
LDL species (Figure 4.1A). Similar to the results demonstrated in the LDH assay, there was 
no significant change in relative formazan production between oxidised LDL treatments after 
24 h incubation (Figure 4.1B). At 48 h, whilst there was no change in HCAEC viability between 
the treatment group, there was a marked increase in formazan production with LDL (both 
control and oxidised) treatment, although this did not reach statistical significance. Thus, 
treatment of HCAEC with 0.1 mg•mL
-1 of incubation control LDL, HOSCN- or HOCl-
modified LDL species was not cytotoxic to HCAEC, but had a slight stimulatory metabolic 
effect on the cells.  
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Figure 4.1. Cell viability and activity of HCAEC after incubation with oxidised LDL for 
24 h and 48 h. Firstly, 1.0 mg•mL
-1 control LDL or LDL incubated with 250 µM HOSCN or 
250 µM HOCl were incubated at 37 °C for 24 h. Subsequently, HCAEC were treated with 0.1 
mg•mL
-1 of LDL or (250 μM HOSCN or HOCl) oxidised LDL species at 37 °C for 24 h (white 
bar) or 48 h (black bar) in treatment medium. (A) Cell viability was measured by the LDH 
activity assay. (B) Cell activity was measured by the production of formazan (MTT assay). 
Three independent HCAEC and LDL donors were used. Bars represent the mean ± SD (n = 3). 
Two-way ANOVA with Dunnett’s multiple comparison test between treatment groups and 
Sidak multiple comparison test between time points. No significant difference between 
treatments or time points were found.  
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4.3.2. Cell Migration 
Atherosclerotic injury is known to cause endothelial denudation at the site of the injured 
vessel and when this occurs, nearby endothelial cells will migrate to the denuded area in an 
attempt to close the wound [578]. To simulate a wound in the endothelium to assess the effect 
of MPO oxidant-modified LDL on endothelial cell migration, a scratch was made across a 
cultured HCAEC monolayer, as described in Section 2.8. The width of the scratch, as an 
indicator of cell migration, was measured at intervals between 0 and 24 h oxidised LDL 
treatment or until the scratch closed, for cells in medium alone or incubated with 0.1 mg•mL
-1 
of each LDL treatment. The scratch width was measured at four different sites around the 
scratch intersection indicated by the white arrows in Figure 4.2A. Generally, re-establishment 
of the endothelial cell monolayer occurred after approximately 18 h across all treatments. 
Additionally, the average migration rate of the HCAEC was calculated as approximately 2.5 
µm•h
-1 and likewise did not significantly differ across treatment groups (Figure 4.2B).  
129 | P a g e  
 
 
Figure 4.2. Cellular migration rate of HCAEC during incubation with oxidised LDL for 
24 h. Firstly, 1.0 mg•mL
-1 control LDL or LDL incubated with 250 µM HOSCN or 250 µM 
HOCl were incubated at 37 °C for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or 
oxidised LDL species at 37 °C for up to 24 h in treatment medium. (A) Scratch width was 
measured at intervals from 0 h up to 24 h of treatment to calculate the (B) migration rate. 
Arrows indicate where scratch width was measured in quadruplicate for each sample. Scale 
bar represent 200 µm. Two independent HCAEC and LDL donors were used. Bars represent 
the mean ± SD (n = 3). One-way ANOVA with Dunnett’s multiple comparison test. No 
significant difference between treatments or time points was found. 
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4.3.3. LDL uptake by HCAEC 
Given the aforementioned increases in HCAEC metabolic activity with either control LDL 
or MPO oxidant-modified LDL treatments, the next experiment assessed the uptake of LDL-
sourced lipids by HCAEC. Initial experiments were performed to measure changes in 
cholesterol and cholesteryl esters following exposure of LDL modified by HOSCN, HOCl or 
CuSO4, which is reported to be taken up by endothelial cells [579, 580]. After treatment, the 
LDL associated lipids and cholesterol were extracted and analysed following HPLC separation 
as described (Section 2.9). As indicated in the HPLC trace of LDL-sourced lipids (Figure 4.3) 
it was determined that there was no significant loss of cholesterol or cholesteryl esters after 
incubation with 100 µM or 250 µM HOSCN or HOCl for 24 h at 37 °C. In contrast, LDL 
incubated with 5 µM CuSO4 for 24 h at 37 °C resulted in a near total depletion of the cholesteryl 
linoleate, docosahexanoate and arachidonate esters in LDL (Figure 4.3; grey line). This is 
consistent with previous reports showing extensive lipid modifications and oxidation on 
exposure to CuSO4 [266, 375]. 
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Figure 4.3. Representative HPLC trace of cholesterol and cholesteryl ester separation 
from 10 µg LDL. 1.0 mg•mL-1 control LDL (black) or LDL modified by 100 µM HOSCN (red), 
250 µM HOSCN (green), 100 µM HOCl (blue), 250 µM HOCl (purple) or 5 µM CuSO4 (grey) 
for 24 h at 37 °C. The labels for each peak are (C) Cholesterol; (CD) Cholesteryl 
docosahexanoate; (CA) Cholesteryl arachidonate; (CL) Cholesteryl linoleate; (CO) 
Cholesteryl oleate; (CP) Cholesteryl palmitate; (CS) Cholesteryl stearate. Data are 
representative of three independent experiments. 
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Having demonstrated that LDL modified by MPO oxidants HOSCN or HOCl does not 
significantly lead to a loss of native cholesterol or cholesteryl esters, the next experiments 
similarly measured the content of cholesterol and cholesteryl esters in HCAEC following 
exposure to each type of modified LDL. Cholesterol and cholesteryl ester uptake by HCAEC 
was measured following the incubation of cells with medium alone or either control LDL, 
HOSCN- or HOCl-modified LDL for 24 h and 48 h (Figure 4.4A). Whether in the presence or 
absence of LDL or each MPO oxidant-modified LDL, there was an increase in total cholesterol 
content within HCAEC between 24 and 48 h. In the control LDL-treated group, this increase 
was found to be statistically significant (shown by #) and was paralleled with a reproducible, 
but non-significant increase in the proportion of intracellular cholesteryl esters (Figure 4.4B). 
No significant changes were observed between treatments within each time point. When the 
time-dependent accumulation of the total cholesterol was expressed as the difference between 
24 and 48 h measurements, there was a significant accumulation of total cholesterol with all 
LDL treatments compared to the control (Table 4.1). LDL cholesterol and cholesteryl ester 
uptake was also measured in HCAEC exposed to Cu2+-oxidised LDL, however the near-
complete depletion of native cholesteryl esters following exposure to Cu2+ (Figure 4.3) made 
this HPLC method inappropriate to measure uptake of Cu2+-oxidised LDL. Overall, prolonged 
in vitro exposure of HCAEC to each LDL treatment resulted in an accumulation of cholesterol, 
however this was independent of LDL modification by MPO.
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Figure 4.4. Total cholesterol and cholesteryl ester levels of HCAEC after incubation with 
oxidised LDL. Firstly, 1.0 mg•mL
-1 control LDL or LDL incubated with 100 or 250 µM 
HOSCN, or 100 or 250 µM HOCl were incubated at 37 °C for 24 h. HCAEC were treated with 
0.1 mg•mL
-1 of LDL or oxidised LDL species at 37 °C for 24 h (white bar) or 48 h (black bar) 
in treatment media. Cholesterol and cholesteryl esters were normalised to cellular protein 
concentration as assessed by the BCA assay. Total cholesterol represents the sum of the free 
cholesterol and the cholesteryl esters detected by HPLC in the HCAEC lysate samples (A). 
Cholesteryl esters are represented as a percentage of the total cholesterol measured in HCAEC 
lysates (B). Three independent HCAEC and LDL donors were used. Bars represent the mean 
± SD (n = 3). Two-way ANOVA with Dunnett’s multiple comparison test between treatment 
groups and Sidak multiple comparison test between time points. # represent p < 0.05 between 
24 and 48 h time point.
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Table 4.1. Difference in total cellular cholesterol in HCAEC between 24 h and 48 h 
incubation with MPO oxidant-modified LDL. The change in intracellular lipids was 
calculated between 24 h and 48 h incubation times (ΔIntracellular lipid) from the data in 
Figure 4.4A to compare the change in intracellular lipids due to LDL uptake, independent of 
lipids already present in the cells. One-way ANOVA with Holm-Sidak multiple comparison test. 
* and ** represent p < 0.05 and 0.01 respectively compared to the control. 
 
4.3.3.1. Scavenger receptor expression in 
HCAEC 
The removal of modified proteins, including oxidised LDL, from the circulation is mediated 
by scavenger receptors expressed on cells of the vasculature [421]. There are several different 
scavenger receptors that are present on endothelial cells that have been reported to bind to 
modified LDL for removal from the circulation and transcytosis to the intima [535]. As there 
was no apparent increased uptake of cholesterol and cholesteryl esters by HCAEC after 
incubation with each modified LDL species compared to the control, the expression of various 
endothelial scavenger receptors was assessed. 
HCAEC were incubated with each MPO-oxidant modified LDL or Cu2+-modified LDL (0.1 
mg•mL
-1 apoB-100) for 3 or 24 h, at which time the relative mRNA expressions of LDL 
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receptor (LDLR) and scavenger receptors were measured by qPCR relative to the expression 
of constitutive genes 18S ribosomal subunit and β2-microglobulin (β2M) for normalisation. 
Compared to non-treated HCAEC, expression of LDLR was decreased following exposure to 
each MPO oxidant-modified LDL for 24 h (Figure 4.5). Scavenger receptor class A 1 (SR-A1), 
SR class B 2 (SR-B2, also known as CD36) and scavenger receptor for endothelial cell 1 
(SREC-1) were unchanged across LDL treatments at both the 3 and 24 h time points analysed 
(Figure 5.5). In contrast, the expression of the scavenger receptors SR-B1 and LOX-1 were 
decreased following exposure to MPO oxidant-modified LDL (Figure 4.6). Compared to 
control, SR-B1 was significantly decreased after 24 h incubation with 250 µM HOCl-modified 
LDL whilst the mRNA expression of the LDL receptor (LDLR) was decreased in all HCAEC 
exposed to either control LDL or MPO oxidant-modified, reaching statistical significance 
across all MPO oxidant-modified LDL treatments. Similarly, LOX-1 expression was also 
decreased following MPO oxidant-modified LDL exposure but this did not reach statistical 
significance. In contrast, there was no significant changes in LDLR expression in HCAEC 
treated with Cu2+-modified LDL treatment. However, the expression of LOX-1 with Cu2+-
modified LDL was significantly increased following 3 h incubation time, but decreased to basal 
levels following increased treatment time (24 h).  
After having demonstrated that each MPO oxidant-modified LDL can reduce the expression 
of scavenger receptors SR-B1 and LDLR after 24 h incubation with HCAEC, we next assessed 
the protein expression after 24 h incubation with control LDL, (250 µM oxidant) HOSCN- or 
HOCl-modified LDL by Western blot (Figure 4.7). However, no changes in SR-B1 and LDLR 
protein expression were observed relative to the β-actin loading control. Similarly, no changes 
in SR-B2 protein expression was observed. The expression of LOX-1 was also probed, but no 
LOX-1 protein expression in HCAEC was detected by the Western blot techniques employed 
in this study (data not shown).  
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Figure 4.5. HCAEC LDLR mRNA expression measured by qPCR after incubation with 
LDL modified by HOSCN, HOCl or CuSO4. Firstly, 1.0 mg•mL
-1 control LDL or LDL 
modified by 100 or 250 µM HOSCN, 100 or 250 µM HOCl, or 5 µM CuSO4 at 37 °C for 24 h. 
HCAEC were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species at 37 °C for 3 h (white 
bar) or 24 h (black bar) in treatment medium. LDLR mRNA expression was normalised to 18S 
and β2M as housekeeping genes. Two independent HCAEC and three independent LDL donors 
were used. Bars represent the mean ± SD (n = 3). Two-way ANOVA with Dunnett’s multiple 
comparison test between treatment groups and Sidak multiple comparison test between time 
points. *, ** and *** represent p < 0.05, 0.01 and 0.001 respectively compared to their 
respective control.
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Figure 4.6. HCAEC scavenger receptor mRNA expression measured by qPCR after 
incubation with LDL modified by HOSCN, HOCl or CuSO4. Firstly, 1.0 mg•mL
-1 control 
LDL or LDL modified by 100 or 250 µM HOSCN, 100 or 250 µM HOCl, or 5 µM CuSO4 at 
37 °C for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species at 37 
°C for 3 h (white bar) or 24 h (black bar) in treatment medium. Scavenger receptor mRNA 
expression was normalised to 18S and B2M as housekeeping genes. Two independent HCAEC 
and three independent LDL donors were used. Bars represent the mean ± SD (n = 3). Two-
way ANOVA with Dunnett’s multiple comparison test between treatment groups and Sidak 
multiple comparison test between time points. * represent p < 0.05 respectively compared to 
their respective control. ## represent p < 0.01 respectively between 24 and 48 h time point.
138 | P a g e  
 
 
Figure 4.7. HCAEC LDLR and scavenger receptor protein expression of SR-B1 and SR-
B2 measured by Western blot after incubation with LDL modified by HOSCN or HOCl. 
Firstly, 1.0 mg•mL
-1 control LDL or LDL incubated with 250 µM HOSCN or 250 µM HOCl 
were incubated at 37 °C for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or oxidised 
LDL species for 37 °C for 24 h in treatment medium. (A) Representative Western blots of SR-
B1, SR-B2, LDLR and β-actin, column 1: control without LDL, column 2: control LDL, column 
3: LDL modified by HOSCN, column 4: LDL modified by HOCl. LOX-1 was not detected in 
any blots when using two independent LOX-1 antibodies. (B) Expression of scavenger 
receptors measured by densitometry, relative to the control; control (black), control LDL 
(chequered), HOSCN-LDL (vertical line) and HOCl-LDL (diagonal line). Scavenger receptor 
protein expression was normalised to β-actin as the housekeeping protein. Three independent 
HCAEC and LDL donors were used. Bars represent the mean ± SD (n = 3). Two-way ANOVA 
with Dunnett’s multiple comparison test between treatment groups and Sidak multiple 
comparison test between time points. No statistical difference was found between treatments.
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4.3.3.2. Cys-dependent cathepsin activity  
Cathepsins are a family of lysosomal protease enzymes that hydrolyse the peptide bonds of 
proteins [581]. The Cys-dependent cathepsins (named due to the cathepsin activity depending 
on the Cys residue in the active site) are heavily implicated in cardiovascular disease with 
cathepsins capable of degrading LDL, which decreases cholesterol efflux from macrophages 
and propagates foam cell formation (reviewed [581]). In addition, (MPO- and Cu2+-) oxidised 
LDL has been reported to alter cathepsin activity in macrophages, which compromises the 
ability of cells to process LDL [582, 583]. Endothelial cells also contain cathepsin B and L, 
which are important for neovascularisation [584-586] and, like macrophages, may be involved 
in the degradation of oxidised LDL in endothelial cells to prevent apoptosis [587], though other 
physiological consequences of this still remains uncertain.  
Given the finding that intracellular cholesterol increased, while scavenger receptor protein 
expression was unchanged after incubation with LDL modified by HOSCN or HOCl, the 
activity of Cys-dependent cathepsins B and L to assess lysosomal function after 24 h treatment 
of the cells was then assessed. Cathepsin L activity was approximately 5.6-fold higher than 
cathepsin B in HCAEC under control conditions as measured at 24 h (Figure 4.8A). Treatment 
of cells with 0.1 mg•mL
-1 of control LDL, 250 µM HOSCN-modified LDL or 250 µM HOCl-
modified LDL, did not significantly alter cathepsin B or L activity in the HCAEC compared to 
the untreated control cells (Figure 4.8B).  
In summary, there was a time-dependent accumulation of cholesterol in HCAEC exposed 
to control LDL or MPO oxidant-modified LDL in vitro that was concurrent with a reduction in 
LDLR mRNA, but not protein expression, which was significant for each MPO oxidant-
modified LDL. Similarly, HOCl-modified LDL significantly reduced the mRNA expression of 
140 | P a g e  
 
SR-B1, whilst other scavenger receptors and Cys-dependent cathepsin activity remained 
unaffected by LDL treatment.  
 
Figure 4.8. Cys-dependent cathepsin (B & L) activity in HCAEC treated with LDL 
modified by HOSCN or HOCl. Firstly, 1.0 mg•mL
-1 control LDL or LDL modified by 250 µM 
HOSCN or 250 µM HOCl at 37 °C for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or 
oxidised LDL species at 37 °C for 24 h in treatment medium. (A) Comparison of the activity of 
Cathepsin B and L in control HCAEC measured by the rate of release of the fluorescent AMC 
compound from the proteolytic degradation of the cathepsin substrates (Z-Arg-Arg-AMC and 
Z-Phe-Arg-AMC, respectively) measured at 360 and 460 nm. Fluorescence was normalised to 
cell protein measured by the BCA assay. (B) Cathepsin B (white bars) and cathepsin L (Black 
bars) activity was measured in the cell lysate similarly to A and normalised to the respective 
control. Three independent HCAEC and two independent LDL donors were used. Bars 
represent the mean ± SD (n = 4). One-way ANOVA with Dunnett’s multiple comparison test. 
No statistical difference was found between treatments.
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4.3.3.3. Leukocyte adhesion molecule expression 
Given that exposure of HCAEC to LDL was not causing extensive toxicity or altered lipid 
profiles, the next series of experiments sought to investigate whether MPO oxidant-modified 
LDL induced an inflammatory or stress response in HCAEC. Given the previous data that 
showed other types of modified LDL can promote inflammation by altering adhesion molecule 
expression and cytokine/chemokine release [433, 435, 588-590], initial studies assessed 
ICAM-1, VCAM-1 and E-selectin expression. As demonstrated in Figure 4.9, following 
incubation of HCAEC for 3 h or 24 h with 0.1 mg•mL
-1 control LDL, 100 µM or 250 µM 
HOSCN- or HOCl-modified LDL, no significant change in ICAM-1, VCAM-1 or E-selectin 
expression was observed. In comparison, the expression of ICAM-1, VCAM-1 and E-selectin 
were induced by stimulation with 0.2 mg•mL
-1 TNF-α within 3 h and maintained at a 
significantly elevated level over the 24 h incubation. The elevated expression at 3 and 24 h 
(respectively) compared to the respective controls were as follows; ICAM-1 (9.6- and 4.8-
fold), VCAM-1 (15.5- and 3.8-fold) and E-selectin (27- and 4-fold).
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Figure 4.9. HCAEC leukocyte adhesion molecule mRNA expression measured by qPCR 
after incubation with LDL modified by HOSCN or HOCl. Firstly, 1.0 mg•mL
-1 control LDL 
or LDL modified by 100 or 250 µM HOSCN, 100 or 250 µM HOCl for 24 h at 37 °C. HCAEC 
were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species at 37 °C for 3 h (white bar) or 
24 h (black bar) in treatment medium. A 21 h control incubation followed by 3 h treatment with 
TNF-α (0.2 ng•mL-1) totalling 24 h was used as a positive control for leukocyte adhesion 
molecule gene expression. Expression was normalised to 18S and β2M as housekeeping genes. 
Three independent HCAEC and LDL donors were used. Bars represent the mean ± SD (n = 3). 
Two-way ANOVA with Dunnett’s multiple comparison test between treatment groups and 
Sidak multiple comparison test between time points. *** and **** represent p < 0.001 and 
0.0001 respectively compared to their respective control. #### represents p < 0.0001 between 
24 and 48 h time point.
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4.3.3.3.a. Neutrophil adhesion to endothelial 
cells 
Functional assessment of HCAEC adhesion molecule expression was next undertaken by a 
neutrophil adhesion assay. The adhesion of human neutrophils to HCAEC following incubation 
with 0.1 mg•mL
-1 control LDL, (250 µM oxidant) HOSCN- or HOCl-modified LDL for 24 h 
was performed under static conditions in vitro. Neutrophils were stained with 1 μM calcein for 
visualisation during microscopy and to quantify the adhesion of neutrophils through the 
measurement of the calcein fluorescence emission.   
As shown in Figure 4.10A, neutrophils are clearly distinguishable from HCAEC due to the 
calcein fluorescence. The neutrophils adherent to HCAEC after treatment was quantified by 
the fluorescence measured before and after five washes with PBS to remove non-adherent cells. 
The population of adherent neutrophils (%) was calculated as the ratio of the fluorescence after 
five washes compared to before washing. In confirmation of the HCAEC adhesion molecule 
mRNA data above, there was no significant change in the population of neutrophils adherent 
to HCAEC following treatment with each type of modified LDL. This was calculated to be 
between 10.6 % (control) and 13 % (HOCl-modified LDL; Figure 4.10B), indicating that under 
the conditions employed in this study, MPO-modified LDL is not an independent inducer of 
endothelial cell-dependent leukocyte adhesion.
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Figure 4.10. Neutrophil adhesion to HCAEC after incubation of HCAEC with LDL 
modified by HOSCN or HOCl. Firstly, 1.0 mg•mL
-1 control LDL or LDL modified by 250 µM 
HOSCN or 250 µM HOCl at 37 °C for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or 
oxidised LDL species at 37 °C for 24 h in treatment medium. Neutrophils were stained with 1 
µM calcein for fluorescence measurement at 492 and 515 nm for live neutrophil adhesion to 
HCAEC. HCAEC and neutrophils were incubated together for 30 min prior to removal of non-
adherent neutrophils with repeated rinsing. (A) Representative brightfield (left) and 
fluorescence (calcein: right) microscopic images of neutrophils adherent to HCAEC after 
washing. (B) Percentage adhesion of neutrophils after 24 h LDL treatment to HCAEC and 20 
min incubation of neutrophils to HCAEC. Two independent HCAEC and LDL donors were 
used. Bars represent the mean ± SD (n = 3). One-way ANOVA with Dunnett’s multiple 
comparison test. No statistical difference was found between treatments.
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4.3.3.4. IL-6 and MCP-1 expression and 
secretion 
Although neutrophil adhesion to HCAEC was not enhanced by incubation with MPO 
oxidant-modified LDL, IL-6 released by endothelial cells can lead to switching of neutrophil 
infiltration to the recruitment of monocytes [563] and concurrent secretion of MCP-1 to attract 
monocytes to the site of inflammation [561]. The next set of experiments investigated whether 
expression of chemotactic cytokines MCP-1 and IL-6 was upregulated in HCAEC. 
In Figure 4.11A and B, respectively, expression of both IL-6 and MCP-1 was significantly 
upregulated by exposure of HCAEC to 0.2 ng•mL
-1 TNF-α, which was used as a positive 
control.  However, after incubation with LDL modified by either (100 μM or 250 μM oxidant) 
HOSCN or HOCl for 3 or 24 h, no significant change in IL-6 (Figure 4.11A) or MCP-1 (Figure 
4.11B) mRNA expression was observed compared to the control.  
Similarly, incubation of HCAEC with 0.1 mg•mL
-1 control LDL or LDL modified by (250 
μM oxidant) HOSCN or HOCl for 24 h did not result in alteration of the levels of IL-6 (Figure 
4.12A) and MCP-1 (Figure 4.12B) secreted from HCAEC following 24 h incubation compared 
to the respective controls. In summary, these data implicate a lack of monocyte recruitment 
response by endothelial cells exposed to each MPO oxidant-modified LDL.
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Figure 4.11. HCAEC mRNA expression of cytokines IL-6 and MCP-1 measured by qPCR 
after incubation with LDL modified by HOSCN or HOCl. Firstly, 1.0 mg•mL
-1 control LDL 
or LDL modified by 100 or 250 µM HOSCN, 100 or 250 µM HOCl at 37 °C for 24 h. HCAEC 
were treated with 0.1 mg•mL
-1 of control LDL or oxidised LDL species at 37 °C for 3 h (white 
bar) or 24 h (black bar) in treatment medium. A 21 h control incubation followed by 3 h 
treatment with TNF-α (0.2 ng•mL-1) totalling 24 h was used as a positive control for IL-6 (A) 
and MCP-1 (B) gene expression. Expression was normalised to 18S and β2M as housekeeping 
genes. Three independent HCAEC and LDL donors were used. Bars represent the mean ± SD 
(n = 3). Two-way ANOVA with Dunnett’s multiple comparison test between treatment groups 
and Sidak multiple comparison test between time points. * and *** represent p < 0.05 and 
0.001 respectively compared to their respective control. No statistical difference was found 
between time points.
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Figure 4.12. HCAEC protein expression of cytokines IL-6 and MCP-1 measured by 
ELISA after incubation with LDL modified by HOSCN or HOCl. Firstly, 1.0 mg•mL
-1 
control LDL or LDL modified by 250 µM HOSCN or 250 µM HOCl at 37 °C for 24 h. HCAEC 
were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species at 37 °C for 24 h in treatment 
medium. The treatment media from untreated and treated HCAEC was collected after 24 h to 
measure IL-6 (A) and MCP-1 (B) released from HCAEC. Three independent HCAEC and LDL 
donors were used. Bars represent the mean ± SD (n = 3). One-way ANOVA with Dunnett’s 
multiple comparison test. No statistical difference was found between treatments.   
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4.3.4. Stress response pathways in HCAEC 
4.3.4.1. Unfolded protein response 
ER stress is a key response of vascular cells to oxidised LDL in the development of 
atherosclerotic lesions (reviewed [591]). ER stress triggers that activation of the UPR, which 
is an integrated signalling pathway designed to restore cellular homeostasis or failing that, 
trigger cell death by apoptosis, which involved activation of the effector protein CHOP [458]. 
The UPR consist of three separate pathways termed PERK, IRE1 and ATF6 (as described in 
Chapter 1, see Figure 1.14), which are activated following dissociation of the chaperone 
GRP78 from the ER membrane [592]. Thus, in situations of ER stress, the mRNA expression 
of UPR genes, activating transcription factor-4 (ATF4), 78 kDa glucose-regulating protein 
(GRP78), spliced X-box binding protein-1 (sXBP1) and CHOP are induced leading to synthesis 
of the respective proteins [457]. Tunicamycin (TM) was used as a positive control, as it is 
promotor of UPR by blocking the N-linked glycosylation of proteins [593], leading to the 
accumulation of unglycosylated proteins and subsequent induction of ER stress and the UPR. 
The expression of ATF4, GRP78, sXBP1and CHOP mRNA was significantly upregulated 
when cells were stimulated with 5 µg•mL
-1 TM (Figure 4.13). The elevated expression at 3 and 
24 h (respectively) compared to the respective controls were as follows; CHOP (69- and 6.6-
fold), ATF4 (2.7- and 1.9-fold), GRP78 (7.4- and 3.7-fold) and sXBP1 (4- and 1.2-fold). 
The mRNA expression of activating transcription factor-6 (ATF6) was not upregulated with 
TM treatment. However, ATF6 is constitutively expressed and inactive until accumulation of 
misfolded proteins results in the proteolytic cleavage of ATF6 and translocation to the nucleus 
[594]. Thus, ATF6 activity in the activation of the UPR may not be dependent on the induction 
of gene expression. The expression of ATF4, GRP78, sXBP1 and CHOP induced by TM 
decreased significantly between 3 and 24 h treatment, indicating the induced gene expression 
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of UPR by TM is a relatively fast and acute response in this case. This has also been 
demonstrated in other studies with human endothelial cells exposed to (5 – 10 µg•mL-1) TM 
for 4 – 6 h, which upregulated ATF4, CHOP, GRP78 and splicing of XBP1 [465, 592, 595]. 
However, the aforementioned studies did not extend the TM exposure to 24 h to compare to 
the results of this Chapter. Having shown that HCAEC have the capacity to invoke the UPR, 
these studies were extended by exposing HCAEC with LDL modified by either HOSCN or 
HOCl under conditions described above. However, in each case no significant changes in the 
above mentioned UPR genes were apparent after 3 or 24 h incubation of the HCAEC with each 
oxidised LDL. This suggests that HCAEC exposed to oxidised LDL, under these experimental 
conditions at least, does not invoke these cellular responses.
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Figure 4.13. HCAEC mRNA expression of unfolded protein response (UPR) genes 
measured by qPCR after incubation with LDL modified by HOSCN or HOCl. Firstly, 1.0 
mg•mL
-1 control LDL or LDL modified by 100 or 250 µM HOSCN, 100 or 250 µM HOCl at 37 
°C for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species at 37 °C 
for 3 h (white bar) or 24 h (black bar) in treatment medium. Incubation with tunicamycin (TM; 
5 µg•mL
-1) for 3 or 24 h was used as a positive control for UPR gene expression. Bars represent 
the mean ± SD (n = 3). Expression was normalised to 18S and β2M as housekeeping genes. 
Two-way ANOVA with Dunnett’s multiple comparison test between treatment groups and 
Sidak multiple comparison test between time points. *, **, *** and **** represent p < 0.05, 
0.01, 0.001 and 0.0001 respectively compared to their respective control. ##, ### and #### 
represent p < 0.01, 0.001 and 0.0001 respectively between 24 and 48 h time point. 
4.3.4.2. Antioxidant response element genes 
 Previous studies have also shown that oxidised LDL species, including LDL oxidised by 
HOCl, can induce Nrf2 activation [596, 597]. Activation of Nrf2 leads to upregulated 
expression of antioxidant genes, including GS, Gclc and HO-1 [569, 570, 598]. As shown in 
Figure 4.14, incubation of HCAEC with 0.1 mg•mL
-1 of control LDL, or LDL incubated with 
100 µM or 250 µM HOSCN or HOCl for 3 or 24 h, mRNA expression of Nrf2, GS and Gclc 
was not significantly changed. However, incubation with 100 µM and 250 µM HOSCN-
modified LDL for 3 h significantly increased HO-1 expression by 1.7- and 2.9-fold, 
respectively, compared to the control. This increased mRNA expression returned to control 
levels after 24 h treatment. In contrast, HOCl-modified LDL did not significantly induce HO-
1 expression after 3 h, but did significantly elevate HO-1 mRNA expression (approximately 
1.5-fold) compared to the control after 24 h exposure to (250 μM oxidant) HOCl-modified 
LDL. 
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Figure 4.14. HCAEC mRNA expression of antioxidant response genes measured by 
qPCR after incubation with LDL modified by HOSCN or HOCl. Firstly, 1.0 mg•mL
-1 
control LDL or LDL modified by 100 or 250 µM HOSCN, 100 or 250 µM HOCl at 37 °C for 
24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species at 37 °C for 3 h 
(white bar) or 24 h (black bar) in treatment medium. Expression was normalised to 18S and 
β2M as housekeeping genes. Three independent HCAEC and LDL donors were used. Bars 
represent the mean ± SD (n = 3). Two-way ANOVA with Dunnett’s multiple comparison test 
between treatment groups and Sidak multiple comparison test between time points. *, **, *** 
and **** represent p < 0.05, 0.01, 0.001 and 0.0001 respectively compared to their respective 
control. ## and #### represent p < 0.01 and 0.0001 respectively between 24 and 48 h time 
point.  
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These studies were extended by examination of the protein expression of HO-1 by Western 
blotting. Initial studies showed that following exposure of HCAEC to 0.1 mg•mL
-1 LDL 
modified by HOSCN or HOCl (250 μM oxidant) for 24 h, there was a large induction of HO-
1 protein expression (Figure 4.15, n = 2). Regardless of the 2.9-fold spike in HO-1 mRNA 
expression after 3 h treatment with (250 μM oxidant) HOSCN-modified LDL, which returned 
to similar levels induced by HOCl-modified LDL after 24 h exposure, HOCl-modified LDL 
induced considerably greater HO-1 protein expression than the equivalent HOSCN-modified 
LDL after 24 h exposure. However, the lack of reproducibility, which may be due to HCAEC 
donor variation or problems with the current Western blot procedure, makes interpretation of 
this result difficult. Overall, these experiments show the antioxidant response to MPO oxidant-
modified LDL may involve induction of HO-1, but this study was not conclusive. 
 
Figure 4.15. HCAEC protein expression of HO-1 after incubation with LDL modified by 
HOSCN or HOCl. Firstly, 1.0 mg•mL
-1 control LDL or LDL modified by 250 µM HOSCN or 
HOCl at 37 °C for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species 
for 24 h at 37 °C. Bars represent the mean ± SD (n = 2). 
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 Discussion 
The experiments in this Chapter involved the in vitro exposure of HCAEC to LDL after the 
lipoprotein had been incubated with up to 250 μM HOSCN or HOCl, which is believed to be 
achievable under physiological conditions as it has previously been shown that plasma SCN- 
concentrations in smokers have been detected up to 250 μM [42]. The impact of exposure of 
HOSCN- or HOCl-modified LDL upon HCAEC was assessed in terms of cytotoxicity, 
metabolic activity, lipid uptake and induction of pro-inflammatory and stress-related pathways 
in endothelial cells. The extent of cholesterol and cholesteryl ester accumulation, even at 
prolonged incubation times (48 h), did not significantly differ to the control, with no alteration 
in viability, metabolic activity or cell migration in this study. This is likely related to a lack of 
change in scavenger receptor expression. Further, no overall change in expression of leukocyte 
adhesion molecules, cytokines, or UPR and ARE pathway signalling molecules was observed, 
apart from HO-1 being stimulated by HOSCN-modified LDL.  
In this study, no evidence was obtained for cell death, whereas previous data have shown 
that Cu2+- or cell-dependent oxidised LDL induced apoptosis in endothelial cells in vitro [514, 
523, 599, 600]. In HCAEC exposed to Cu2+-oxidised LDL, apoptosis was associated with the 
downregulation of bcl-1 protein and induced caspase activation by the independent activation 
of protein kinase C or protein tyrosine kinase [514, 523]. However, LDL modified by HOSCN 
or HOCl in this study did not induce significant cell death in HCAEC following up to a 48 h 
incubation time. This is likely due in large part to the difference in the extent and nature of 
LDL modification seen with reactivity of MPO oxidants compared to Cu2+ ions to LDL. Cu2+-
modified LDL is largely characterised by extensive lipid oxidation [303], which has been 
shown to cause endothelial cell apoptosis [514, 523, 526, 601]. In contrast, MPO oxidants 
display more limited reactivity with the lipid moiety of LDL, except at high molar excesses 
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[53]. In the studies which used a higher molar ratio of HOCl to LDL (2000: 1), apoptosis was 
induced in macrophages [602, 603], therefore extensively modified LDL particles are required 
to elicit this response, which may also be the case for endothelial cells.  
4.4.1. LDL uptake and scavenger receptor 
expression 
The increase in intracellular lipid (Δintracellular lipid) concentration in HCAEC over time 
was significantly greater after incubation with control LDL and each MPO oxidant-modified 
LDL compared to cells incubated without LDL. However, there was no difference in 
intracellular lipids between HCAEC treated with these different forms of LDL. HCAEC 
exposed to LDL for longer incubation times may have led to cell-mediated modification of 
LDL by lipoxygenases [341]. As lipoxygenases target the arachidonate and linoleate moiety of 
LDL [335, 336], and hypohalous acids used at the concentrations of this study did not 
significantly deplete native arachidonate and linoleate levels (shown in Figure 4.3), measuring 
these cholesteryl esters post-incubation with cells could be performed to determine if cell-
mediated oxidation of LDL occurred, as well as if MPO-modified LDL upregulates 
lipoxygenase activity. Further, the use of serum-supplemented treatment media which would 
contain lipids may mask the uptake of the MPO oxidant-modified LDL. The use of lipoprotein-
deficient serum would remove this potential limitation and future experiments could be 
optimised for these experimental conditions. 
Endothelial cells express several classes of scavenger receptors that have classically been 
associated with elevated uptake and accumulation of LDL-sourced lipids in macrophages 
[421]. HOCl-modified LDL (400:1 molar ratio of HOCl to apoB-100) binding to SR-B1 and 
SR-B2 has been shown to be competitive to Cu2+-oxidised LDL in THP-1 monocytes [604] 
and suggests that uptake of LDL modified by HOCl by endothelial cells may be via scavenger 
receptors. This is supported by another study which found that immunological blocking of SR-
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B2 largely inhibited adhesion of polymorphonuclear leukocytes to HUVEC that was induced 
by exposure to HOCl-modified LDL [438]. However, alterations in the gene or protein 
expression of these SR-B1 and SR-B2 was not investigated in those studies. Yet, the expression 
of scavenger receptors was mostly unaltered in the current study, with a modest downregulation 
of SR-B1 after 24 h incubation with HOCl-modified LDL. This contrast may be due to the 
higher HOCl: apoB-100 ratio in those previous studies (approximately 400:1 [604], and up to 
2716:1 [438]) compared to the current study (up to 125:1) resulting in greater extent of 
modification of the LDL. This is pertinent when the REM of HOCl-modified LDL is compared 
from those studies (cf. 2.1-fold [604] and 7.2-fold [438]) to the current study (approximately 
1.8-fold; Figure 3.1), despite the fact that the LDL was incubated for only 40 min to 1 h in 
those studies, while LDL was incubated for 24 h in the current study. 
Cu2+-oxidised LDL may have induced a rapid response in upregulating LOX-1 expression, 
but the expression was highly variable, and only significant following 3 h incubation, with 
downregulation to below control levels by 24 h exposure. This contradicts a similar study in 
HCAEC, which did observe mRNA and protein upregulation of LOX-1 following 24 h 
incubation to 0.04 mg•mL
-1 Cu2+-oxidised LDL [518]. This difference could be attributed to 
Cu2+-oxidised LDL inducing greater extent of apoptosis in HCAEC at 0.1 mg•mL
-1 Cu2+-
oxidised LDL in that study [518], which was also the concentration used in the current study 
to assess scavenger receptor expression. However, no data was obtained in this current study 
for comparing the cell toxicity of Cu2+-modified LDL when treated to HCAEC. 
Interestingly, the LDLR mRNA expression was downregulated after 24 h treatment with 
HOCl- and HOSCN-modified LDL, but not Cu2+-oxidised LDL. This may be related to the 
extensive lipid modification observed, as Cu2+-oxidised LDL is depleted of native cholesterol 
and cholesteryl ester content, as shown in Figure 4.3. LDLR expression is transcriptionally 
regulated by the sterol regulatory element-binding proteins (SREBP), which is inhibited by 
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LDL uptake, but the LDLR protein is also recycled back to the plasma membrane after 
dissociating from LDL [605]. The LDLR was shown to have a long half-life of 25 h in human 
fibroblasts [606], which could be similar in endothelial cells. The reduction in LDLR mRNA 
may indicate a negative feedback of LDLR synthesis to counteract the LDLR recycling to reach 
cholesterol homeostasis. However, downregulation of the LDLR was only apparent at the 
mRNA but not protein level. In this case, 24 h may not have been enough time to observe a 
downregulation in LDLR protein expression due to the long half-life of the protein.  
HOSCN- and HOCl-modified LDL were shown to reduce cathepsin B and L activity in 
mouse J774A.1 macrophages [582], but this was not the case in this study of HCAEC, which 
exhibited no change in cathepsin B or L activity upon incubation with similar types of modified 
LDL. Cathepsins are important lysosomal and endosomal proteases that digest biomolecules 
taken up by endocytosis [581]. Overall, the unchanged cathepsin B and L activity and SR 
expression after uptake of MPO oxidant-modified LDL could exhibit competent processing of 
the modified LDL by endosomal digestion. Alternatively, the modified LDL species may be 
transported by transcytosis to embed under the endothelium, which has been shown to be 
LDLR- and SR-mediated [607], and which occurs in vivo [608, 609] and has been modelled in 
vitro [607, 609]. The transport of LDL and oxidised LDL through the cell by endocytosis or 
transcytosis was not interrogated in this study, but future investigation into these transport 
pathways could gauge the extent of the role of cathepsins in LDL or MPO oxidant-modified 
LDL processing in endothelial cells. 
4.4.2. Leukocyte adhesion and inflammatory 
cytokines 
Multiple studies have shown that vascular inflammation can be endothelial cell-mediated 
by modulating the adhesion of leukocytes, which can be induced by pro-inflammatory 
cytokines [610] or alterations in vascular shear stress/disturbed flow [307, 611, 612]. However, 
158 | P a g e  
 
in this study, incubation of HCAEC with HOSCN- or HOCl-modified LDL for up to 24 h did 
not alter expression of several well-established mediators of cell adhesion, or adhesion of 
neutrophils to the endothelial monolayer. These findings contradict some previous studies 
utilising Cu2+-oxidised LDL [307, 433-435, 613]. However, the literature is conflicted 
regarding the ICAM-1 and VCAM-1-dependent monocyte–endothelial adhesion, with some 
reports finding no induction of either VCAM-1 or ICAM-1 when endothelial cells are exposed 
to Cu2+-oxidised LDL [433, 560, 589, 614]. In respect to HOCl-modified LDL, one study by 
Kopprasch et al found that leukocyte adhesion was elevated when HUVEC were co-incubated 
with either RAW 264.7 murine macrophages or isolated human neutrophils exposed to native 
LDL and HOCl-modified LDL [438]. However, this study also noted that HUVEC incubated 
with native or HOCl-modified LDL alone prior to incubation with RAW 264.7 cells had no 
change in cell adhesion, except for a modest significant increase in adhesion when incubated 
with heavily modified LDL (2716:1 molar ratio of HOCl to apoB-100) [438]. Furthermore, 
antibody inhibition of the leukocyte SR-B2 completely blocked native LDL-induced adhesion 
and significantly reduced HOCl-modified LDL-induced adhesion of HUVEC and leukocytes 
when co-incubated with LDL [438]. Not only did the adhesion depend on the extent of LDL 
modification by HOCl, but also on the presence of leukocytes and CD-36-dependent uptake of 
LDL. 
The uptake of Cu2+-oxidised LDL by monocytes and macrophages induces the release of 
IL-6 and TNF-α [610], which can stimulate adhesion molecule expression in endothelial cells 
as shown by the TNF-α-induced positive control. In this study, HCAEC were incubated with 
control LDL and LDL modified by HOSCN or HOCl prior to incubation with human isolated 
neutrophils, and the molar excess of HOCl used to modify LDL was comparatively modest 
(125:1 rather than 2516:1 molar ratio [438]), which is in agreement with the findings by 
Kopprasch et al [438]. However, endothelial cells can also modulate neutrophil infiltration by 
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secreting IL-6 and transition to monocyte infiltration by the release of MCP-1 [563, 615]. In 
this study, no changes in IL-6 or MCP-1 mRNA or protein were detected following up to 24 h 
incubation with MPO oxidant-modified LDL. Thus, uptake of either HOSCN- or HOCl-
modified LDL alone does not induce pro-inflammatory proteins in HCAEC under the 
conditions employed in this study. 
4.4.3. UPR and ARE genotypic expression 
In recent years, ER stress has been causally linked to endothelial dysfunction and 
atherosclerosis (reviewed [462, 616, 617]). The two major transport destinations of native LDL 
cholesterol in the cell are the ER and the plasma membrane by endosomal transport, which is 
mediated by lysosome-associated membrane protein type 2 (LAMP-2; [618]). The ER plays a 
critical role in lipid metabolism in the cell and disturbance in lipid metabolism can lead to ER 
stress [619]. One of the possible causal factors linked to UPR-induced endothelial dysfunction 
has been exposure to oxidised LDL, which is based upon the observations that the Cu2+-
oxidised form, but not control LDL, can induce ER stress in human and animal endothelial 
cells in vitro as well as in mouse overexpressing the 150-kDa oxygen-regulated protein or 
apoE-/- and apoE-/-/AMPKα2-/- mice fed a high-fat diet in vivo [464, 620]. Incubation of 
HUVEC in vitro with Cu2+-oxidised LDL was shown to lead to an upregulation of GRP78, 
XBP1, IRE-1 and PERK protein expression mediated by LOX-1-dependent induction of ER 
stress [565] and lead to apoptosis induced by CHOP activity [463]. The effect of MPO oxidant-
modified LDLs upon ER stress and UPR in endothelial cells has not been reported. The results 
of this study show that LDL modified by up to 250 μM HOSCN or HOCl did not induce mRNA 
expression of UPR components in HCAEC. 
The difference between LDL modified by HOCl or HOSCN and other modified forms of 
LDL in part relates to difference in the extent of lipid modification. The reaction of HOCl with 
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phospholipids in LDL (such as phosphatidylserine and phosphatidylethanolamine) is 
competitive with apoB-100 oxidation by HOCl, but likely only becomes a major product at 
very high molar ratios (approximately 2.4 % HOCl consumption by lipids in LDL at 200:1 
molar ratio HOCl:apoB-100 [135]), whereas in this study, a maximum of 125:1 molar ratio 
was used. Incubation of HUVEC and human aortic endothelial cells (HAEC) with isolated 
oxidised phospholipids instead of oxidised LDL activated the ATF4 branch of the UPR [465, 
566, 621, 622]. This oxidised phospholipid-mediated induction of UPR was in parallel with 
increased expression of inflammatory mediators such as IL-6, IL-8 and MCP-1, and antioxidant 
genes such as HO-1, NADPH quinone dehydrogenase-1 (NQO-1) and Gclc/m [566, 622], 
strongly linking the ER stress and activation of the UPR and inflammatory response in 
endothelial cells exposed to oxidised phospholipids. 
In the current study, no evidence for Nrf2 upregulation was found following exposure to 
HOSCN- or HOCl-modified LDL, but evidence for induction of HO-1 mRNA expression by 
HOSCN-modified LDL was observed. There was a stronger upregulation of HO-1 mRNA 
expression following incubation with HOSCN-modified LDL than after incubation with HOCl-
modified LDL (cf. three-fold expression after 3 h with HOSCN-modified LDL vs 1.5-fold 
expression after 24 h treatment with HOCl-modified LDL). Initial results showed that 
regardless of the difference in HO-1 mRNA expression following exposure to HOSCN- or 
HOCl-modified LDL, HO-1 protein expression was upregulated by both MPO oxidant-
modified LDL species (n = 2), but unfortunately this was not reproducible upon further 
replication and further work is required to assess alterations in HO-1 expression.  
There is some evidence that exposure of endothelial cells to the MPO-H2O2-halide system 
can lead to HO-1 activation. A study by Porubksy et al found that HO-1 gene expression was 
significantly upregulated in human proximal tubular cells following 4 – 8 h exposure of HOCl-
modified LDL [437]. Yet, proximal tubular cells are not of vascular origin and the HOCl: LDL 
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ratio was higher than in the current study (cf. 1:400 vs 1:125 LDL: HOCl ratio, respectively). 
Another study by Daher et al found that MPO-oxidised LDL (likely by chlorinating activity) 
induced HO-1 mRNA expression in the absence of apoptosis in HUVEC [623], however the 
authors did not investigate the protein expression. HUVEC and HAEC incubated with 3 – 300 
μM HOCl for 24 h induced mRNA expression and synthesis of HO-1 and subsequent elevated 
CO production which were associated with increased cell viability [624]. In macrophages, 
incubation with enzymatic MPO-modified LDL induced Nrf2-dependent activation of HO-1 
and Gclm mRNA expression and synthesis to a larger extent than Cu2+-oxidised LDL [597]. 
However, there was no change in the mRNA expression of ARE genes Nrf2, Gclc and GS in 
the current study.  
Daher et al also noted the co-expression of microRNA-22 (miR-22) with HO-1 following 
incubation with enzymatic MPO-modified LDL, which has recently been demonstrated to 
interact with the 3ʹ-untranslated region (3ʹ-UTR) of HO-1 mRNA to supress translation [625]. 
Given the findings by Daher et al, HCAEC exposed to HOSCN- or HOCl-modified LDL in 
this study may have induced miR-22 expression, which could explain the difficulty in 
replicating induction of the HO-1 protein following treatment with MPO oxidant-modified 
LDL in the current study. Induction of HO-1 and production of CO is an important redox 
feedback mechanism in the cell [626]. Stimulation of HO-1 activity and expression in vascular 
endothelial cells by oxidised LDL has again been attributed to the oxidised (phospho)lipid 
moiety of oxidised LDL [596, 627]. Fatty acid hydroperoxides strongly stimulated HO-1 
mRNA and protein expression in HAEC and renal epithelial cells [627]. Similarly, exposure 
of HAEC to oxPAPC lead to upregulated HO-1 expression and activity through activation of 
Nrf2 [596]. Additionally, pre-stimulation of HO-1 activity in a co-culture of endothelial and 
smooth muscle cells prior to treatment with cell-modified LDL significantly inhibited 
monocyte adhesion, this was replicated with exposure to oxPAPC which also upregulated HO-
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1, but not with exposure to native LDL [628]. Although this was not examined in the current 
study, the phospholipids of LDL can be oxidised by HOCl at concentrations used in the current 
study [135] and could explain the induction of HO-1. However, HOSCN-modified LDL also 
induced HO-1 mRNA and protein expression in this study, and though HOSCN does not react 
with phospholipids [147], HOSCN elicits a greater extent of oxidation of other lipid species in 
LDL compared to HOCl [146] which may also be inductive of HO-1 expression. Additionally, 
HO-1 mRNA expression was strongly induced by LDL modified by HOSCN and not HOCl, 
which suggests induction of HO-1 could be through different pathways between the two 
oxidised LDL epitopes. 
4.4.4. Limitations 
The quantification of cellular RNA and protein expression, cellular lipid content and 
cathepsin activity after exposure to LDL modified by HOSCN or HOCl represent static 
measures at 3 and 24 h treatment. These results cannot be interpreted as time-dependent 
responses to LDL modified by either HOSCN or HOCl. Repeating these experiments over 
shorter incubation intervals may detect acute fluxes in expression or protein activity in 
endothelial cells which may have been missed. HO-1 protein expression also was not 
reproducible and requires further experiments. 
 Conclusion 
Overall, this Chapter demonstrates that the uptake of each type of MPO oxidant-modified 
LDL did not significantly alter pro-inflammatory mechanisms in HCAEC. Scavenger receptor 
protein expression was not significantly altered, but for the exception of downregulation of SR-
B1 mRNA following incubation with HOCl-modified LDL. Further, LDLR mRNA, though 
not protein, expression was significantly downregulated by exposure to LDL modified by either 
HOSCN or HOCl. Leukocyte adhesion molecule expression, neutrophil adhesion and cytokine 
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(IL-6 and MCP-1) expression were also unchanged following incubation with MPO oxidant-
modified LDL. These data contrast with the literature that exhibited the pro-inflammatory 
effects of other modified forms of LDL (Cu2+- or cell-mediated). Concerning anti-
inflammatory mechanisms, HO-1 mRNA was significantly upregulated by HOSCN-modified 
LDL, while both HOSCN- and HOCl-modified LDL could induce HO-1 protein expression. 
This would suggest that MPO oxidant-modified LDL may influence redox signalling pathways 
in HCAEC. These data highlight the importance of the extent of LDL modification reflected 
by the concentration of oxidant utilised on the nature of the cellular responses observed. The 
current study was extended to examine the role of LDL modified by either HOSCN or HOCl 
in inducing endothelial dysfunction; a key contributor to atherosclerosis.
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 LDL modified by HOSCN or HOCl causes 
eNOS dysfunction in endothelial cells  
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 Introduction 
Atherosclerosis is characterised by the narrowing and stiffening of arteries. Disease 
progression is recognised by a loss in vascular endothelial function [629] and chronic 
inflammation [630], arising from LDL accumulation in the arterial intima [631]. Endothelial 
dysfunction in arteries is an early hallmark of atherosclerosis [629], which is defined by the 
reduction in eNOS activity and the consequent decrease in NO production, leading to impaired 
arterial distensibility [408] (Figure 5.1). Given that NO is a potent vasodilator, the reduction in 
eNOS activity resulting in endothelial dysfunction and impaired arterial vasorelaxation in vivo 
has been implicated as having a key role in atherosclerosis [408]. Coupled eNOS exists as a 
dimeric enzyme which produces NO via one-electron reduction of the haem centre to catalyse 
the conversion of L-Arg to NO and L-Cit [632]. Uncoupling of the eNOS dimer results in 
disrupted electron-transport, leading to direct reduction of O2 to O2
•- instead of producing NO 
[633]. This one-electron oxidation leading to O2
•- formation can further deplete NO by the 
formation of peroxynitrite (ONOO-), which itself is a potent oxidant that can cause further 
damage is capable of further exacerbating endothelial dysfunction [446]. 
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Figure 5.1. Endothelial dysfunction is linked to eNOS uncoupling and impaired 
vasodilation (adapted from [634]). eNOS as a functional dimer (coupled eNOS) is activated 
by binding to calmodulin (CaM), heat shock protein 90 (hsp90), residue phosphorylation and 
cofactor BH4 to convert L-Arg to L-Cit and NO. NO activates soluble guanylyl cyclase (sGC) 
to cyclise GMP to cGMP, which activates protein kinase G (PKG) to promote vasodilation by 
smooth muscle. Coupled eNOS can be inactivated by binding to cav-1. Uncoupled eNOS does 
not function as a dimer and leads to the production of O2
•-, which can react with NO to reduce 
NO bioavailability and impair vasodilation. The reaction of O2
•- and NO also produces the 
potent oxidant ONOO-. The production of O2
•- and ONOO- increases oxidative stress which 
can further uncouple eNOS in a vicious cycle to further cement endothelial dysfunction. 
167 | P a g e  
 
It is well established that LDL oxidation is a key factor in atherosclerotic lesion development 
through numerous pathways (reviewed [280, 631]) and there is strong evidence to implicate 
oxidised LDL as a causal factor in endothelial dysfunction by its effect on eNOS in vitro [448, 
516, 635]. This is further supported by evidence that exposure to oxidised LDL impairs the 
endothelium-dependent vasodilatory capacity of animal aortae ex vivo [455, 636, 637]. Despite 
this knowledge that oxidised LDL can perturb endothelial function, there is still debate 
regarding the precise mechanisms responsible.  
The presence of eNOS has been found to be predominantly localised to the caveolae within 
endothelial cells [638]. Caveolin-1 (cav-1; named after the caveolae) is one of the proteins 
known to negatively regulate eNOS activity by blocking the Ca2+-dependent, calmodulin 
(CaM)-mediated electron transport to the eNOS oxidase domain [639]. The importance of cav-
1-dependent eNOS regulation is also supported by studies using cav-1-/- mice, which 
demonstrated significantly greater capacity for endothelium-dependent vasodilation and eNOS 
hyperactivity compared to their wild type counterparts [640, 641]. Furthermore, alterations in 
the cellular compartmentalisation of eNOS can also alter the production of NO by endothelial 
cells in vitro [448, 516], which can be mediated by endocytosis of caveolae [642-644]. It has 
previously been shown that incubation of porcine pulmonary aortic endothelial cells with Cu2+-
oxidised LDL, but not native LDL, resulted in delocalisation of eNOS and cav-1 from the 
caveolae to the cytosol, which also reduced acetylcholine (ACh)-stimulated eNOS activity 
without reducing total eNOS expression or phosphorylation [516]. Similarly, treatment with 
HOCl-modified LDL has been shown to delocalise eNOS from cav-1 and impair eNOS activity 
in HUVEC, the occurrence of which was proposed to leave eNOS vulnerable to uncoupling 
[448]. In addition, eNOS activity is also positively or negatively regulated by several post-
translational modifications, including phosphorylation, acylation, S-nitrosylation and 
acetylation [645, 646].  
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As of yet, the comparative effect of LDL modified by physiological levels of the MPO-
derived oxidants HOSCN or HOCl on eNOS activity has not been elucidated. This is significant 
in light of the presence of higher circulating concentrations of SCN- in smokers [42, 43], which 
can shift MPO activity to significant production of HOSCN [39]. In this study, we hypothesised 
that LDL modified by HOCl and HOSCN would cause endothelial dysfunction by uncoupling 
eNOS, leading to the reduction in NO production in HCAEC in vitro. 
 Aims 
The aim of the studies in this Chapter was to examine whether LDL modified by the MPO-
derived oxidants HOCl and HOSCN could alter the endothelial production of NO via 
influencing the activity of eNOS. This was assessed in vitro using HCAEC as a model, and ex 
vivo, using rat aortic segments. 
 Results 
5.3.1. NO production 
HCAEC were treated with LDL (0.1 mg•mL
-1) modified by HOSCN or HOCl (100 or 250 
μM) for 24 h before assessing intracellular NO levels by DAF-FM fluorescence using flow 
cytometry. DAF-FM is a very weakly fluorescent, cell-permeable molecule which reacts with 
NO, to form a highly fluorescent benzotriazole derivative, with an excitation and emission 
maximum of 495 nm and 515 nm, respectively [647]. On visual assessment of the distribution 
of the DAF-FM fluorescence histograms in all three experimental replicates, a Gaussian 
(normal) distribution was not observed in all treatment groups (Figure 5.2A – D). This made 
the mean of total DAF-FM fluorescence an inappropriate descriptive statistic for analysis of 
NO levels by this method, as the cell population was bimodal in all three experimental 
replicates. Therefore, the DAF-FM fluorescence was categorised into two populations; 
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“percentage-negative” (P0) and “percentage-positive” (P1), and the percentage of the parent 
population (P) represented in each category was calculated [648]. This showed that compared 
to the control, a significantly lower proportion of P1 cells were detected in HCAEC following 
treatment with LDL exposed to 250 μM HOSCN or LDL exposed to HOCl (100 or 250 μM), 
corresponding with a significant increase in P0 cells (Figure 5.3).
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Figure 5.2. Intracellular measurement of DAF-FM fluorescence by flow cytometry to 
measure NO levels in HCAEC after incubation with LDL modified by HOSCN or HOCl. 
1.0 mg•mL
-1 control LDL or LDL modified by 100 or 250 µM HOSCN or 100 or 250 µM HOCl 
for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species for 24 h at 37 
°C. After treatment, HCAEC were incubated with 1 µM DAF-FM for 30 min at 37 °C to react 
with intracellular NO. Representative flow cytometry forward-scatter (FSC) and side-scatter 
(SSC) plots and DAF-FM fluorescence (FIT-C) histograms are shown; (A) control, (B) control 
LDL, (C) 250 µM HOSCN-modified LDL and (D) 250 µM HOCl-modified LDL. Data are 
representative of three independent experiments 
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Figure 5.3. Proportion of low fluorescence and high fluorescence cell populations 
following 24 h exposure to LDL modified by HOSCN or HOCl. DAF-FM fluorescence 
quantified by the percentage of parent population (P) of the FIT-C histogram, with the low 
fluorescence population (P0; white bars) and high fluorescence population (P1; black bars). 
Two-way ANOVA with Dunnett’s multiple comparison test between treatment groups and the 
control (n = 3). *, ** and *** represent p < 0.05, 0.01 and 0.001, respectively compared to 
the control for low fluorescence population. #, ## and ### represent p < 0.05, 0.01 and 0.001, 
respectively compared to the control for high fluorescence population. 
These studies were extended to examine the effect of each modified LDL on NO release. 
To quantify the amount of NO produced by HCAEC following 24 h treatment with MPO 
oxidant-modified LDL, the iron-dithiocarbamate (Fe(MGD)2) spin trap was used to trap NO 
[649], which results in the formation of a Fe(MGD)2-NO complex that can be detected by EPR. 
This method was verified using the NO donor, spermine NONOate in the absence of cells prior 
to every experiment, as a positive control, which had a characteristic hyperfine splitting of 13.2 
G and g-value of 2.04 (Figure 5.4A). Then, to ensure that the Fe(MGD)2-NO signal was 
dependent on eNOS activity in HCAEC, 100 μM of the eNOS inhibitor, N5-(1-iminoethyl)-L-
ornithine dihydrochloride (L-NIO) was incubated with untreated HCAEC prior to addition of 
the spin trap. L-NIO significantly decreased the Fe(MGD)2-NO signal compared to the 
corresponding HCAEC control (Figure 5.4B). Therefore, the EPR signal detected following 
incubation with HCAEC was dependent on eNOS-dependent NO production. 
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Incubation of HCAEC with LDL modified by HOSCN or HOCl (100 or 250 μM) for 24 h 
resulted in a significant reduction in the EPR signal of the Fe(MGD)2-NO adduct compared to 
the non-treated cells, consistent with a decrease in NO production by the cells (Figure 5.4C). 
A loss in EPR signal intensity was also observed with control LDL. The relative abundance of 
NO detected by EPR is proportional to the EPR signal intensity and hence can be quantified 
by determining the area under the curve of the signal. Since the EPR trace is the derivative of 
the Fe(MGD)2-NO signal, NO detection was quantified by double integration of the signal 
from 3387 G and 3452 G. This analysis showed that the NO released from HCAEC was 
significantly reduced following 24 h incubation with both the control LDL and all subsequent 
MPO oxidant-modified LDL treatments (Figure 5.4D).
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Figure 5.4. Spin trapping of NO by iron-dithiocarbomate complex Fe(MGD)2 measured 
by EPR spectroscopy from HCAEC after incubation with LDL modified by HOSCN or 
HOCl. 1.0 mg•mL
-1 control LDL or LDL modified by 100 or 250 µM HOSCN or 100 or 250 
µM HOCl for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species for 
24 h at 37 °C. After treatment, HCAEC were incubated with the spin trap Fe(MGD)2 for 36 
min at 37 °C to bind with NO. Representative EPR spectra; (A) Fe(MGD)2-NO spin trap using 
the NO donor spermine NONOate, (B) signal inhibition by the eNOS inhibitor, L-NIO, and (C) 
NO released from HCAEC after each 24 h incubation of; (1) control, (2) control LDL, (3) 100 
µM HOSCN, (4) 250 µM HOSCN, (5) 100 µM HOCl, (6) 250 µM HOCl. (D) Area under the 
curve (AUC) of the EPR spectra to measure proportionate NO production from HCAEC after 
treatment. Data represent mean ± SD (n = 3). One-way ANOVA with Dunnett’s multiple 
comparison test between treatment groups and control. ** and *** represent p < 0.01 and 
0.001 respectively, compared to control.
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5.3.2. eNOS activity and expression 
As endothelial production of NO is dependent on eNOS activity, these studies were 
extended to measure eNOS activity by assessing the conversion of 3[H]arginine to 
3[H]citrulline. As demonstrated in Figure 5.5, incubation of HCAEC with either HOCl- or 
HOSCN-modified LDL resulted in the reduction of 3[H]citrulline produced, (when compared 
to cells exposed to control LDL) indicative of reduced eNOS activity. Furthermore, the 
demonstrated decrease in eNOS activity was dose-dependent on the concentration of HOSCN 
or HOCl used to modify LDL, and was shown to be more markedly decreased with the 
HOSCN-modified LDL compared to the HOCl-modified LDL, with the 3[H]citrulline 
produced decreasing to approximately 37 % of the control for the HOSCN-modified LDL and 
55 % of control for the HOCl-modified LDL, when LDL was modified by 250 μM of HOSCN 
or HOCl. These results support the reduced NO production by HCAEC detected by EPR 
following 24 h MPO oxidant-modified LDL treatment, although the reduction in NO synthesis 
following 24 h exposure to control LDL was not reflected in a similar reduction in eNOS 
activity by 3[H]citrulline detection. This is likely due to higher variability between 
experimental replicates. Together however, these data indicate that there is a reduced capability 
for eNOS to synthesise NO after treatment with HOSCN- and HOCl-modified LDL. 
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Figure 5.5. Enzymatic activity of eNOS in HCAEC measured by the conversion of 3[H]-
L-arginine to 3[H]-L-citrulline after incubation with LDL modified by HOSCN or HOCl. 
1.0 mg•mL
-1 control LDL or LDL modified by 100 or 250 µM HOSCN or 100 or 250 µM HOCl 
for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species for 24 h at 37 
°C. 3[H]citrulline is separated from unreacted 3[H]arginine by charge affinity 
chromatography using an equilibrated resin. 3[H]citrulline levels were determined using liquid 
scintillation counting compared to that of the total reaction mixture and then normalised to the 
control. Data represent the mean ± SD (n = 3). One-way ANOVA with Dunnett’s multiple 
comparison test between treatment groups and control. * and ** represent p < 0.05 and 0.01 
respectively compared to control LDL. 
To determine the mechanism involved in modified LDL-induced loss in eNOS activity and 
subsequent decrease in NO production, eNOS mRNA and protein expression was assessed by 
qPCR normalised to the expression of the 18S and β2M housekeeping genes, and Western 
blotting normalised to β-actin normalising protein, respectively. No change in eNOS mRNA 
expression was observed when HCAEC were incubated with control LDL or LDL modified by 
HOCl for 3 or 24 h (Figure 5.6A). In comparison, HCAEC incubated with LDL modified by 
250 μM HOSCN significantly upregulated mRNA expression of eNOS at both 3 and 24 h time 
points (Figure 5.6A). Next, Western blot experiments were performed to determine both the 
total eNOS expression and activating phosphorylation site Ser1177 of eNOS (which is Akt-
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dependent and promotes NO synthesis [650]). From these experiments, no significant change 
in total eNOS or eNOS phosphorylation was observed after 24 h incubation with control LDL 
or MPO oxidant-modified LDL relative to the β-actin loading control (Figure 5.6B and C). 
Given that electron transfer between the monomers of the homodimeric form of eNOS is 
necessary for L-Arg catalysis and NO production [651], further assessment of the dimer-to-
monomer ratio of eNOS to assess the coupling state of eNOS was also undertaken. Following 
24 h exposure to LDL modified by 250 μM HOSCN, there was a significant decrease in the 
expression of the dimer: monomer ratio of eNOS compared to the HCAEC exposed to 
untreated control or incubation control LDL (Figure 5.6D). A similar trend in eNOS uncoupling 
was also observed within HCAEC exposed to HOCl-oxidised LDL, although this did not reach 
statistical significance (Figure 5.6D). 
Given these results, it was prudent to assess the extent of eNOS phosphorylation following 
shorter incubation times with LDL modified HOSCN or HOCl was further analysed in a 
preliminary time-course plotting MPO oxidant-modified LDL exposure over 1, 3 and 24 h on 
the extent of eNOS S1177 phosphorylation (Figure 5.7). Following HCAEC exposure to 
oxidised LDL for either 1, 3 or 24 h exposure, the data demonstrated that there was no clear 
difference in the proportion of phosphorylated eNOS between LDL treatments. These data 
suggest that it is therefore unlikely that LDL modified by HOSCN or HOCl decreases eNOS 
activity through disruption of eNOS phosphorylation, at the very least with respect to 
phosphorylation occurring at the S1177 residue. 
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Figure 5.6. Expression, post-translational modification and uncoupling of eNOS in 
HCAEC after incubation with LDL modified by HOSCN or HOCl. 1.0 mg•mL
-1 control 
LDL or LDL modified by 100 or 250 µM HOSCN or 100 or 250 µM HOCl for 24 h. HCAEC 
were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species for 24 h at 37 °C. (A) eNOS 
mRNA expression following 3 h (white bar) and 24 h (black bar) incubation with each LDL 
treatment was normalised to 18S and β2M normalising genes (n = 3). (B, C) eNOS 
normalisation to β-actin loading control and phosphorylation of S1177-eNOS (p-eNOS; n = 3). 
(D) eNOS coupling assessed by the dimer: monomer ratio of eNOS (n ≥ 3). Representative 
blots are displayed on top of and in line with the bar graph labels. One-way ANOVA with 
Dunnett’s multiple comparison test between treatment groups and control LDL. * represent p 
< 0.05 compared to control LDL.
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Figure 5.7. Time-course of S1177 phosphorylation of eNOS in HCAEC after incubation 
with LDL modified by HOSCN or HOCl. 1.0 mg•mL
-1 control LDL or LDL modified by 100 
or 250 µM HOSCN or 100 or 250 µM HOCl for 24 h. HCAEC were treated with 0.1 mg•mL
-1 
of LDL or oxidised LDL species for 1, 3 or 24 h at 37 °C. β-actin was used as a loading control. 
Representative blots are labelled as; (1) control, (2) control LDL, (3) LDL modified by 250 μM 
HOSCN, and (4) LDL modified by 250 μM HOCl (n = 2).
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5.3.3. O2•- production in HCAEC 
Uncoupling of eNOS results in the failure of eNOS to catalyse a reaction with O2 and L-Arg 
to form NO and L-Cit, decreasing NO production but favouring the reduction of O2 to O2
•-, 
which, in addition to reducing NO levels can also lead to formation of a potent oxidant ONOO- 
[633]. Due to the eNOS uncoupling observed following incubation of HCAEC with HOSCN-
modified LDL, O2
•- production was next investigated by measuring the formation of 2-OH-E+ 
following supplementation of DHE to the cells. DHE oxidation and fluorescence is commonly 
used to detect the production of O2
•- by the formation of the specific product 2-OH-E+. As 2-
OH-E+ has a similar fluorescence profile to E+ which is not specific to reaction with O2
•- [652], 
HPLC was further used to separate and quantify these products (retention time of 2-OH-E+ ~ 
23 min and E+ ~ 25 min; Figure 5.8A).  
HCAEC were incubated with each modified LDL treatment for 24 h, before addition of 
DHE and further incubated for 30 min to assess O2
•- formation. HCAEC were then lysed and 
subjected to HPLC separation of DHE, 2-OH-E+ and E+, and fluorescent detection of 2-OH-E+ 
was undertaken to determine if there was any alteration to O2
•- production, as previously 
described [653, 654]. No change in 2-OH-E+ formation was observed on exposure of HCAEC 
to either HOCl- or HOSCN-modified LDL compared to the cells exposed to control LDL alone, 
whilst HCAEC incubated with menadione as a positive control [655] had nearly double the 2-
OH-E+ formation (hence, O2
•- production) after 30 min (Figure 5.8B). This supports that O2
•- 
produced by HCAEC is not increased when measured for a defined period of 24 h after 
treatment with LDL modified by MPO-derived oxidants under the conditions employed in this 
study. 
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Figure 5.8. Detection of O2•- in HCAEC following 24 h incubation with LDL modified by 
HOSCN or HOCl.  1.0 mg•mL
-1 control LDL or LDL modified by 250 µM HOSCN or 250 µM 
HOCl for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of LDL or oxidised LDL species for 24 
h at 37 °C. (A) Representative HPLC and fluorescence trace of DHE, 2-OH-E+ and E+ 
separation. (B) Quantification of 2-OH-E+ fluorescence by area under the curve analysis, 
normalised to cellular protein measured by BCA assay. MD represents menadione exposure 
for 30 min. Data represent the mean ± SD (n = 3). One-way ANOVA with Dunnett’s multiple 
comparison test. *** represent p < 0.001 respectively compared to the control. 
The extent of 3-nitroTyr formation on proteins in HCAEC following incubation with MPO 
oxidant-modified LDL was also measured by Western blot (Figure 5.9) to assess any increase 
in the production of ONOO- due to eNOS uncoupling [351, 352]. From those experiments, 
there was no discernible evidence for increased 3-nitroTyr formation following exposure to 
LDL modified by MPO-derived oxidants. However, as the results presented here were 
performed ad hoc from the Western blot of the supernatant run-off of the eNOS co-
immunoprecipitation experiments described above, there is likely a loss of cellular protein that 
could unduly influence these results. Additionally, a positive control for the detection of 3-
nitroTyr (e.g. nitrated albumin) has not been used to confirm the efficiency of the 3-nitryoTyr 
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antibody. Hence experiments must be repeated prior to any definitive interpretation of the data 
presented. 
 
Figure 5.9. No changes in 3-nitroTyr formation in HCAEC exposed to LDL modified by 
HOSCN or HOCl for 24 h. 1.0 mg•mL
-1 control LDL or LDL modified by 250 µM HOSCN or 
250 µM HOCl for 24 h. HCAEC were untreated (lane 1 and 5) or treated with 0.1 mg•mL
-1 of 
control LDL (lane 2 and 6) or LDL modified by HOSCN (lane 3 and 7) or HOCl (lane 4 and 
8) for 24 h at 37 °C. The production of ONOO- was assessed by Western blot and 
immunodetection of 3-nitroTyr (3NT) in the supernatants of the co-immunoprecipitation 
experiments of cav-1 and eNOS. Representative blot of two independent experiments under 
high chemiluminescence exposure shows no detectable changes in 3-nitroTyr formation.
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5.3.4. eNOS and cav-1 in HCAEC 
Plasma membrane-bound eNOS is particularly concentrated in the caveolae of endothelial 
cells [656]. Caveolae are rich in the structural and functional protein cav-1, which has been 
shown to functionally reduce eNOS activity by direct binding [639]. However, this is 
contradicted in a study of HUVEC, which showed that reduced eNOS activity in response to 
exposure to LDL modified by HOCl was linked to eNOS delocalisation from the plasma 
membrane independent of eNOS binding to cav-1 [448]. To confirm the involvement of cav-1 
in our model, we next studied cav-1 binding and localisation of eNOS in HCAEC, a cell lineage 
of physiologically relevant vascular origin, in response to LDL modified by HOCl or HOSCN. 
Firstly, cav-1 and eNOS colocalisation was assessed by immunofluorescence microscopy 
(Figure 5.10). Following incubation for 24 h with or without control LDL, eNOS and cav-1 
colocalisation was diffuse in the cell, likely throughout the plasma membrane. In contrast, cells 
incubated with HOSCN- and HOCl-modified LDL generally showed some cellular 
redistribution of eNOS and cav-1 in some cells, where discrete speckling of colocalised eNOS 
and cav-1 were observed in the cytoplasm (indicated by the white arrows in Figure 5.10). This 
likely reflected internalisation of the caveolae from the plasma membrane into the cytoplasm, 
in which eNOS may be bound to the caveolae and inactivated. 
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Figure 5.10. Fluorescence microscopic colocalisation of cav-1 and eNOS in HCAEC after 
incubation with LDL modified by HOSCN or HOCl. 1.0 mg•mL
-1 control LDL or LDL 
modified by 250 µM HOSCN or 250 µM HOCl for 24 h. HCAEC were treated with 0.1 mg•mL
-
1 of LDL or oxidised LDL species for 24 h at 37 °C. Columns represent different treatments 
labelled control, control LDL, 250 µM HOSCN modified LDL and 250 µM HOCl modified 
LDL. Rows represent staining for the nucleus with DAPI (blue), cav-1 (green), eNOS (red) and 
the merged image on the bottom. White arrows indicate colocalised fluorescence of eNOS and 
cav-1 in HCAEC treated with LDL modified by either HOSCN or HOCl. This experiment was 
replicated three times.  
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Next, the binding of cav-1 and eNOS was assessed by cav-1 co-immunoprecipitation by 
Western blot following immunoprecipitation using an antibody against eNOS. In Figure 5.11, 
in both eNOS and cav-1 immunoprecipitates (IP: eNOS and IP: cav-1), there were other bands 
detected by Western blot at approximately 25 and 50 kDa, which is likely the IgG light and 
heavy chain of the eNOS and cav-1 antibodies of the respective immunoprecipitate. In the IP: 
eNOS, eNOS was detected, but cav-1 chemiluminescence could not be confirmed because the 
cav-1 protein is detected at 21 – 24 kDa; approximately the same molecular weight of the IgG 
light chain (IgGL). This is shown by the IP: cav-1, which had more intense chemiluminescence 
at the cav-1 and IgGL. Therefore, chemiluminescent detection of the immunoprecipitates was 
performed by substituting the conventional secondary HRP-conjugated antibody for an 
antibody that only detects the intact (non-denatured) IgG.  
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Figure 5.11. IgG contamination in coimmunoprecipitation of cav-1 and eNOS in HCAEC 
after incubation with LDL modified by HOSCN or HOCl. 1.0 mg•mL
-1 control LDL or LDL 
modified by 250 µM HOSCN or 250 µM HOCl for 24 h. HCAEC were treated with; lane 1: no 
LDL, lane 2: control LDL, lane 3: 250 µM HOSCN-modified LDL, lane 4: 250 µM HOCl-
modified LDL. Each LDL treatment was at a concentration of 0.1 mg•mL
-1 for 24 h at 37 °C. 
Both immunoprecipitation (IP) of eNOS and cav-1 was performed to isolate from cell lysates 
and an immunoblot (IB) of eNOS and cav-1 was performed. Intact IgG, and the heavy (IgGH) 
and light (IgGL) chains sourced from the eNOS and cav-1 IP antibodies were detected and 
contaminated the immunoblots. This blot is representative of three independent experiments. 
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The co-immunoprecipitation results suggest that reduced eNOS activity and NO production 
in HCAEC by LDL modified by MPO-derived oxidants was not related to altered cav-1-eNOS 
binding. This is demonstrated through comparison of the IP: eNOS and lysate supernatant blots 
in the eNOS immunoblot (IB: eNOS) which indicate that immunoprecipitation was efficiently 
achieved with comparable amounts of eNOS immunoprecipitated from the lysates and low 
amounts of residual eNOS detected in the lysate supernatant and only following high 
chemiluminescence exposure. However, in the corresponding immunoblot of cav-1 (IB: Cav-
1) in the IP: eNOS, no detectable cav-1 was co-immunoprecipitated with eNOS following 24 
h incubation of the HCAEC with control LDL or MPO oxidant-modified LDL, where all the 
cav-1 detected was in the lysate supernatant, unbound to eNOS (Figure 5.12). These results are 
disparate to the former fluorescence microscopy which demonstrated that cav-1 and eNOS 
were colocalised in the cytosol of cells following exposure to LDL modified by HOSCN or 
HOCl.
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Figure 5.12. Coimmunoprecipitation of cav-1 and eNOS in HCAEC after incubation with 
LDL modified by HOSCN or HOCl. 1.0 mg•mL
-1 control LDL or LDL modified by 250 µM 
HOSCN or 250 µM HOCl for 24 h. HCAEC were treated with; lane 1: no LDL, lane 2: control 
LDL, lane 3: 250 µM HOSCN-modified LDL, lane 4: 250 µM HOCl-modified LDL for 24 h at 
37 °C.  IP: immunoprecipitate, IB: immunoblot. Cell lysate supernatant shows the presence of 
cav-1 after eNOS IP. No cav-1 was detected to be coimmunoprecipitated with eNOS. Blots are 
representative of three independent experiments. 
188 | P a g e  
 
5.3.5. Intracellular Ca2+ levels in HCAEC 
Increases in intracellular calcium levels are a positive regulator of eNOS activity by 
activating CaM, which then binds to eNOS to promote electron shuttling through the reductase 
domain to reduce the haem group [657]. Intracellular calcium levels were next assessed in 
HCAEC incubated with each modified LDL treatment for 1 and 24 h. Specifically, cells were 
incubated with the fluorescent probe Fluo-4AM; a membrane-permeable which upon binding 
to Ca2+ has an absorption and emission spectra of 488 and 516 nm, respectively [501], 
following 1 h and 24 h incubation with MPO oxidant-modified LDL. The fluorescence upon 
Fluo-4AM binding to intracellular Ca2+ was measured by flow cytometry. 
The representative flow cytometry histogram displays a slight right-shift of the fluorescent 
population in HCAEC incubated for 24 h with LDL modified by 250 μM HOSCN or HOCl 
(Figure 5.13A), compared to the non-treated control cells, indicating increased cytosolic Ca2+ 
accumulation. Although quantification of the geometric mean fluorescence of Fluo-4AM 
within the cells demonstrated no significant increase in intracellular Ca2+ following either 1 h 
or 24 h incubation with control LDL or LDL modified by 250 μM HOSCN or HOCl LDL 
compared to the control (Figure 5.13B). These data indicate that changes in total intracellular 
calcium levels are not likely to be involved in altered NO production and eNOS activity in 
HCAEC.
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Figure 5.13. Intracellular Ca2+ levels in HCAEC incubated with control LDL, HOSCN- 
and HOCl-modified LDL. 1.0 mg•mL
-1 control LDL or LDL modified by 250 µM HOSCN or 
250 µM HOCl for 24 h. HCAEC were treated with 0.1 mg•mL
-1 of control LDL or LDL modified 
by 250 μM HOSCN or HOCl for 1 h (black) or 24 h (white) at 37 °C. (A) Representative 
histograms of Fluo-4AM fluorescence measured in 24 h treated samples by flow cytometry; 
top-left; control, top-right; control LDL, bottom-left; HOSCN-modified LDL, bottom-right; 
HOCl-modified LDL. (B) Geometric mean of the Fluo-4AM fluorescence normalised to the 
control. Data represent the mean ± SD (n = 3). One-way ANOVA with Dunnett’s multiple 
comparison test.  
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5.3.6. Rat aortic ring myography 
The impairment of eNOS activity and subsequently reduced NO production in vivo plays a 
key role in endothelial dysfunction in the progression of atherosclerosis [658], therefore the 
study was extended to consider the effect of LDL modified by HOSCN or HOCl on 
vasorelaxation using pre-constricted rat aortic tissue. Rat aortic vessel vasodilation was 
assessed by wire myography following 1 h incubation with (250 μM oxidant) HOSCN- or 
HOCl-modified LDL ex vivo. Figure 5.14A shows the control aortic segment preconstricted 
with NE (10-9 – 10-5 M) and dilated with increasing doses of ACh (10-8 – 10-3 M) until a return 
to baseline tension was achieved. The sub-maximal dose of 1 μM NE was used for pre-
constriction in each experiment prior to ACh- and SNP-induced vasodilation.  
Using a non-linear regression model of ACh-induced vasodilation, it was found that control 
segments reached a maximum vasodilation (Emax) of approximately 94 % (Figure 5.14B). 
Following a 1 h incubation of the aortic segments with control LDL, the Emax was mildly, but 
non-significantly reduced to approximately 81.4 %. However, incubation of the aortic 
segments with HOSCN-modified LDL or HOCl-modified LDL for 1 h resulted in impaired 
endothelium-dependent Emax of approximately 61.6 % and 59.3 %, respectively. This reached 
statistical significance for both HOSCN- and HOCl-modified LDL compared to the untreated 
segments, but not compared to the control LDL. Endothelium-independent vasodilation was 
also assessed using SNP; a pharmacological NO donor that directly stimulates smooth muscle 
relaxation [659]. In contrast to the ACh-induced vasodilation, SNP-induced vasorelaxation 
responses following preconstriction with NE, were not significant different between the control 
and all LDL treatments (control: 99.4 %, control LDL: 99.5 %, HOSCN-modified LDL: 93.3 
% and HOCl-modified LDL: 98.8 %; Figure 5.12C). This suggests that the impaired 
vasodilation observed with modified LDL was endothelium-dependent.
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Figure 5.14. Vasodilation dose-response of rat aortic segments to acetylcholine and 
sodium nitroprusside following incubation with LDL modified by HOSCN or HOCl for 
1 h. 1.0 mg•mL
-1 control LDL or LDL modified by 250 µM HOSCN or 250 µM HOCl for 24 h. 
Sprague-Dawley Rat aortic rings were treated with 0.1 mg•mL
-1 of LDL or LDL modified by 
250 μM HOSCN or HOCl for 1 h in HBSS at 37 °C. (A) Representative example of a 
myographic trace of rat aortic segment vasoconstricted with increasing doses of NE (5 × 10-7 
to 1 × 10-4 M) and vasodilated with increasing doses of ACh (1 × 10-7 to 1 × 10-4 M). Rat aortic 
segments were preconstricted with a submaximal dose of NE and relaxation was assessed by 
accumulative doses of (B) ACh (10-9 to 10-3 M) and (C) SNP (10-9 to 10-5 M). Symbols represent 
(●) control, (□) control LDL, (▲) 250 µM HOSCN-modified LDL and ( ) 250 µM HOCl-
modified LDL. Non-linear dose-response curves; (solid line) control, (dashed line) control 
LDL, (dotted line) 250 µM HOSCN-modified LDL and (dashed and dotted line) 250 µM HOCl-
modified LDL. Data represent the mean ± SE (n = 5). Two-way ANOVA with Dunnett’s 
multiple comparison test. * and ** represents significant difference (p < 0.05 and 0.01, 
respectively) between HOSCN-modified LDL compared to the control. ## represents 
significant difference (p < 0.01) between HOCl-modified LDL compared to the control. 
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Rat aortic segments were also incubated with LDL modified by 250 μM HOSCN or HOCl 
for 24 h in endothelial treatment media in order to align the time points used for the in vitro 
experiments with HCAEC to the ex vivo setting. Unlike the SNP-dependent dose-response 
curve, a non-linear dose-response model could not be obtained for ACh-dependent 
vasodilation. This was due to the large variance of the response to ACh-induced vasodilation 
at each dose of ACh between each experiment following the extended incubation time.  
The dilation of the control segment was largely reduced to approximately 60 % of the 
maximum level and there was no significant difference between the control LDL or LDL 
modified by MPO oxidants compared to the control (Figure 5.15A). Like the treatment of 
vessels for 1 h, the endothelium-independent vasodilation stimulated by SNP was not affected 
by incubation with MPO oxidant-modified LDL for 24 h (Figure 5.15B).  This confirmed that 
the impaired ACh-induced relaxation was due to endothelial dysfunction. However, the large 
reduction in the maximum relaxation in the control after 24 h compared to 1 h incubation, 
suggests that prolonged ex vivo incubation of the vessel may have damaged the endothelium.
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Figure 5.15. Vasodilation dose-response of rat aortic segments to acetylcholine and 
sodium nitroprusside following incubation with LDL modified by HOSCN or HOCl for 
24 h. 1.0 mg•mL
-1 control LDL or LDL modified by 250 µM HOSCN or 250 µM HOCl for 24 
h. Sprague-Dawley Rat aortic rings were treated with 0.1 mg•mL
-1 of LDL or LDL modified by 
250 μM HOSCN or HOCl for 24 h in endothelial cell treatment media at 37 °C. Rat aortic 
segments were preconstricted with a submaximal dose of NE and relaxation was assessed by 
accumulative doses of (A) ACh (10-10 to 10-3 M) and (B) SNP (10-11 to 10-5 M). Symbols 
represent (●) control, (□) control LDL, (▲) 250 µM HOSCN-modified LDL and ( ) 250 µM 
HOCl-modified LDL. Non-linear dose-response curves for SNP-dependent vasodilation; (solid 
line) control, (dashed line) control LDL, (dotted line) 250 µM HOSCN-modified LDL and 
(dashed and dotted line) 250 µM HOCl-modified LDL. Data represent the mean ± SE (n = 3). 
Two-way ANOVA with Dunnett’s multiple comparison test. 
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 Discussion 
Endothelial dysfunction is a key process in the development of atherosclerosis. A major 
attribute of endothelial dysfunction has been the reduction in eNOS-dependent vasodilation, 
due to the reduced bioavailability of NO, causing the characteristic arterial stiffening in 
atherosclerosis [407, 629, 658, 660]. The disruption of endothelium-dependent NO and 
vasodilation by some forms of oxidised LDL, particularly Cu2+-oxidised LDL, is well 
established [408, 661]. The most commonly studied form of oxidised LDL is LDL modified 
by Cu2+ ions (5 – 10 μM), which forms an extensively-modified particle with reactive lipid 
oxidation products. In contrast, few studies have investigated effects of LDL modified directly 
by MPO or by its oxidant product HOCl upon endothelial cells, though there is evidence for 
this type of modified LDL in both the diseased tissue and the circulation of people with 
atherosclerosis [233, 290]. Additionally, the contribution of the other major MPO-derived 
oxidant, HOSCN, to the modification of LDL and the effect of HOSCN-modified LDL on 
endothelial function remains to be characterised. This is significant in light of the correlation 
between plasma SCN- (the precursor of HOSCN) levels and foam cell formation in early 
atherosclerotic development in smokers [254, 662] as well as the link to coronary artery 
disease, future myocardial infarction and death [255].  
The results of this Chapter clearly demonstrate that LDL modified by HOSCN or HOCl 
causes endothelial dysfunction by impairing eNOS activity and subsequently decreased NO 
production. LDL modified by HOSCN or HOCl induced eNOS uncoupling after 24 h, as shown 
by a loss of the functional eNOS dimer, but did not alter S1177 eNOS phosphorylation or eNOS 
protein expression. One difference was that HOSCN-modified LDL significantly elevated 
eNOS mRNA expression, while HOCl-modified LDL did not; possibly indicating an 
independent cell response to HOSCN-modified LDL. However, O2
•- production was not 
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elevated, nor was there increased detection of 3-nitroTyr to indicate reduction of NO by O2
•- to 
produce ONOO-. Fluorescence microscopic analysis of cav-1 as a key regulator of eNOS 
activity showed there was increased presence of eNOS colocalised with cav-1 in the cytosol 
following exposure to LDL modified by either HOSCN or HOCl, but despite this, 
immunoprecipitation of eNOS following exposure to these LDL treatments did not show cav-
1 binding. Regardless, when extended to treating intact rat aortic segments ex vivo, LDL 
modified by either (250 μM oxidant) HOSCN or HOCl significantly impaired eNOS-dependent 
vasodilation. 
Therefore, this study shows for the first time that LDL modified by HOSCN alters eNOS 
gene expression and functionality, decreases the endothelial production of NO and impairs the 
endothelium-dependent vasodilation. In comparison, the effect of HOSCN-modified LDL on 
eNOS activity and NO production are similar to or, in some cases, greater than that seen in 
with LDL modified by HOCl. 
5.4.1. Regulation of endothelial cell NO production, 
eNOS expression, uncoupling and vessel 
relaxation 
Both intracellular and extracellular NO levels were reduced by incubation of HCAEC with 
either control LDL or each type of MPO oxidant-modified LDL. That is, a significant reduction 
of NO production was measured after 24 h incubation with control LDL, HOSCN-modified 
LDL and HOCl-modified LDL compared to the untreated control as determined by direct 
measurement using both flow cytometry and EPR analysis. Similar results were seen on 
measuring eNOS activity in terms of the formation of 3[H]citrulline. The observed effects were 
independent of intracellular calcium levels as assessed by Fluo-4AM fluorescence, or changes 
in the phosphorylation of the Ser1177 residue of eNOS, which is known to promote NO 
production [663]. In this case, the difference in 3[H]citrulline formation between treatments 
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was larger than the difference in NO detected by EPR between the treatments. Conditions were 
slightly different in the two experiments; EPR was performed following 30 min incubation at 
37 °C with the Fe(MGD)2 spin trap to adduct with NO produced by intact HCAEC, while eNOS 
activity was measured by 3[H]citrulline formation over the course of 1 h at 21 °C in HCAEC 
lysates. Although both methods are highly sensitive to changes in eNOS activity, it is 
speculated that this difference arises from the eNOS activity being measured in cell lysates, 
while the detection of NO in the supernatant by EPR was from intact cells directly after 
treatment. Intact cells will maintain structural and protein-protein interactions which can 
regulate eNOS activity, which is unlikely to be the case in cell lysates. Additionally, EPR 
provides a direct measure of NO, which could be influenced by other factors though the signal 
was significantly decreased by the specific inhibitor L-NIO, other factors could influence the 
NO adduct stability. However, the measurement of 3[H]citrulline formation incorporates 
several sample processing steps, which take time and add to the sources of experimental error, 
as can be the case with commercial kits. Nevertheless, collectively the results demonstrate a 
reduction in eNOS activity with a concurrent decrease in NO production in HCAEC following 
incubation with control LDL or MPO oxidant-modified LDL. Similar effects have also been 
shown in previous studies that demonstrated eNOS activity was sensitive to other types of 
oxidised LDL [664]. 
No change in total intracellular Ca2+ levels was detected by Fluo-4 AM fluorescence 
measured by flow cytometry. However, a limitation to note is that flow cytometry is not 
sensitive to measuring Ca2+ flux in cells over time. Early fluctuations in Ca2+ influx seconds to 
minutes after initial exposure to LDL modified by MPO-derived oxidants were not measured. 
It may also be pertinent to assess possible alterations in Ca2+ localisation in endothelial cells, 
as a spike in Ca2+ flux to the cytosol may not only come from the influx of extracellular Ca2+, 
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but from release of Ca2+ from granules or organelles inside the cell [665]. This could be 
investigated by fluorescence confocal microscopy and would be valuable in future studies. 
One major difference between the treatment of HCAEC with LDL modified by HOSCN or 
HOCl was treatment with the former resulted in the approximately two-fold upregulation of 
the eNOS mRNA after both 3 h and 24 h treatment, though this did not translate to an increase 
in eNOS protein expression after 24 h when measured by Western blot. This difference in 
mRNA gene expression after treatment with HOSCN- compared to control LDL and HOCl-
modified LDL could be indicative of a disparate response of endothelial cells to these different 
LDL species. Determining the mechanism of uptake of LDL modified by either HOSCN or 
HOCl could explain this difference, however the current study did not determine endothelial 
cell receptor binding to HOSCN- or HOCl-modified LDL. The reaction of HOSCN with LDL 
lipids to form linoleate-derived oxidation products, which are formed significantly at HOSCN 
concentrations as low as 50 μM per 1 mg•mL-1 LDL, but do not form at significant levels when 
LDL was exposed to HOCl [146], have been shown to modulate eNOS mRNA expression. 
Linoleate-derived oxidation products, such as 13-hydroperoxyoctadecadienoate (13-HODE) 
have been demonstrated to increase eNOS mRNA expression in BAEC [666]. However, this 
also translated to upregulated eNOS protein expression and proportionate increase in activity 
[666], which was not observed in this study with HOSCN-modified LDL. It could also be 
possible that parallel post-transcriptional regulatory mechanisms, such as eNOS antisense 
RNA (called NOS3AS or sONE) could be activated which prevent the translation of eNOS 
protein by compromising eNOS mRNA stability [667]. Alternatively, a number of microRNAs 
(small ~22 nucleotide non-coding single-stranded RNA) including miRNA-24 [668] and 
miRNA-27 [669] are known to post-transcriptionally regulate eNOS expression. The current 
study did not investigate on eNOS sense-antisense or miRNA interactions, hence future studies 
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interrogating the effects of HOSCN-modified LDL or related products (e.g. 13-HODE) in these 
pathways could be of interest.  
In each case, the extent of eNOS uncoupling, rather than phosphorylation aligned with the 
reduced eNOS activity and NO• production. However, no change in O2
•- production was 
detected upon measuring the formation of 2-OH-E+ following addition of DHE and further 
incubation in HCAEC at the same time point. One study by Fleming et al observed increased 
reactive oxygen species production in HUVEC incubated for 24 h with Cu2+-oxidised LDL 
[524]. The reactive oxygen species produced was assumed to be O2
•-, but the luminol 
chemiluminescence detection utilised in that study is known to detect other reactive oxygen 
species and thus it is not a conclusive measure of O2
•- [670, 671]. Regardless, this was 
concurrent with increased Akt phosphorylation and T495 dephosphorylation, and reduced 
downstream PKC phosphorylation and activity, while CaM binding was unaltered [524]. 
Similar to this study, the same authors also observed no change in S1177 phosphorylation, while 
eNOS became delocalised from the plasma membrane into the cytosol. Perturbations in O2•- 
production in endothelial cells exposed to (non-MPO-mediated) oxidised LDL leading to 
eNOS uncoupling have also been causatively linked to LOX-1 binding (reviewed [672]). It is 
also founded that other types of oxidised LDL can activate MAPK and PKC-mediated 
pathways, which can influence eNOS phosphorylation and alter O2
•-
 production [664, 673]. The 
role of these pathways in the altered NO production of HCAEC exposed to HOSCN- and 
HOCl-modified LDL in these experimental conditions was not assessed, however, no changes 
in scavenger receptor expression nor evidence of sterol accumulation via modified LDL uptake 
were apparent on comparison to control LDL, as described in the previous Chapter (Section 
4.3.3.1; Figure 4.5 and 4.6). 
A limitation for the measurement of O2
•- production in the current study is that O2
•- was 
measured over a defined time-period of 30 min following 24 h treatment of HCAEC with 
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modified LDL. Altered flux in reactive oxygen species production can rapidly occur in 
endothelial cells in response to other types of oxidised LDL [672], so it is possible that 
increased O2
•-
 production as a result of eNOS uncoupling could be induced by MPO oxidant-
modified LDL in early response phases of endothelial cells. The lack of change in O2
•- detected 
also does not seem to be due to scavenging of O2
•- by NO to form ONOO-, as no change in the 
formation of 3-nitroTyr (a marker of ONOO- reactivity) in HCAEC was observed by 
immunodetection using Western blot. However, it would be useful to confirm these data in 
experiments in the absence of conditions pertaining to co-immunoprecipitation. Currently, no 
comparative studies have been undertaken to determine the effect of MPO-derived oxidation 
of LDL on ONOO- formation in endothelial cells. However, one study by Steffen et al 
demonstrated that MPO-derived nitration of LDL (with a MPO-H2O2-NO2
- system) promoted 
carbonylation, nitration (by detection of 3-nitroTyr) and 4-hydroxynonenal (4-HNE; lipid 
peroxidation product) modification of cellular proteins in BAEC and HUVEC [674]. However, 
this was related to an increase in O2
•- production, downregulation of eNOS expression and 
concurrent upregulation of iNOS, overall increasing NO production in endothelial cells [674], 
likely leading to ONOO- formation; none of which was observed in the current study. Given 
that increased NO and O2
•- production and 3-nitroTyr formation were observed in that study 
[674], while NO was decreased and O2
•- was unchanged in this study, it is likely no significant 
ONOO- formation was induced by HOSCN- or HOCl-modified LDL. 
The lack of altered O2
•-
 production could also be related, at least in part, by the reliance of 
eNOS activity upon endogenous cofactors, like BH4, which bind to haem and L-Arg to 
facilitate NO release [445]. In the catalytic process, BH4 is oxidised to the BH3
• radical, which 
can be recovered to BH4 with ascorbate and eNOS itself in a BH4/BH3
• redox cycle [675]. In 
the current study, eNOS coupling was impaired by HOSCN-modified LDL and to a lesser 
extent with HOCl-modified LDL, so depletion or displacement of BH4 may be an important 
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factor in modulating eNOS activity in MPO-oxidant modified LDL due to reduced cycling of 
BH3
• to BH4, but this was not assessed. Further, O2
•- production can be dependent on the 
equilibrium between BH4 and the oxidised product BH2, where BH4 favours NO production 
while BH2 promotes production of O2
•-, mediated by uncoupled eNOS activity and independent 
of the L-Arg concentration [444]. Small trials of acute BH4 supplementation were found to 
improve endothelial function in the brachial artery and coronary artery of 
hypercholesterolaemia patients [676, 677] and the brachial artery of long-term smokers [678]. 
Further, a small double-blind, randomised trial of acute and chronic BH4 supplementation in 
patients with hypercholesterolaemia indeed showed a benefit towards endothelial function with 
increased NO and decreased O2
•- production [679]. These results suggest that the inflammation 
and elevated LDL levels that contributed to endothelial dysfunction could be partially 
reversible by administration of eNOS cofactors. However, the contribution of BH4 to eNOS 
(re)coupling in these studies are difficult to determine, as BH4 is not eNOS specific and can act 
as general antioxidant through redox cycling, such as ascorbate as described above. Notably, 
in the study by Nuszkowski et al, the loss of eNOS activity in HUVEC incubated with LDL 
modified by HOCl was not due to changes in BH4 levels or binding to eNOS [448]. 
5.4.2. Caveolae and cav-1 
Cav-1 has been shown to regulate eNOS specifically inhibiting eNOS activity resulting in 
an inhibition of NO-dependent vascular distensibility in vivo [680]. As caveolae are key 
structures for the endocytosis of LDL and oxidised LDL from the circulation [656, 681-683], 
the effect of MPO oxidant-modified LDL upon eNOS may involve cav-1-linked eNOS 
inactivation [684-686]. In HCAEC, the data presented supports alterations in cellular 
compartmentalisation of eNOS in response to HOSCN- and HOCl-modified LDL, which was 
more pronounced on exposure to the latter. eNOS appeared to colocalise with cav-1 based on 
immunofluorescence detection, in contrast to a previous study in HUVEC, where there was no 
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change in cav-1 localisation alongside eNOS [448]. However, cav-1 did not co-
immunoprecipitate with eNOS, indicating that no direct binding of cav-1 to eNOS was 
demonstrable. Disruption of the interaction between eNOS and cav-1 proteins resulting from 
the experimental conditions used to precipitate and resolubilise the cell lysates for analysis 
cannot be ruled out. The current study analysed total cav-1-eNOS binding in the cell, however 
separating the cellular compartments (caveolae, plasma membrane and Golgi apparatus) from 
the cytosol for individual analysis may be helpful for determining the intracellular fate of eNOS 
following exposure to MPO oxidant-modified LDL. This has been performed in previous 
studies that individually analysed cav-1-eNOS binding in the plasma membrane and the cytosol 
[448, 687].  
Further experiments are required to focus on the effects of HOSCN- and HOCl-modified 
LDL on the caveolae which may be mediated by the scavenger receptor binding and/or 
membrane cholesterol content, in order to determine if cav-1 plays a direct role in eNOS 
uncoupling, or mediates transport of eNOS (along with other caveolae-bound proteins) to other 
cellular compartments for degradation or functional repurposing. This redistribution of eNOS 
has been characterised as a response to changes in the physicochemical properties of the plasma 
membrane, independent of eNOS myristoylation or palmitoylation [448]. This was previously 
observed with Cu2+-oxidised LDL [516, 682], which ilicited the cytosolic translocation of 
eNOS as a response to cholesterol depletion in the caveolae, which was prevented by blocking 
oxidised LDL binding to CD36 [682]. This could be pertinent to HOCl-modified LDL, which 
has been shown to bind to the same receptor in HUVEC [604], though this has not been 
examined in HCAEC. Interestingly, HDL was able to reverse delocalisation of eNOS and cav-
1 from the caveolae induced by SR-B1-mediated binding of oxidised LDL, resulting in 
restoration of ACh-stimulated eNOS activity [688]. This was due to preventing loss of 
cholesterol by HDL donating cholesterol to the caveolar membrane [688]. Whereas, native 
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LDL alone, albeit at very high concentrations, was shown to promote promote caveolar 
localisation of eNOS by the promotion of stress fibres by Ras homolog gene family, member 
A (RhoA) [689]. 
Uncoupling of eNOS has been shown to be in large part dependent on its interaction with 
cav-1. Although studies with cav-1-/- mice have exhibited a profound effect of cav-1 upon 
eNOS functionality [640, 641], the role of cav-1 in cardiovascular system is complex, as 
deficiency in cav-1-/- in mice also resulted in cardiomyopathies not directly related to eNOS 
functionality [690, 691]. Instead this appears to be linked to inflammation, as p42/44 MAPK 
is activated in cardiac fibroblasts of mice lacking cav-1 [691]. Wunderlich et al hypothesised 
that a lack of cav-1 to regulate eNOS leads to an overproduction of NO, thus causing nitrosative 
stress [692]. This was supported by their observation that young cav-1-/- mice exhibit 
cardiohypertrophy linked to severely reduced cardiac output, together with enhanced eNOS 
activity and elevated staining of nitrotyrosine in cardiac tissue [692]. Further, cav-1-/- mice had 
elevated vascular O2
•- production, which was prevented by endothelial denudation, 
supplementation with BH4 (but not tetrahydroneopterin; an analogue of BH4 unrelated to eNOS 
activity) or the pharmacological eNOS inhibitor, L-NAME [693]. Together, this evidence links 
a lack of cav-1 to increased uncoupling of eNOS, oxidative (and nitrosative) stress, tissue 
damage and cardiac remodelling, which may be a unique oxidative scenario to cardiac tissue 
as this contradicts the previous findings in peripheral arteries [640, 641]. The colocalisation, 
but lack of binding of cav-1 and eNOS observed in the current study following treatment with 
MPO oxidant-modified LDL is difficult to compare to studies using cav-1-/- mice, as the effect 
of MPO-modified LDL or hypercholesterolaemia on atherosclerosis is these strains are 
unknown. However, the findings that O2
•- levels remained unchanged while NO production 
was decreased may indicate that cav-1-dependent endocytosis may lead to inactivation and 
degradation of the eNOS dimer, but not the resultant O2
•- production by uncoupling.  
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5.4.3. Rat aortic segment vasodilation 
The relevance and significance of the findings from the in vitro studies with HCAEC were 
assessed using an ex vivo rat model. Under similar experimental conditions to previous studies 
that used native LDL, Cu2+- or cell-modified LDL [451, 455, 456], incubation of rat aortic 
segments with 0.1 mg•mL
-1 LDL modified by HOSCN or HOCl for 1 h caused a significant 
reduction in ACh-(endothelium-)dependent vasodilation, with no effect on endothelium-
independent vasodilation (measured by the response to SNP). LDL modified by either 250 μM 
HOSCN or HOCl, which significantly decreased eNOS activity and NO production in HCAEC 
in vitro, significantly reduced endothelium-dependent (ACh-induced) vasodilation, but did not 
alter aortic vasodilation induced by SNP, meaning the impaired arterial distensibility was due 
to effects on the endothelium and not the underlying smooth muscle. These results have not 
been reported in the literature previously for HOSCN- or HOCl-modified LDL, and are in line 
with what was expected based on the in vitro findings in HCAEC exposed to the MPO oxidant-
modified LDL.  
Although treatment with the control LDL significantly reduced NO production in HCAEC 
in vitro, endothelium-dependent vasodilation was not significantly lower in rat aortae 
stimulated with ACh following exposure to control LDL. Another previous study has shown 
that 0.5 mg•mL
-1 control LDL also did not impair endothelium-dependent vasodilation in 
porcine coronary arterioles [455], supporting the findings here. This indicates that although 
LDL can modulate eNOS activity, this does not interfere as much with ACh signaling to 
promote NO production in the endothelium compared to HOSCN- or HOCl-modified LDL. 
This could be attributed to eNOS remaining coupled when endothelial cells were exposed to 
control LDL, compared to the increased uncoupling seen with exposure to HOSCN- or HOCl-
modified LDL, which was demonstrated in the current study in HCAEC in vitro. 
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An aspect of endothelium-derived vasodilation that has not been addressed in the preceding 
experiments, factors that can influence vasodilation. is the role other endothelium-derived 
vasodilators. Endothelium-derived hyperpolarising factor (EDHF) is proposed to be released 
as a compensatory mechanism by endothelial cells to maintain vascular tone should NO 
production be impaired [694]. NO production was reduced by over 50 % from exposure to 
HOSCN-modified LDL and 75 % from HOCl-modified LDL as shown by EPR (Figure 5.4), 
but ACh-dependent vasodilation was only reduced by approximately 40 % by both modified 
LDL species. This difference may be related to EDHF which is also released by rat vessels in 
response to stimulation by ACh [695]. Therefore, it would be helpful to perform experiments 
to measure the release of EDHF in response to modified LDL-induced endothelial dysfunction. 
 Conclusions 
Together, the data in this study support a role for both HOSCN- and HOCl-modified LDL 
in decreasing NO production, which translated to impaired endothelium-dependent arterial 
distensibility in functioning rat aortic vessels by inducing endothelial dysfunction. The 
comparable decreases in NO production and vasodilation induced by exposure to LDL 
modified by both HOSCN and HOCl is significant, as there is evidence to support the beneficial 
effects of SCN-, which may slow lesion development in atherosclerosis, evidenced by HOSCN-
modified LDL not being taken up by macrophages to the same extent as HOCl-LDL [146, 290]. 
This may have detrimental implications in smokers who have augmented levels of plasma SCN- 
and are burdened by increased endothelial dysfunction. This also highlights the need to 
interrogate other mechanistic pathways to better understand how SCN- promoting HOSCN 
formation rather than HOCl influences disease progression, where there can be detrimental or 
beneficial aspects depending on the inflammatory situation (e.g. thiol availability, MPO 
activity, presence of lipids) in atherosclerosis or other chronic inflammatory conditions.  
Although MPO oxidant-modified LDL did not affect vascular smooth muscle relaxation in a 
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short incubation time, as they are protected by the endothelium, LDL and oxidised LDL can be 
transported through the endothelium over time to embed in the intimal layer [608, 685, 686, 
696], where smooth muscle cells can be directly exposed to oxidised LDL. Therefore, the effect 
of MPO oxidant-modified LDL on vascular smooth muscle cells was investigated in the 
following Chapter. 
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 Smooth muscle cell uptake and response to 
MPO oxidant-modified LDL  
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 Introduction 
Vascular smooth muscle cells (VSMC) have been implicated in the progression of 
atherosclerotic plaques by several mechanisms, including foam cell formation and ECM 
synthesis, the latter of which can lead to the establishment of a fibrous cap and eventually 
calcification (reviewed [697]). It has been demonstrated that VSMC can take up modified LDL, 
which accumulates to an extent comparable to macrophage foam cells [475, 698-700]. Notably, 
in Watanabe heritable hyperlipidaemic rabbits, a greater proportion of foam cells were of SMC 
origin than macrophage origin in advanced lesions, evidenced by cell-specific monoclonal 
antibodies (cf. 45 % and 30 %, respectively [701]). This has also been shown in atherosclerotic 
plaques of human coronary arteries, demonstrating that intimal SMC can transform into foam 
cells [702]. SMC, like endothelial cells and macrophages, express multiple classes of scavenger 
receptors; such as LOX-1, SR-A and CD36, for which all have demonstrated affinity for Cu2+-
oxidised LDL and can promote the intracellular accumulation of lipids [306, 703-705]. 
However, current evidence for a role of LDL modified by MPO-derived oxidants in VSMC 
foam cell formation has not been established.  
It is generally accepted that the major role of VSMC in the development of atherosclerosis 
relates to aiding in vascular remodelling (reviewed [697]). VSMC can do this due to their 
heterogeneity; being able to switch from a contractile phenotype, which mediates vascular 
contractility in healthy vessels, to a synthetic phenotype, which promotes SMC proliferation, 
migration, and production of synthetic proteins to aid in repair of the injured vessel [706]. The 
change in phenotype results in drastic structural and functional changes, where contractile SMC 
have high abundance of myofilaments for vessel contraction, while synthetic SMC have a high 
number of synthetic organelles and sparse myofilaments [706, 707]. This is mediated by an 
array of alterations in gene expression (Figure 6.1). 
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Figure 6.1. Contractile and Synthetic phenotype markers and morphology. Common 
markers of VSMC contractile and synthetic phenotypes which were assessed in this current 
study. Contractile VSMC display a highly striated morphology due to the large abundance of 
myofilaments (image adapted from [706]), while synthetic phenotypes lose the majority of 
myofilaments and have a high number of synthetic organelles (image adapted from [707]). 
Muscle contraction-associated genes/proteins, α-smooth muscle actin (α-SMA), smooth 
muscle-myosin heavy chain (SMMHC) and calponin are constitutively highly expressed in 
mature contractile VSMC and modulate vasorelaxation/contraction [469, 708-710]. These 
contractile genes are downregulated upon switching to synthetic-state [711-713]. Osteopontin 
(OPN); a bone-associated extracellular structural protein with similar role to other structural 
ECM proteins, is upregulated in the synthetic VSMC [714]. The expression of connexin-43 
(Cx43), the primary gap junction protein expressed in VSMC [715], is also upregulated in 
synthetic SMC [716]. Cx43 upregulation also correlates with increased proliferation and 
migration of VSMC [711], which was reduced in Cx43 knockdown rat in a balloon angioplasty-
model of intimal hyperplasia [717]. Of particular relevance to atherosclerosis, decorin, a 
dermatan sulfate proteoglycan that links adjacent collagen proteins to form collagen matrices 
[718]; is highly expressed in arterial SMC [719] and is localised in atherosclerotic lesions [720, 
721], particularly near lipid/lipoprotein deposits [722, 723]. An increase in decorin expression 
also accompanies a shift of less collagen III production and greater collagen I production in 
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synthetic VSMC [724] and aids in linking LDL to collagen I, providing a mechanism of 
retaining LDL in lesions [722, 723]. The Ca-binding protein S100A4 is also expressed in 
synthetic (“rhomboid-shaped”) proliferating SMC and human atheromas [725], and was 
demonstrated to promote proliferation and migration through receptor for advanced glycation 
end products (RAGE)-dependent NF-κB activation in human pulmonary artery SMC [726, 
727]. Recently, olfactomedin-like 3 (Olfml3), a gene encoding a family of proteins with 
olfactomedin domains which is also involved in cell cycle regulation and tumorogenesis [728], 
was shown not to be expressed in contractile VSMC subpopulation, but was upregulated in a 
synthetic subpopulation VSMC which promoted cell proliferation [729].  
Calcification; a process of mineralisation of cells/tissue, which is involved in advanced 
atherosclerotic plaques [730], is positively correlated to an increased risk of MI [731] 
concurrent with plaque instability [732]. VSMC uptake of oxidised LDL has also been linked 
to calcification [733, 734]. The synthetic phenotype protein, OPN negatively modulates 
calcification [735-737], and is found highly expressed in calcified regions of human 
atherosclerotic plaques near cholesterol depositions and macrophages/smooth muscle cells 
[738]. OPN inhibits apatite crystallisation to perturb mineralisation, and hence plays a key role 
in preventing vascular calcification [739]. Conversely, calcification is promoted by the 
expression of calcification factors, core binding-factor subunit α-1/runt-related transcription 
factor-2 (Cbfa1/Runx2) and osteocalcin [740, 741]. Unlike in bone, where a loss of decorin is 
associated with collagen fibril mineralisation [742], decorin expression in synthetic VSMC 
eventually promotes calcification [741, 743] and is colocalised with calcium deposits in 
atherosclerotic lesions of sudden coronary death patients [743]. Bovine aortic SMC (BASMC) 
undergoing calcification had reduced expression of α-SMA and SM22α and upregulation of 
OPN and osteocalcin, which was followed by Cbfa1 upregulation and corroborated in vivo in 
calcified arterial SMC from MGP-/- mice that exhibit spontaneous arterial calcification [744].   
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Changes to SMC phenotype, including in response to LDL, could represent a synthetic 
phenotype transition to stabilise the atherosclerotic plaque and aid in vessel repair. Notably, 
myosin, myocardin and α-SMA (associated with myofilaments) and calponin expression 
decreased in VSMC in response to Cu2+- and Fe2+-oxidised LDL [475, 703, 745], which also 
upregulated expression of toll-like receptor 4 (TLR4), and the scavenger receptors LOX-1 and 
CD36 in VSMC [475, 703]. Together these studies indicate oxidised LDL promoting a 
transition away from a contractile phenotype and lipid accumulation, although the expression 
of classic synthetic markers (such as OPN, decorin, S100A4, Olfml3 and Cx43) have not been 
assessed following exposure to oxidised LDL. Further, there is currently a lack of data on the 
role of MPO- or MPO oxidant-modified LDL in modulating VSMC phenotype. 
 Aims 
The aim of the preliminary studies in this Chapter, using human coronary artery smooth 
muscle cells (HCASMC) as a model, was to compare HOSCN-modified LDL with HOCl-
modified LDL with regard to the degree of LDL uptake, cell viability and gene expression of 
contractile, synthetic and calcification markers. 
 Results 
6.3.1. Cell viability and metabolic activity 
The effect of each modified LDL on cell viability was determined in HCASMC following 
exposure to 0.1 mg•mL
-1 modified LDL (prepared from a stock of 1.0 mg•mL
-1 LDL treated 
without oxidant, or either 250 µM HOSCN or HOCl for 24 h) in a similar manner to that 
reported in Chapter 4 for HCAEC. HCASMC (seeded at 0.1 × 106 cells•mL
-1) were exposed to 
each type of modified LDL species for 24 h and 48 h in SMC basal media supplemented with 
insulin and 5 % v/v FBS, before performing the LDH assay for cell viability, or the MTT assay 
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for cell metabolic activity (as described in Section 2.7). Viability was unaltered when 
HCASMC were incubated with or without control LDL, or HOSCN- or HOCl-modified LDL 
for 24 or 48 h (Figure 6.2A). Formazan production was also unaltered by treatment with 
HOSCN- or HOCl-modified LDL treatments after 24 h incubation (Figure 6.2B). Compared to 
24 h treatment, there was a general increase in formazan production in the control and LDL 
treatment groups after 48 h incubation, but this was not statistically different, whilst there was 
high variability between the HCASMC donors. In summary, HCASMC treated with 0.1 
mg•mL
-1 of incubation control LDL, HOSCN- or HOCl-modified LDL remained viable, while 
there was a slight stimulatory metabolic effect, similar to the response by HCAEC (refer to 
Figure 4.1). 
 
Figure 6.2. Cell viability and activity of HCASMC after incubation with oxidised LDL 
for 24 h and 48 h. Firstly, 1.0 mg•mL
-1 control LDL, or LDL incubated with 250 µM HOSCN 
or 250 µM HOCl, were incubated at 37 °C for 24 h. Subsequently, HCASMC were treated with 
0.1 mg•mL
-1 of LDL or (250 μM HOSCN or HOCl) oxidised LDL species at 37 °C for 24 h 
(white bar) or 48 h (black bar) in treatment medium. (A) Cell viability was measured by the 
LDH activity assay. (B) Cell activity was measured by formazan production (MTT assay). 
Three independent HCASMC and LDL donors were used. Bars represent the mean ± SD (n = 
3). Two-way ANOVA with Dunnett’s multiple comparison test between treatment groups and 
Sidak multiple comparison test between time points. No significant difference between 
treatments or time points were found. 
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6.3.2. Uptake of MPO oxidant-modified LDL 
Several studies have shown that human and rat VSMC accumulate lipids following exposure 
to several forms of modified LDL, including Cu2+-oxidised, which led to foam cell formation 
in vitro [698, 746, 747]. Yet, whether VSMC challenged with LDL modified by MPO or MPO-
derived oxidants contributes to lipid accumulation remains to be established. Therefore, given 
the lack of toxicity and increases in HCASMC metabolic activity following incubation with 
either control LDL or each MPO oxidant-modified LDL, the next experiment assessed the 
accumulation of lipids by HCASMC. Cholesterol and cholesteryl ester uptake by HCASMC 
was measured following the incubation of cells with treatment medium (basal medium 
supplemented with 5 % FBS and insulin, without growth factors) alone, or with medium with 
either control LDL, HOSCN- or HOCl-modified LDL, for 24 h and 48 h.  
Intracellular lipid levels were increased in HCASMC incubated with the incubation control 
LDL at both 24 and 48 h time points, however there was no considerable difference between 
the control and MPO oxidant-modified LDL treatments (Figure 6.3A). At both 24 and 48 h 
measurements, the proportion of cholesteryl esters in the cell was augmented in incubation 
control- and MPO oxidant-modified LDL compared to the no LDL-control, but this varied 
between HCASMC donors and was not significant (Figure 6.3B). However, the time-
dependent accumulation of intracellular lipid, expressed as the difference in lipid levels 
between 24 and 48 h measurements (ΔIntracellular lipids), was generally decreased between 
the 24 and 48 h time points within each treatment. This suggests that intracellular lipids were 
not accumulating in the cells upon exposure to LDL for up to 48 h (Table 6.1).
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Figure 6.3. Total cholesterol and cholesteryl ester levels of HCASMC after incubation 
with oxidised LDL. Firstly, 1.0 mg•mL
-1 control LDL, or LDL incubated with 100 or 250 µM 
HOSCN, or 100 or 250 µM HOCl, were incubated at 37 °C for 24 h. HCASMC were treated 
with 0.1 mg•mL
-1 of LDL or oxidised LDL species at 37 °C for 24 h (white bar) or 48 h (black 
bar) in treatment media. Cholesterol and cholesteryl ester content were normalised to cellular 
protein concentration as assessed by the BCA assay. Total cholesterol represents the sum of 
the free cholesterol and the cholesteryl esters detected by HPLC in the HCASMC lysate 
samples (A). Cholesteryl esters are represented as a percentage of the total cholesterol 
measured in HCAEC lysates (B). Three independent HCASMC and LDL donors were used. 
Bars represent the mean ± SD (n = 3). Two-way ANOVA with Dunnett’s multiple comparison 
test between treatment groups and Sidak multiple comparison test between time points. No 
significant differences were found between 24 and 48 h time point.
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Table 6.1. Difference in total cellular cholesterol in HCASMC between 24 h and 48 h 
incubation with MPO oxidant-modified LDL. The change in intracellular lipids was 
calculated between 24 h and 48 h incubation times (ΔIntracellular lipid) from the data in 
Figure 6.2A to compare the change in intracellular lipids due to LDL uptake, independent of 
lipids already present in the cells. One-way ANOVA with Holm-Sidak multiple comparison test. 
No significant differences were found compared to the control. 
 
6.3.3. SMC phenotype gene expression 
6.3.3.1. Contractile markers 
The uptake of oxidised LDL by VSMC has been linked to reduced expression of contractile 
markers concurrent with increased proliferation [475, 703], indicative of a shift from 
contractile to synthetic phenotype. However, these studies were performed in a Cu2+-modified 
LDL model [475, 703] and the comparative effect of LDL modified by MPO-derived oxidants 
has not been reported. Therefore, both contractile and synthetic phenotype markers were 
examined following 24 and 48 h treatment of HCASMC with LDL modified by HOSCN or 
HOCl (250 μM, 24 h). No significant alterations were observed the mRNA expression of the 
contractile markers α-SMA or calponin following 24 h incubation of the cells with each LDL. 
LDL treatment ΔIntracellular lipid (mean ± SD) Significance 
Control -59.92 ± 53.24 NS 
Control LDL -71.15 ± 74.24 NS 
100 μM HOSCN-LDL -45.79 ± 38.92 NS 
250 μM HOSCN-LDL -64.14 ± 67.10 NS 
100 μM HOCl-LDL -29.19 ± 31.02 NS 
250 μM HOCl-LDL -19.36 ± 36.00 NS 
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However, after 48 h treatment, HOSCN- and HOCl-modified LDL reduced α-SMA mRNA 
expression and all LDL treatments reduced calponin mRNA expression in the HCASMC 
compared to the respective no LDL control (Figure 6.4A and B). The mRNA expression of α-
SMA and calponin was increased between 24 and 48 h time points in the cells in the absence 
of LDL, though this was only significant for calponin expression (shown by #), while α-SMA 
was not significant (p = 0.10). This result indicates that LDL, and to a greater extent HOSCN- 
and HOCl-modified LDL, halted the mRNA expression of both α-SMA and calponin. In 
contrast, no change in collagen I was observed between treatments at 24 or 48 h time points 
(Figure 6.4C).
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Figure 6.4. Gene expression of contractile phenotype-associated genes in HCASMC 
following exposure to LDL modified by HOSCN or HOCl. 1.0 mg•mL
-1 control LDL or LDL 
modified with 250 µM HOSCN or 250 µM HOCl for 24 h. HCASMC were treated with 0.1 
mg•mL
-1 of control LDL or oxidised LDL species for 24 h (white bar) or 48 h (black bar) at 37 
°C before measuring the mRNA expression of (A) α-SMA, (B) calponin and (C) collagen 1 by 
qPCR. Expression was normalised to 18S and β2M as housekeeping genes. Three independent 
HCASMC and LDL donors were used. Bars represent the mean ± SD (n = 3). Two-way ANOVA 
with Dunnett’s multiple comparison test between treatment. * and ** represent p < 0.05 and 
0.01, respectively, compared to the control. # represents p < 0.05 compared to 24 and 48 h 
time points.   
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6.3.3.2. Synthetic markers 
Studies were undertaken to corroborate the alteration in contractile marker expression with 
the expression of synthetic markers. The HCASMC were treated with HOSCN- or HOCl-
modified LDL as in Section 6.3.3.1, before determining the mRNA expression of synthetic 
markers OPN, Olfml3, S100A4, Cx43, decorin and MMP9. There was no difference in OPN 
mRNA expression between the non-treated LDL control and control LDL treatments after 24 
or 48 h exposure, nor was there a difference between the time points within those treatments 
(Figure 6.5A). In contrast, HCASMC exposed to HOSCN- and HOCl-modified LDL displayed 
a time-dependent elevation in OPN mRNA expression, which reached significance following 
48 h exposure. Olfml3 expression was not altered between treatments after 24 h incubation, 
but was elevated in the non-treated HCASMC between 24 and 48 h incubation, though this was 
not significant (p = 0.081; Figure 6.5B). However, upon exposure to HOSCN-modified LDL, 
Olfml3 expression remained unchanged at both 24 and 48 h incubation and the expression of 
Olfml3 was significantly reduced compared to the respective control after 48 h. This trend was 
also observed to a lesser extent with HOCl-modified LDL, but this was not significant (p = 
0.0502). S100A4 expression in the HCASMC between 24 and 48 h incubation remained 
unchanged in the control and control LDL treatment groups, but was increased on exposure of 
the cells to HOSCN- and HOCl-modified LDL, though these changes were not significant (p 
= 0.2860 and 0.1549, respectively; Figure 6.5C). Other synthetic phenotype markers, Cx43, 
decorin and MMP-9 were unaltered in all treatment groups at both 24 and 48 h time points 
(Figures 6.5D – F). 
218 | P a g e  
 
 
Figure 6.5. Gene expression of synthetic phenotype-associated genes in HCASMC 
following exposure to LDL modified by HOSCN or HOCl. 1.0 mg•mL
-1 control LDL, or 
LDL modified with 250 µM HOSCN or 250 µM HOCl for 24 h. HCASMC were treated with 
0.1 mg•mL
-1 of control LDL or oxidised LDL species for 24 h (white bar) or 48 h (black bar) 
at 37 °C before measuring the mRNA expression of (A) OPN, (B) S100A4, (C) Cx43, (D) 
decorin, (E) Olfml3 and (F) MMP-9 by qPCR. Expression was normalised to 18S and β2M as 
housekeeping genes. Three independent HCASMC and LDL donors were used. Bars represent 
the mean ± SD (n = 3). Two-way ANOVA with Dunnett’s multiple comparison test between 
treatment groups. * and ** represent p < 0.05 and 0.01, respectively, compare to the control.  
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6.3.3.3. Calcification markers 
The synthetic phenotype-associated protein, OPN plays a key role in the calcification of 
VSMC [736, 737, 748] and was shown to be upregulated following 48 h incubation with 
HOSCN- and HOCl-modified LDL (Figure 6.5A). Therefore, the expression of calcification 
markers, osteocalcin and Runx2 were measured following 24 and 48 h incubation of HCASMC 
with each type of modified LDL. No significant alteration in osteocalcin was observed at either 
time point (Figure 6.6A). In general, Runx2 expression increased between the 24 and 48 h 
incubation times between all treatment groups, which nearly approached significance with 
HOCl-modified LDL treatment (p = 0.053; Figure 6.6B). However, this was due to the decrease 
in Runx2 expression with HOCl-modified LDL compared to the control after 24 h incubation, 
whereby the Runx2 mRNA expression levels became equal across all treatments by 48 h.
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Figure 6.6. Gene expression of calcification-associated genes in HCASMC following 
exposure to LDL modified by HOSCN or HOCl. 1.0 mg•mL
-1 control LDL, or LDL modified 
with 250 µM HOSCN or 250 µM HOCl for 24 h. HCASMC were treated with 0.1 mg•mL
-1 of 
control LDL or oxidised LDL species for 24 h (white bar) or 48 h (black bar) at 37 °C. 
Expression was normalised to 18S and β2M as housekeeping genes. Three independent 
HCASMC and LDL donors were used. Bars represent the mean ± SD (n = 3). Two-way ANOVA 
with Dunnett’s multiple comparison test between treatment groups. 
 Discussion 
The experiments in this Chapter examined the in vitro exposure of HCASMC to LDL 
oxidised with either 250 μM HOSCN or HOCl, which is believed to be achievable under 
physiological conditions [42]. These oxidised LDL treatments did not result in cytotoxicity, as 
measured by the LDH; nor was any modulation of metabolic activity as determined using the 
MTT assay; nor did these forms of oxidised LDL promote excessive accumulation of lipids in 
HCASMC with up to 48 h exposure. Despite this, the contractile genes α-SMA and calponin, 
were not as highly expressed following 48 h exposure to HOSCN- or HOCl-modified LDL 
compared to the 48 h control, while the synthetic gene OPN was significantly upregulated by 
48 h exposure to both HOSCN- and HOCl-modified LDL compared to the control, which has 
not been reportedly previously. However, other synthetic and calcific genes were not altered. 
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Overall, the expression array of phenotype markers did not change significantly enough to 
demonstrate a strong oxidized-LDL induced transition of VSMC phenotype to a synthetic or 
calcific state under the conditions employed in this study. 
Whilst there was a modest rise in intracellular cholesterol levels when HCASMC were 
exposed to incubation control LDL, the results of the current study do not support the excessive 
accumulation of cholesterol upon exposure to each MPO oxidant-modified LDL. This contrasts 
with other previous studies, where rat thoracic aortic- and bone marrow-derived SMC exposed 
to Cu2+-oxidised LDL at similar concentrations for 24 to 48 h formed into foam cells, as 
measured by Oil Red O staining or quantification by a fluorescence enzymatic assay [475, 746, 
747]. As LDLR mRNA expression was reduced in endothelial cells, as shown in Chapter 4, a 
similar mechanism may have been in action upon exposure of HCASMC to incubation control- 
and MPO oxidant-modified LDL. This notion is supported by a prior study that showed that 
LDLR expression in HCASMC was sensitive to lipid loading, as 25 μg•mL-1 of native LDL 
significantly reduced LDLR mRNA and protein expression under both inflammatory (LPS-
stimulated) and non-inflammatory conditions [700]. VSMC-derived foam cell formation is also 
linked to synthetic transdifferentiation [699].  
In the current study, only OPN was significantly elevated following exposure to each MPO 
oxidant-modified LDL over the course of 48 h. Olfml3 mRNA expression was lower following 
incubation with HOSCN- and HOCl-modified LDL, while S100A4 expression inclined 
towards increased expression by the same treatments. Pericytes, highly proliferative cells 
which can originate from VSMC lineages, express Olfml3 to promote angiogenesis, which is 
important to vascular remodelling [729]. However, pericytes also highly express α-SMA 
together with Olfml3; the expressions of which are linked as Olfml3 silencing reduced α-SMA 
expression and proliferation [729]. The same expression pattern was also observed between α-
SMA and Olfml3 in this current study. However, in the current study, the slight increase of 
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S100A4 mRNA expression with exposure to HOSCN- or HOCl-modified LDL over 24 and 48 
h closely reflected the increased production of formazan as an indicator of proliferation. 
Elevated S100A4 expression has been detected in “rhomboid” (synthetic) pulmonary artery 
SMC, but not “spindle” (synthetic) SMC under hypoxia in vitro, which was associated with 
augmented proliferation and migration by NF-κB activation [727, 749]. Further, in a calf 
animal model of hypoxic pulmonary hypertension, blockade of S100A4 and RAGE attenuated 
SMC migration [750]. However, it has not been previously reported if oxidised LDL could 
promote S100A4-mediated responses in SMC.  
The synthetic VSMC phenotype, particularly linked to the expression of OPN and decorin, 
also cross-functionally promotes VSMC calcification. However, in the current study, elevated 
OPN mRNA expression upon exposure to HOSCN- and HOCl-modified LDL was not 
reciprocated with decorin, Runx2 or osteocalcin expression, indicating that calcification was 
not an active process following exposure to LDL modified by HOSCN or HOCl. Several 
studies have shown that acetylated LDL [733], Cu2+-oxidised LDL [734, 751], or oxidised 
LDL-associated lipids (7-ketocholesterol [752]) induced calcification in human arterial SMC. 
This is concurrent with an upregulation of OPN and Cbfa1/Runx2 expression [753], which are 
co-localised in advanced atherosclerotic lesions and are crucial to calcification [713]. Exposure 
of human aortic SMC to 7-ketocholesterol was shown to induce calcification linked to the loss 
of lysosomal function [752]. However, the reaction of HOCl with cholesterol does not form 7-
ketocholesterol [135, 298], and while HOSCN can react with LDL-derived lipids, whether this 
leads to formation of 7-ketocholesterol has not yet been reported [146]. Therefore, other 
mechanisms of LDL oxidation may be relevant to promoting calcification.   
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6.4.1. SMC transdifferentiation/calcification: a 
matter of time? 
A possible limitation faced in this study is the relatively short incubation time of up to 48 h 
of the HCASMC to LDL treatments when compared to other in vitro studies. Several other 
studies have investigated SMC phenotype transitions over the course of between 6 to 28 days 
[711, 717, 719, 725, 740, 743, 744, 754, 755], including those studies investigating the impact 
of modified LDL [475, 733, 734] or related oxidation products [752, 753], on SMC 
transdifferentiation and calcification. The proliferation of rabbit arterial and venous SMC did 
not significantly increase in culture until the fifth day of treatment in conditioned media [719]. 
Further, arterial SMC were less proliferative than the venous counterpart [719] and may be 
slower to transdifferentiate. Downregulation of α-SMA and SM22α, upregulation of OPN and 
osteocalcin, and calcification, were not induced until day 7 of incubation with organic 
phosphate (β-glycerophosphate) in BASMC, with the exception of Cbfa1 expression 
upregulated at day 3 of treatment [744]. This was similar to two independent studies exposing 
human VSMC to Cu2+-oxidised LDL, though decorin expression was almost completely abated 
at day 4 of treatment [734, 751]. In light of this, as the gene expression of contractile markers, 
α-SMA and calponin were stunted, and the expression of the synthetic marker OPN was 
elevated by exposure to LDL modified by HOSCN or HOCl in this study. This could be an 
early indicator of phenotype shift that is still in a transitionary stage at a shorter incubation time 
of 48 h. 
The cases for which SMC differentiation was studied in accordance with 24 and 48 h time 
points was that this was previously enough of an incubation period for with oxidised LDL 
induced foam-cell formation. Specifically, in bone marrow-derived SM progenitor cells 
(SMPC; mesenchymal cells that are differentiated to smooth muscle-like cells over 30 days), 
exposure to 25 – 100 μg•mL-1 DiI-labelled Cu2+-oxidised LDL, equivalent LDL concentration 
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to this current study, significantly reduced α-SMA and myocardin expression within 48 h of 
incubation [475]. When HCASMC were exposed to low levels (4 – 15 μg•mL-1) of Cu2+-
modified LDL (less than the 100 μg•mL-1 of HOSCN- or HOCl-modified LDL used in the 
current study), there was an induction of up to 3-fold greater proliferation (measured by 
fluorochrome incorporation into DNA during replication) and migration, which receded at 
concentrations > 7.5 μg•mL-1 [703]. This was concurrent with an approximate 70 % reduction 
in calponin and SM22α, and 40 % reduction in α-SMA protein expression, which was linked 
to NF-κB, stimulated the production of G-CSF and GM-CSF and subsequently stimulated 
monocytes and macrophages to release MCP-1 when cultured in the medium of the VSMC 
treated with oxidised LDL [703]. The results of that study showed that 24 h exposure to Cu2+-
oxidised LDL induced a pro-inflammatory response and promoted switching to a synthetic 
phenotype. It is difficult to predict if a similar outcome would have been observed if this current 
study utilised an equivalent 0.1 mg•mL
-1 Cu2+-oxidised LDL by the finding that significant cell 
death was incurred at 0.1 mg•mL
-1 Cu2+-oxidised LDL [703], which was not the case upon 
exposure to HOSCN- or HOCl-modified LDL in the current study. In that case, investigating 
whether comparatively lower concentrations of HOSCN- or HOCl-modified LDL would 
induce these proliferative and phenotypic changes observed in Cu2+-oxidised LDL-treated 
SMC would be more determinative. 
Although a degree of phenotype switching was observed, SMC-derived foam cell formation 
was not investigated in that study. Additionally, S100A4 stimulation of VSMC also activates 
NF-κB to promote proliferation, migration, and production of cytokines MCP-1 and IL-6 [727, 
749]. Regardless, these studies demonstrated the transdifferentiation of (bone marrow- and 
vascular-derived) SMC by oxidised LDL, but did not investigate the expression of synthetic 
phenotype markers; such a study has yet to be reported in the literature. Given the trending, but 
non-significant increase in S100A4 mRNA expression and formazan production in this current 
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study, longer exposure to HOSCN- or HOCl-modified LDL may have resulted in a greater 
extent of altered S100A4 expression and/or significant proliferation.  
6.4.2. Limitations and conclusion 
There are key limitations to this study that need to be acknowledged. One issue that is likely 
present in this study is subculturing the cells through multiple cell divisions in growth medium 
to achieve confluence may have shifted the HCASMC to a more synthetic phenotype [756, 
757]. Although HCASMC were incubated with LDL treatments in the absence of growth 
factors, the cells may have been in a mixture of cell-cycle phases before treatment, while 
contractile VSMC are usually in the G0 phase of mitosis [758]. This variable may be somewhat 
controlled by the preincubation of HCASMC for several days in nutrient media (such as 
Dulbecco’s Modified Eagle’s Media) in the absence of growth factors and serum to return cells 
to G0 phase (referred to as synchronisation) [475, 741]. Another limitation is the gene 
expression variations between primary cell donors, which may make the use of three HCASMC 
donors too few to assess gene expression alterations. The three HCASMC donors were all of 
male origin, but of different ages and races. Although the variation was not attributed to one 
particular donor for each gene, using different donors but normalising for also age and race 
may reduce the variation in response to HOSCN- and HOCl-modified LDL. Further, as per the 
discussion in Section 6.4.1, investigating longer treatment times (e.g. 7 – 14 days) may better 
assess phenotypic changes in HCASMC. 
Overall, this study showed for the first time that LDL modified by HOSCN or HOCl 
upregulated OPN mRNA expression in vitro, though this did not cause VSMC foam cell 
formation or a change in VSMC phenotype over 48 h. Additionally, LDL modified by either 
HOSCN or HOCl inhibited the upregulation of α-SMA and calponin, indicating that the 
contractile phenotype of VSMC was impaired. Further higher-powered studies are required to 
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corroborate whether exposure to LDL modified by MPO over longer terms can significantly 
elevate levels of intracellular LDL-derived lipids and evoke a synthetic SMC phenotype 
mediated by OPN and S100A4 upregulation in SMC transdifferentiation. 
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 General Discussions and Future Directions 
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 Overview 
The research performed in this Thesis was designed to explore the role of the MPO-derived 
oxidants, HOSCN and HOCl, in the modification of LDL and whether such modifications lead 
to impaired vascular endothelial and SMC function. Oxidised LDL is a key component of 
atherosclerotic plaques, and is proposed to be critical in the initiation and progression of 
atherosclerosis [759]. MPO is likely to be an important pathway to LDL oxidation, whereby 
neutrophils infiltrate the intima of atherosclerotic plaques and release MPO during the 
inflammatory response. Notably, functional MPO has been shown to colocalise in human 
atherosclerotic plaques with LDL modified by HOCl [233, 234, 284]. The development of 
atherosclerotic plaques leads to arterial stiffening by impaired endothelium-dependent dilation 
of arteries, termed endothelial dysfunction [760]. The severity of endothelial dysfunction can 
be independently predicted by measuring the circulating levels of MPO [761], lending further 
support to a central role for the enzyme in the development of atherosclerosis. Concomitant 
with endothelial dysfunction are alterations in VSMC function, linked to a phenotypic shift, 
which causes hyperplasia and vascular remodelling [697]. However, a role of MPO as a driver 
for altered VSMC function in vascular inflammation and atherosclerosis has yet to be 
established. Given the evidence for MPO-derived oxidants in the promotion of atherosclerosis 
by altering several vascular cell functions, such as endothelial dysfunction and macrophage 
foam cell formation [146, 292, 446, 447], this could be a key pathway to target for 
pharmacological therapy, and such therapy is likely to have a wide range of beneficial effects 
for preventing atherosclerosis and its related cardiovascular complications. 
Several studies have shown that elevated MPO levels are associated with the severity of 
atherosclerosis and are an independent predictor and risk factor of coronary artery disease 
(CAD) [235, 236, 238-241] and acute coronary syndromes (ACS) [245-247]. Given that MPO 
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is present in atherosclerotic lesions [21], and shown to be active by the detection of chlorinated 
products on LDL and other biomolecules [141, 233, 284] indicates that MPO is not just a 
marker, but is enzymatically active in producing the reactive oxidant HOCl. Several studies 
have demonstrated a capacity of HOCl and MPO-chlorinating activity to modify LDL, altering 
the functionality in diverse ways relevant to atherosclerosis [53, 111, 288, 290, 293, 762, 763]. 
However, the role of HOSCN, the other major MPO-derived product formed under 
physiological conditions, in the onset and progression of atherosclerosis has not been well 
characterised. This is related to the lack of a distinct biomarker for HOSCN reactivity, which 
has made elucidating the role of HOSCN formation in vivo difficult. Regardless, HOSCN 
production by MPO is believed to be relevant in smokers, who compared to non-smokers have 
significantly elevated circulating levels of the precursor, SCN- [42, 43, 296, 297, 764], together 
with a significantly lower presence of chlorinated products [120]. This implicates a shift from 
production of HOCl to HOSCN in smokers, who concurrently exhibit accelerated 
atherosclerotic lesion development [254]. Augmented HOSCN production in smokers is also 
implicated in inducing LDL modification in vivo, with the thoracic and abdominal aorta of 
smokers exhibited substantial macrophage infiltration and foam cell formation correlating with 
elevated plasma SCN- levels [253], together with elevated levels of the lipid peroxidation 
markers malondialdehyde- and 4-hydroxynonenal (4-HNE)-modified Lys [254], compared to 
the respective samples from non-smokers. However, experiments in atherosclerosis-prone 
mice that express human MPO demonstrate reduced lesion development when supplemented 
with SCN- in their drinking water, implicating HOSCN formation by MPO in this case, as 
protective [261]. Considering this discrepancy, investigating whether LDL modified by 
HOSCN can alter vascular function, by inducing endothelial dysfunction and/or SMC 
transdifferentiation, may shed light on whether elevated HOSCN production is a detrimental 
or protective factor in the progression of atherosclerosis. 
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The results in this study have demonstrated that LDL modified by either HOCl or HOSCN 
induced endothelial dysfunction by impairing eNOS activity, and reduced endothelium-
dependent vasodilation of rat aortae ex vivo. Further, HOSCN- and HOCl-modified LDL 
influenced the expression of some phenotype markers in a vascular smooth muscle cell model 
(HCASMC), which could demonstrate a long-term response to LDL modified by MPO-derived 
oxidants. 
 HOSCN-induced apoB-100 fragmentation 
HOSCN and HOCl induced modification to LDL, after 24 h exposure, albeit to very 
different extents. Oxidation of LDL by 250 μM HOCl led to formation of a more negatively 
charged LDL particle, with extensive aggregation and fragmentation of apoB-100. Conversely, 
oxidation of LDL by 250 μM HOSCN also led to aggregation, but with selective fragmentation 
of apoB-100, with no significant alteration in LDL charge. This is attributed to a free radical-
dependent pathway as it was significantly abated by concurrent incubation with the anti-
oxidant BHT. This fragmentation had been observed previously [146], but identification and 
sequencing had not been performed to identify the molecular weight and cleavage site of the 
apoB-100-derived peptides. A peptide mass-mapping approach with LC-MS/MS showed that 
HOSCN caused fragmentation of apoB-100, leading to cleavage of the C- and N-termini of the 
protein. From these studies, it was apparent that two peptides with similar molecular-mass 
(approximately 91.7 and 96.6 kDa for the N- and C-terminal fragment, respectively) were 
formed, though experiments to locate the specific cleavage site were not successful.  
The N- and C-terminal fragments produced following exposure of LDL to HOSCN were 
calculated to have a pI of 7.59 and 5.19, respectively, making it possible in theory to purify 
each fragment from the rest of the LDL molecule by 2D-PAGE for additional analysis. 
Complete separation of the terminal fragments and the remaining middle fragment, from intact 
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apoB-100, would allow for more extensive proteomic analysis of the individual fragments and 
other chemical modifications. From previous studies, it has been reported that high circulating 
SCN- levels correspond to an elevation of malondialdehyde- and 4-HNE-modified Lys residues 
on LDL [254]. This type of LDL modification has been shown to mediate oxidised lipid-
dependent protein cross-linking [507, 765, 766]. Future studies could therefore characterise 
both the cleavage site and post-translational modifications of apoB-100, particularly lipid-
derived oxidation products. The formation of 4-HNE by HOSCN could explain why apoB-100 
aggregation was not prevented or reversed by DTT and could potentially serve as a biomarker 
to assess HOSCN formation in vivo. But a caveat to any interpretation in this manner would be 
that 4-HNE can be formed by several chemical pathways and is not a specific product of 
HOSCN-mediated oxidation [767]. 
A further implication for the specific fragmentation of apoB-100 by HOSCN is related to 
changes to the recognition of LDL by the LDLR and/or scavenger receptors. In this study, it 
was shown that only the LDLR expression was downregulated, though only at the mRNA level, 
while no changes were observed in scavenger receptors SR-B1, SR-B2, LOX-1 or SREC-1 on 
exposure of HCAEC to HOSCN-modified LDL. Moreover, no increase in LDL uptake 
following exposure to HOSCN-modified LDL was seen in either HCAEC or HCASMC. 
Previous studies have tested several potential binding sites, and discerned that two basic 
regions of the LDLR are important in binding to apoB-100, named site A (L3147 - G3157) and 
site B (Q3359 - S3369) [267, 768-770], the latter being essential to apoB-100 binding to the LDLR 
[771]. However, these regions are well outside where the apoB-100 is likely to be cleaved by 
HOSCN (in proximity to residue 3725, based on LC-MS/MS sequence of the C-terminal 
fragment). Therefore, the LDLR binding domain is not likely removed after exposure to 
HOSCN. Further, truncation of the C-terminus is able to increase the binding strength of apoB-
100 to the LDLR [771], which may be relevant to LDL modified by HOSCN (or HOCl, which 
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also induced fragmentation of the apoB-100, though not in a site-specific manner). As the 
LDLR is recycled back to the plasma membrane after dissociating from LDL in the endosome 
[605], stronger binding of HOSCN- or HOCl-modified LDL to the LDLR may prolong the 
recycling process and hold the LDL-LDLR complex in the cell longer, which might dysregulate 
lipid metabolism in the cell. The reduced expression of LDLR mRNA following exposure to 
HOSCN- or HOCl-modified LDL may be a negative feedback mechanism to reduce 
transcriptional LDLR expression by sterol-dependent response elements, such as inhibiting 
SREBP binding to the LDLR promotor region [772]. A future study could examine the binding 
of HOSCN- or HOCl-modified LDL to LDLR, for example, by performing a competitive 
binding assay to the LDLR using labelled LDL (e.g. DiI-, I125-) modified by HOSCN or HOCl. 
 Stress signalling induced by HOSCN- or HOCl-
modified LDL 
Several studies have observed detrimental effects of oxidised LDL (most commonly LDL 
modified by Cu2+) on endothelial function, finding that oxidised LDL promoted pro-
inflammatory cell adhesion molecule expression [307, 433-435, 613], impaired eNOS function 
[455, 516, 524] and induction of cell death by apoptosis [514, 523, 599, 600]. Similarly, HOCl-
modified LDL has been shown in previous work to impair eNOS function by delocalising 
eNOS from the plasma membrane [448]. However, the role of HOSCN-modified LDL on 
endothelial function has not been previously reported. This may be of significance, as the 
difference in molecular reactivity of HOSCN and HOCl on LDL may alter the cellular response 
to these modified LDL species.  
Cu2+-modified LDL has been previously demonstrated to cause an increase in arginase 2 
activity and expression, which reduced L-Arg availability to competitively decrease eNOS 
activity in HCAEC, as the rate of L-Arg consumption by arginase 2 is almost 200-fold greater 
compared to consumption by eNOS [773]. This was demonstrated further to influence NO 
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production in rat aortic segments ex vivo [773]. This was further supported by a more recent 
study that showed arginase 2 translocated from the mitochondria to the cytoplasm, in the 
absence of changes to mitochondrial membrane potential, leading to consumption of L-Arg 
[774]. Induction of arginase 2 to compete with eNOS for L-Arg may be of relevance to HCAEC 
exposed to HOSCN- or HOCl-modified LDL, based on the observation of a reduction of eNOS 
activity and NO detection, together with the absence of increased O2
•-, which normally 
accompanies eNOS uncoupling (Figure 7.2). In addition to depleting L-Arg stores, increases 
in arginase 2 activity also result in increased urea production, which could contribute to pro-
atherogenic protein carbamylation, as the increase in urea formation also increases cyanate 
levels in the cell [255]. However, it is not clear if HOSCN- or HOCl-modified LDL alter 
arginase 2 expression or translocation in endothelial cells. Further, arginase 2-/-/apoE-/- double-
knockout mice had a reduced atherosclerotic plaque burden and improved endothelium-
dependent vasodilation compared to apoE-/- mice [774], which further exemplifies the negative 
role of arginase 2 on endothelial function and lesion development. Moreover, it is also not clear 
as to what effect the exposure of HCAEC to native LDL has on arginase 2 activity [773], as 
the current study showed that the control LDL also reduced NO production in HCAEC. 
Cu2+-oxidised LDL-induced arginase 2 activation was also shown to be downstream of 
LOX-1 mediated uptake of the modified LDL in HAEC (Figure 7.1), as arginase 2 activation 
by oxidised LDL was completely ablated by antibody blocking of LOX-1 [775]. This was also 
demonstrated to be LOX-1-dependent in primary endothelial cell culture of LOX-1-/- mice, 
which did not exhibit translocation of arginase 2 when exposed to Cu2+-oxidised LDL [774]. 
Additionally, this led to increased ROS production, measured by DHE oxidation fluorescence, 
which was prevented by inhibiting eNOS with L-NAME, implicating eNOS uncoupling-
related O2
•- production induced by arginase 2 activation by oxidised LDL [775]. The current 
study did not confirm whether LDL modified by HOSCN or HOCl is taken up by LOX-1 in 
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HCAEC which would verify a role of LOX-1 and help assess if arginase 2 induction is involved 
in reduced NO production observed in HCAEC exposed to HOSCN- or HOCl-modified LDL. 
To determine this, the comparative level of arginase 2 in the cytoplasm and mitochondria 
following exposure of HCAEC to HOSCN- or HOCl-modified LDL in the presence or absence 
of LOX-1 inhibitors would need to be assessed and corroborated by measuring cellular urea 
content and the extent of resultant protein, all in conjunction with measuring NO production to 
assess alterations in eNOS activity. 
 
Figure 7.1. Proposed schematic for the potential interplay between MPO oxidant-
modified LDL, endothelial dysfunction and protein carbamylation propagated by 
arginase 2 (Arg2) (Adapted from [255, 775] and Figure 1.13). Scheme described in the 
accompanying text. 
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In the current study, treatment of HCAEC with HOSCN-modified LDL resulted in increased 
mRNA expression of both eNOS and HO-1 after 24 h exposure, whereas these gene expression 
changes were not apparent following exposure to HOCl-modified LDL. This corresponded 
with significantly lower NO production, which was attributed to decreased eNOS activity 
following exposure of HCAEC to HOSCN-modified LDL. However, HOCl-modified LDL still 
impaired eNOS activity and NO production in HCAEC, and induced HO-1 protein expression 
to a similar extent as HOSCN-modified LDL. This difference in gene expression between the 
two oxidant-modified LDL treatments, whilst still exhibiting the same extent of eNOS 
dysfunction and HO-1 expression, is attributed to differences in cellular response pathway 
activation to the uptake of HOSCN-modified LDL compared to HOCl-modified LDL. This 
could be related to the differences in the nature and extent of LDL modification in each case.   
To date, no work has reported the effect of HOSCN-modified LDL on eNOS expression, 
while in agreement with the current study, a previous study reported that eNOS activity was 
reduced, in the absence of altered eNOS mRNA or protein expression following incubation of 
HUVEC with HOCl-modified LDL [448]. This at first seemed contrary to studies exposing 
cultured endothelial cells to Cu2+-oxidised LDL, where concentrations of Cu2+-modified LDL 
at 0.05 – 0.1 mg•mL-1 caused a significant reduction in eNOS mRNA and protein expression 
[776, 777]. However, lower concentrations of 0.01 mg•mL
-1 Cu2+-oxidised LDL resulted in 
upregulation of eNOS mRNA expression [776], whilst also displacing eNOS from the plasma 
membrane [516]. It is likely that this concentration-dependent regulation of eNOS gene 
expression is linked to the cytotoxicity of Cu2+-modified LDL, which causes significant cell 
death at concentrations of 0.05 – 0.1 mg•mL-1 in cultured endothelial cells [523, 599, 600]. 
However, cell viability was not investigated in the previous studies that found Cu2+-oxidised 
LDL reduced eNOS gene expression [776, 777]. This is a limitation, particularly if reduced 
expression of eNOS mRNA is a result of increased cell death.  
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Increased HO-1 expression is seen as a protective mechanism which can ameliorate 
endothelial dysfunction by several actions (Figure 7.2). In endothelial cells exposed to Cu2+-
oxidised LDL or TNF-α, bilirubin production through the conversion of biliverdin (released by 
HO-1-degradation of haem) by biliverdin reductase, improves arterial vasodilation and reduces 
VCAM-1, MCP-1 and macrophage colony-stimulating factor (MCSF) gene and protein 
expression [778, 779]. Under oxidative stress, increased NOX activity and O2
•- production is 
also abated by induction of HO-1 [780], both by the formation of CO, biliverdin and bilirubin 
to directly scavenge O2
•- [781, 782], and by HO-1 promoting the expression of SOD and 
catalase to detoxify O2
•- and H2O2, respectively [783, 784]. Additionally, the subsequent CO 
released also acts as a NO analogue, aiding in vascular relaxation by activating sGC [575, 785, 
786]. Further, HO-1 and eNOS are linked by the shared compartmentalisation and interaction 
with cav-1 in endothelial cell caveolae [787], where the HO-1 protein disrupts eNOS-cav-1 
interactions and promotes eNOS phosphorylation to increase NO production and restore 
endothelial function [788].   
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Figure 7.2. The role of HO-1 in ameliorating eNOS dysfunction in endothelial cells 
(adapted from [789]). Risk factors (e.g. TNF-α, ROS, Cu2+-oxidised LDL, LPS) that may alter 
eNOS expression, reduce NO production and cause eNOS dysfunction can be abated by HO-1 
activity. HO-1 can inhibit O2
•- production (and subsequent ONOO- formation) by inhibiting 
both NOX and eNOS uncoupling, in addition to upregulating SOD and catalase to scavenge 
O2
•-. Additionally, CO produced by HO-1 can activate sGC to produce cGMP analogous to 
NO and aid in vascular relaxation. 
When HCAEC were exposed to HOSCN- or HOCl-modified LDL for 3 or 24 h, there was 
no significant change in mRNA expression of leukocyte adhesion molecules ICAM-1, VCAM-
1 or E-selectin, or the inflammatory cytokine MCP-1. Based on the previous studies outlined 
above, the results of the current study indicate that HO-1 induction may have limited the 
response of adhesion molecules and MCP-1 expression in HCAEC after exposure to HOSCN- 
or HOCl-modified LDL. However, assessment of eNOS-cav-1 binding in HCAEC by 
immunoprecipitation did not reveal that eNOS was bound to cav-1 after 24 h incubation with 
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HOSCN- or HOCl-modified LDL, and so the role of HO-1 induction in this regard cannot be 
determined. One complication in investigating the role of cav-1 is that cultured endothelial 
cells are reported to contain up to 1000-fold fewer caveolae than vascular endothelial cells in 
situ [642] with the majority of cav-1 localised to the perinuclear region in culture [790]. This 
may be of relevance to the in vitro experiments in the current study which demonstrated that 
eNOS colocalised, but did not bind to cav-1 in the cytosol of HCAEC following treatment with 
HOSCN- or HOCl-modified LDL. Having fewer caveolae in endothelial cells would affect 
cav-1 compartmentalisation and its function to regulate eNOS activity by binding. Although 
exposure to HOSCN- or HOCl-modified LDL reduced NO production and uncoupled eNOS 
in HCAEC, no significant change in O2
•- 
 or 3-nitroTyr formation was observed. There is a 
limitation to this finding, as alterations in the flux in O2
•- can rapidly occur in endothelial cells 
from eNOS uncoupling in response to oxidised LDL [672]. In this case, O2
•- was measured over 
a defined period of 30 min following 24 h treatment of HCAEC with HOSCN- or HOCl-
modified LDL. Therefore, it would be helpful if the measurement of O2
•- were performed in 
real time to detect flux, which has been performed with HAEC using fluorescence spectroscopy 
optimised for specifically detecting 2-OH-E+ without the need for HPLC separation [791]. 
However, lack of alteration in O2
•- production could be due to HO-1 scavenging and/or the 
subsequent activation of SOD [781-784], with the role of LDL modified by HOSCN or HOCl 
in SOD/catalase expression in endothelial cells was not investigated in the current study.  
Specificity protein-1 (SP-1) and activator protein-1 (AP-1) are transcription factors that bind 
to the promotor region of the eNOS gene to upregulate eNOS mRNA expression [668, 792-
796]. Native and Cu2+-oxidised LDL, and the related oxidation product 
lysophosphatidylcholine, have been shown to enhance SP-1 and AP-1 binding to the respective 
eNOS promotor region [797, 798], whilst conversely inflammatory agents such as H2O2 and 
LPS have been shown to reduce eNOS basal gene expression by inhibiting SP-1 activity [799, 
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800]. Furthermore, both AP-1 and SP-1 together mediate the expression of ATP-binding 
cassette-1 [801], an important cholesterol efflux protein that regulates intracellular cholesterol 
levels. The HO-1 gene promotor also contains AP-1 and SP-1-specific binding sites that 
promote HO-1 mRNA expression [802-806], independent of the ARE (i.e. Nrf2 translocation). 
The significantly large elevation in HO-1 mRNA expression following 24 h exposure to 
HOSCN-modified LDL in the absence of upregulation of other ARE genes (GS, Gclc, Nrf2) 
indicate that HO-1 upregulation occurred via an Nrf2 independent mechanism in conjunction 
with upregulation in eNOS mRNA. However, Nrf2 translocation has not been investigated in 
the current study, and so this pathway cannot be fully ruled out. Regardless, no study to date 
has reported the role of (MPO-derived) oxidised LDL in the signalling of AP-1 and SP-1 to 
promote eNOS and HO-1 transcriptional upregulation. This translocation pathway is 
circumstantially implicated in HCAEC as a response to HOSCN-modified LDL in the current 
study and provides a basis for future investigation, as it may be important for determining how 
the cells respond differently to HOSCN- and HOCl-modified LDL. The activation of these 
transcription factors can be determined by measuring the translocation to the nucleus (Western 
blot detection of AP-1, SP-1 and Nrf2 in the nuclear and cytosolic fractions of cells) and by 
using a dual luciferase reporter system. Additionally, a gel mobility shift assay to determine 
binding of AP-1, SP-1 and Nrf2 to their matching promotor sequence could also be performed 
to confirm the translocation and promotion of gene upregulation of the upstream proteins. This 
could lead to identifying specific therapeutic mechanisms for preventing endothelial 
dysfunction induced by the uptake of oxidised LDL.   
AP-1 and SP-1 also regulate gene transcription in VSMC. As described in Chapter 6, 
HCASMC incubated with either HOSCN- or HOCl-modified LDL exhibited increased OPN 
gene expression, and it may be that HOSCN- and HOCl-modified LDL may alter VSMC gene 
expressions via AP-1 or SP-1 signalling as well. Cu2+-oxidised LDL has also been reported to 
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induce AP-1 and SP-1 activation in VSMC [313, 807]. It was later found that AP-1 
transcription factor c-fos expression and activity was increased, subsequently along with 
proliferation, in the VSMC of aged New Zealand rabbits compared to young rabbits [808]. This 
may be linked to the transition in VSMC phenotype, as AP-1 activation leads to upregulation 
of OPN in VSMC [809], which is associated with transition to a synthetic (proliferative) 
phenotype. However, this was under hyperglycaemic conditions [809] and AP-1-induced OPN 
upregulation has not yet been linked to oxidised LDL.  
 Endothelial dysfunction caused by LDL 
modified by MPO-derived oxidants linked to SMC 
transdifferentiation? 
VSMC play an integral role in the development and complication of atherosclerotic plaques 
by the increase in proliferation and heterogenic transdifferentiation eventually leading to 
vascular remodelling and calcification [466, 697, 699, 737, 758, 810, 811]. These VSMC 
responses to the vascular environment are influenced in large part by the endothelium 
(reviewed [812]). For example, EC-SMC gap junctions are formed by Cx43, but also Cx37, 40 
and 45, to facilitate the spread of hyperpolarisation between EC and SMC during vasodilation 
[813, 814]; this has the advantage of not needing to directly stimulate all cells by 
hyperpolarising factors (e.g. ACh) to induce a general vasodilatory response. 
An endothelial-SMC co-culture system showed that endothelial cells prevented the 
conversion of SMC to a synthetic phenotype, characterised by their lower proliferation, 
spindle-shaped appearance and lack of “hill and valley” growth behaviour under electron 
microscopy, but no mechanism was ascertained [815]. However, in an atherogenic 
environment, reduced NO production leads to an increase in proliferation of VSMC, where 
previous studies have shown that NO-donors inhibited DNA replication and proliferation by 
arresting the cell cycle of VSMC [816-818]. Bovine aortic endothelial cells transfected to over-
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express eNOS largely reduced the proliferation of co-cultured bovine aortic smooth muscle 
cells through NO production [819]. These findings are congruent with highly proliferative 
SMC being more receptive to NO signalling by the increased expression of gap junction 
proteins (Cx43) to help facilitate cross-talk of NO signalling between the endothelium and 
smooth muscle (reviewed [470]). The role of NO as an effector of VSMC phenotype has been 
attributed to protein kinase G (PKG) activity and subsequent cGMP formation [820, 821], and 
activation of the phosphoinositol 3-kinase/Akt pathway [822]. This evidence seems to support 
NO being able to promote the contractile phenotype of SMC, however, little is known about 
the role NO has on modulating SMC contractile and synthetic markers.  
The finding that endothelium-dependent, but not endothelium-independent vasorelaxation 
was impaired in ex vivo rat aortic segments treated with HOSCN- or HOCl-modified LDL, 
while the modified LDL particles did not alter the expression of Cx43 in HCASMC, indicate 
that oxidised LDL may alter VSMC function indirectly by causing endothelial dysfunction. 
Though, it should be noted that Cx37, Cx40 and Cx45 were not assessed in the current study 
and the role of these connexins should also be investigated in future studies. This could be 
performed by the co-culture of SMC under endothelial cells to assess the role of MPO-derived 
oxidant-modified LDL-induced eNOS uncoupling on SMC proliferation and phenotype, and 
whether this is linked to higher expression of connexins. Further, the endothelial cell layer 
could be replaced with fresh, untreated HCAEC to restore eNOS activity and NO production, 
to see if the SMC revert to a contractile phenotype. 
Although no markers for HOSCN are known, characterisation of LDL modification in 
human MPO-transgenic apoE-/- mice compared to apoE-/- only mice supplemented with or 
without SCN- in a normal or high cholesterol diet would provide valuable information on 
whether high plasma SCN- levels are deleterious to LDL modification in vivo. This study could 
be extended to assess vasorelaxation in the mouse arteries in situ or ex vivo, which would 
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validate the finding in the current study that rat aortic rings treated with HOSCN-modified 
LDL ex vivo cause a loss in vasorelaxation, and whether SMC phenotype is affected by these 
conditions in vivo. In a mouse model expressing human MPO, Morgan and colleagues 
demonstrated that SCN- supplementation significantly reduced plaque formation in human 
MPO transgenic LDLR-/- mice [261]. A limitation of this study [261] is that it is not clear 
whether SCN- is influencing lesion formation by altering the ratio of HOCl: HOSCN formed. 
Additional characterisation of the extent of HOCl-induced oxidation is required, particularly 
as SCN- was used extensively as an anti-hypertensive agent, at similar final plasma 
concentrations [56, 823]. 
 Study limitations 
A limitation of the current study is that LDL was modified by reagent HOCl and HOSCN 
rather than a MPO-H2O2-halide enzymatic system. This is an important distinction, as the 
selectivity of isolated oxidants does not necessarily match modifications caused by an 
enzymatic system owing to ability of MPO to bind to LDL [288]. For example, reagent HOCl 
(up to 1:50 LDL: HOCl ratio) mostly oxidised Met residues on LDL, with several oxidised Trp 
and only two Cl-Tyr residues [288]. In contrast, in the same study using an equivalent MPO-
H2O2-Cl
- system, resulted in the oxidation of significantly fewer Met residues and only one Cl-
Tyr and no Trp oxidation were detected [288]. This also applies to HOSCN and an MPO-H2O2-
SCN- system, as exposing LDL to the MPO-H2O2-SCN
- (200 μM SCN-) system did not cause 
fragmentation of the apoB-100 C- and N-termini and 9-HODE formation was considerably less 
than that observed with reagent HOSCN [146]. Therefore, future studies should perform 
comparative investigations of vascular dysfunction caused by LDL modified by MPO-H2O2-
halide systems to alleviate this limitation.  
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The ex vivo rat aortic vasodilation model used in the current study also has drawbacks. 
Although both HOSCN- and HOCl-modified LDL impaired endothelium-dependent 
vasorelaxation, the exposure of rat aortae to LDL modified by HOSCN or HOCl ex vivo for 
only a short time (1 h) does not adequately imitate the physiologically context. What should be 
drawn from this experiment is validation to explore an animal model of high vascular MPO 
activity and its relation to LDL modification and endothelial dysfunction in blood vessels in 
vivo. 
 Conclusions 
The results of this Thesis highlight the differences in cellular responses to LDL that has 
been modified by either HOSCN or HOCl at oxidant concentrations likely to be pathologically 
relevant to inflammation in atherosclerosis. The selective fragmentation of LDL by HOSCN 
may become more prevalent as MPO activity shifts to producing HOSCN when plasma SCN- 
levels are elevated, such as in smokers. This significant post-translational modification may 
have physiological consequences and/or serve as a surrogate marker for HOSCN reactivity in 
vivo, which requires further investigation.  
An increasing number of studies have found that elevated plasma SCN- levels can have 
beneficial anti-inflammatory effects and reduce the severity and extent of inflammatory 
disease, including lesion development [55, 56, 261], though it is not clear if this is related to 
modification of LDL or other proteins by HOSCN instead of HOCl. Although both HOSCN- 
and HOCl-modified LDL caused endothelial dysfunction by impairing NO bioavailability, 
resulting in reduced vasodilation ex vivo, the upregulation of HO-1 in eNOS mRNA in HCAEC 
following exposure to HOSCN-modified LDL could be a pathway to reduce atherogenesis in 
response to the decrease in NO production. This suggests a cellular response to HOSCN-
modified LDL that is distinct to the response to HOCl-modified LDL, which may have a 
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protective effect on endothelial cells. Likewise, it has been previously shown that HOSCN-
modified LDL is not taken up as avidly as HOCl-modified LDL by macrophages [146]. 
Investigations of the role of SCN-, both as an exogenous antioxidant and a substrate for MPO 
producing HOSCN, in cell signalling pathways that maintain health and promote disease are 
still required. 
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